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ABSTRACT 
 
The use of sedation for diagnostic and therapeutic procedures in children is common 
and leads to considerable debate. Evaluating this subject is complicated by differences 
in the methods and the outcomes used for sedation assessment in children reported in 
the literature which are large. This thesis used systematic literature reviews, a 
prospective study and a national survey to evaluate several aspects of paediatric 
sedation. 
A systematic review of the safety and effectiveness of chloral hydrate in three 
categories of procedural sedation was conducted. For painless procedural sedation, 
chloral hydrate was more effective for shorter imaging procedures, such as CT 
scanning. The incidence of adverse events was 1,951 occurring in 14439 patients 
(13.5%), with hypoxia the most frequent. Moderate hypoxia (SpO2 85%–90%) was 
seen in 281 cases of 14439 patients (1.9%) of children.  
For painful procedural sedation, the success rate of chloral hydrate was variable 
(35%–100%). Hypoxia was the most common adverse event, occurring in 95 of 1810 
patients (5.2%). Most (66 cases/1810 patients, 3.6%) were mild however moderate 
hypoxia occurred in 29 of 1810 patients (1.6%). The incidence of adverse events was 
higher during painful procedures than during painless procedures: 313AEs/1810 
patients (17.3%) versus 1,951AEs/14439 patients (13.5%).   
The most frequent use of chloral hydrate as a treatment was to reduce agitation 
during mechanical ventilation, followed by treatment of neonatal diseases and 
treatment of neurological disorders. The reported success rate was high throughout all 
treatment procedures (86%–100%). The incidence of hypoxia was found to be the 
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highest, when it was used for the treatment of agitation 71 cases/438 patients 
(16.2%). 
Due to the heterogeneity between the studies it was not possible to perform 
meaningful statistical analysis. 
The effectiveness and safety of triclofos (a chloral hydrate derivative) was evaluated 
for procedural sedation in children, in a systematic review of the literature. The 
success rate was variable (ranging from 50 to 100%), shorter procedures such as CT 
scanning were more likely to be successful. Vomiting and hypoxia were the most 
frequently reported adverse events, 10% (62/613) and 7.8% (48/613) respectively. 
A systematic literature review of the safety and effectiveness of paraldehyde as a 
sedative agent for children was performed, as it was named as a second line agent in 
the sedation policy of the Derbyshire Children's Hospital. The literature is scant; only 
five studies were located and involved 157 patients. The reported effectiveness of 
paraldehyde ranged from 75- 93%. Vomiting was the most commonly reported 
adverse event (2 cases/8 patients, 25%). Due to the small numbers of patients and 
poor methodology of studies, its clinical use cannot be supported. 
A further systematic literature review of 29 studies involving 6342 children on the 
safety and effectiveness of midazolam for imaging procedures was conducted. The 
procedural success rate was variable (0%–100%, median 82%). Hypoxia was the 
most commonly reported adverse event (74 cases/2046 patients, 3.6%) with (32 
cases/2046 patients) 1.6% of cases being reported as moderate hypoxia. 
Palatability of the two most commonly used sedative agents, chloral hydrate and 
midazolam, was evaluated by conducting a literature review and a prospective study 
at the Derbyshire Children's Hospital. Only 9 studies were identified during the 
literature review. Of these, 8 studies evaluated the palatability of midazolam, while 
only 2 evaluated the palatability of chloral hydrate. Midazolam was reported as more 
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acceptable to patients than chloral hydrate. The prospective study supported this, and 
showed that patient acceptance of midazolam was good, while it was poor for chloral 
hydrate. The success rate of procedures was lower with midazolam, then chloral 
hydrate. 
A further literature review evaluated the use of sedation in Middle Eastern countries. 
Limited numbers of reports were found. Of the 37 studies, the majority (43%) were 
conducted in Turkey, within single centres and only examined a single procedure. Very 
limited evidence on the use of sedation guidelines was reported. 
Further exploration of the current sedation practice in the Kingdom of Saudi Arabia 
was done using a national survey. The questionnaires were completed by 81 health 
care professionals. Only 61% documented the use of sedation guidelines, although 
91% reported monitoring of patients during procedural sedation. The most commonly 
reported agents for both painless and painful procedures were chloral hydrate and 
midazolam. 
This research aimed to add to the evidence base for paediatric sedation. The results 
suggest a need for future research to cover further areas, including the safety and 
effectiveness of other drugs, worldwide practice and patient monitoring.  
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CHAPTER ONE 
General introduction 
1.1 Introduction 
The use of sedatives in the paediatric population has been increasing. This is due to 
advances in the treatment of childhood diseases and the consequent use of newer 
diagnostic procedures, such as computerised tomography (CT) scan and Magnetic 
resonance imaging (MRI) [1]. Dental procedures for instance cause pain, stress and 
even frighten children, hence most medical practitioners have found the need for 
sedatives before such procedures [2]. Despite the benefits of sedatives, inappropriate 
use of this group of drugs can lead to unwanted effects.  
The use of sedatives in children has become a controversial subject among 
paediatricians. While some believe that some diagnostic procedures such as 
radiological imaging can be done without sedating the children, others claim that the 
success of such procedures depends greatly on sedation. For instance, some 
physicians believe that procedural sedation (PS) prior to neuroimaging in paediatric 
patients is less convenient and poorly tolerated compared to general anaesthesia [3, 
4]. Procedural sedation (PS) has an unpredictable onset level and duration of action 
[5]. Besides, sedatives need extensive monitoring due to their long half-life; and 
levels beyond the therapeutic limit may depress the respiratory reflexes and cause 
deep sedation leading to respiratory insufficiency [5].  
With the growing prescription rates of sedatives by clinical professionals for 
therapeutic and diagnostic procedures in paediatrics, there are increasing concerns 
about the safety of these drugs. Therefore, this thesis will focus on the use of 
sedatives in children, particularly with respect to their safety and efficacy. 
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1.2 Background to sedation in children 
Although the use of sedative drugs began as early as the 19th century, data regarding 
their safety and efficacy in children was rather poor. Prior to the 1980s, the 
availability of data about the use of sedatives in children was limited. There were no 
specific paediatric guidelines for appropriate dosage and route of administration [6]. 
In 1985, Dr Charles Cote and Dr Theodore Striker wrote the first guideline for 
sedation in children [7]. This was written with the assistance of the American 
Academy of Pediatrics (AAP). The aim of the guideline was to improve the safety of 
sedatives for children undergoing painless procedures. This guideline classifies the 
depth of sedation into; conscious sedation, deep sedation, and general anaesthesia. It 
also focused on the need for monitoring these children. Measurement of vital signs, 
availability of basic life support, and well trained practitioners were recommended.  
In 1992, the 1985 guideline was revised by the committee on drugs of the AAP 
(American academy of Paediatrics Committee on Drugs 1992) [8]. This guideline 
stated that patients could be given an extra dose of sedation in order to progress from 
one level of sedation to another. It also recommended adequate supervision when 
giving extra doses of sedatives (American Academy of Pediatrics Committee on drugs 
1992) [8]. Furthermore, out of hospital administration of any sedative in children was 
discouraged. 
In 2002, the previous guideline was amended by the AAP Committee and the term 
"conscious sedation" was eliminated. The guideline’s applicability was further 
extended to out of hospital sedative use (Committee on drugs American Academy of 
Pediatrics 2002)[9]. In addition, expressions such as minimal sedation, moderate 
sedation, deep sedation, and anaesthesia which are in fact used in the current 
guidelines were adopted (Committee on drugs American Academy of Pediatrics 2002) 
Currently, there are several guidelines by different organisations such as: the 
1 General introduction 
 
25 
 
American Academy of Pediatrics in the USA (ASA) [8], the Scottish Intercollegiate 
Guidelines Network (SIGN 2014)[10] and the British National Institute for Health and 
Clinical Excellence (NICE 2010) in the UK [11] which were established according to 
the recommendations of literature reviews and health economics data. Although these 
guidelines have some inconsistencies on various points, they all emphasize the 
importance of safety precautions and the need for training and continuous education 
for sedative drug providers. Other key components of most of the guidelines are the 
need for patient assessment before sedation as well as monitoring during and after 
sedation [12]. They are all based on the levels of sedation needed instead of the type 
of sedative drugs.  
1.3 Aims of sedation 
Sedation provides an environment conducive to good patient care, for both treatment 
and diagnostic procedures. There is increasing demand for it from both parents and 
medical practitioners [12].  Parents want their children free from the anxiety that they 
may experience during procedures; while medical practitioners also want cooperative 
and immobile children. This has often led to the misuse of some of the sedative drugs 
during the course of patient care [13]. Depending on the planned diagnostic and/ or 
therapeutic procedure, sedation may be necessary for, immobilisation, induction of 
sleep, reduction of anxiety and reduction of distress [14]. 
Anxiety during diagnostic and therapeutic procedures can seriously put children at 
risk. Krauss and Green (2006) suggested that anxiety and pain during diagnostic 
procedures often stimulate a stress response. Such stimuli can incite the sympathetic 
pathway which can lead to increased heart rate, blood pressure, and blood glucose 
levels [2]. Reduction of anxiety and distress will lead to better acceptance of 
diagnostic or treatment procedures [15].  In addition, the anxiolytic properties of 
sedatives are useful during mechanical ventilation, especially when using newer 
ventilating machines with less physiological mechanisms, such as high frequency 
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oscillatory ventilation with tracheal insufflation. Another major objective of sedation in 
children is immobilisation, in order to ensure cooperation during procedures. Although 
some painful procedures such as wound treatments can be done under local 
anaesthesia in adult patients, it is often impossible to achieve a similar level of 
cooperation in children without some sedation.  As Sury (2004) points out, children 
are less able to tolerate pain and discomfort than adults and the thought of a 
procedure may be sufficient to make a child agitated [16].  
Sedatives have also been used successfully for inducing sleep. This benefit makes 
them a fundamental part of treatment intervention especially for critically ill children. 
Furthermore, the use of sedation can optimise analgesic drugs’ appropriate effects 
while minimising their harmful effects [17] . For example, to reach an optimal level of 
analgesia with an opiate, sedation with drugs such as benzodiazepine should be 
increased to the level of prompting unconsciousness. This combination is commonly 
used in critically ill children [17] . Conversely, concomitant use of analgesics with 
sedatives could increase the incidence of serious adverse events [18]. Sury et al. 
(2011) however affirms that the use of sedatives and analgesia is safe and effective in 
children particularly after evaluation by well-trained practitioners [19]. It is important 
to note that concomitant administration of sedatives with analgesia should be guided 
by  well-planned sedative and analgesic procedures (PSA) in order to avoid adverse 
harmful effects of  either the sedative and analgesic agent [20].   
The benefits of sedation should be adequately weighed against the risk of unwanted 
adverse effects. These two effects must be put in perspective when formulating 
sedation guidelines. 
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1.4 Definitions  
In order to be able to differentiate between anaesthesia and sedation, it is important 
to ascertain the meaning of these terms. The American Society of Anaesthesiologists 
(2002) defines anaesthesia as the use of specific medication or medical intervention to 
induce partial or complete loss of consciousness [21]. However, sedation is defined as 
the decrease of irritability or agitation by the administration of sedative drugs to 
facilitate a medical or diagnostic procedure [22]. Sedation can also be defined as a 
decrease in the level of consciousness [23]. In fact, the decreased level of 
consciousness is usually associated with a reduction of muscle tone of the oropharynx 
and the tongue, including the airways. Indeed airway obstruction could be associated 
with deep sedation, which made the Royal College of Radiologists and Anaesthetists 
define safe sedation or conscious sedation as "a technique.... during which verbal 
contact with the patient is maintained" [24]  
In the USA, the term "deep sedation" was defined as and refers to a state deeper than 
conscious sedation other than anaesthesia [25]. Deep sedation is defined as: "...a 
state of depressed consciousness from which the patient is not easily aroused…" [25]. 
Any sedation deeper than conscious sedation may progress to ‘too deep’ and should 
be supervised by anaesthetists [26]. Table (1.1) shows definitions of sedation and 
anaesthesia. 
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Table 1. 1: Sedation and anaesthesia definitions  
Term  Definition  
Sleep “A quiet and immobile state, induced without drugs or occurring 
spontaneously, from which the individual can be roused”. 
Sedation “A “sleep-like” state induced by drugs, from which the individual may 
be aroused” 
 “Conscious sedation: can be aroused by gentle stimulation” 
 “Unconscious sedation: difficult to arouse even with vigorous 
stimulation. Appreciable depression of vital reflexes must be 
expected”. 
Anaesthesia “An unrousable “sleep-like” state induced by drugs. Appreciable 
depression of vital reflexes is commonplace”. 
 “Conventional anaesthesia: intervention is often necessary to 
support the airway, breathing and circulation”. 
 “Minimal anaesthesia: “Anaesthetic” doses are used to induce 
an unrousable sleep lasting a few minutes”.  
 
This table adapted from [26]. 
 
1.5  Levels of sedation 
Sedation often happens in a continuous pattern [27]. The continuum of sedation is 
dynamic and it depends on individual variables such as: age, weight, surface area of 
the body, general health condition, and use of other drugs as combination. This 
continuum starts from minimal sedation and ends with general anaesthesia[28]. 
Figure (1.1) illustrates the continuum of sedation levels. 
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Figure 1. 1: The continuum of sedation levels  
 
Minimal sedation        Moderate sedation        Deep sedation       General anaesthesia 
 
This figure adapted from American Society of Anaesthesiologist (2009). 
The change from one level to another, such as, from minimal to moderate sedation is 
usually unpredictable. Consequently, any medical practitioner who provides sedative 
medication should understand the possibility of the occurrence of an unexpected level 
of sedation [29]. According to the Joint Commission on Accreditation of Healthcare 
Organizations (JCAHO), medical practitioners responsible for providing sedation should 
have the ability to resuscitate a patient at any level of sedation [30] . Since the level 
of sedation is associated with both pulmonary and cardiovascular functions, the 
current guidelines by the American Academy of Paediatrics (AAP) and the American 
Society of Anaesthesiologists (ASA) have considered these while providing definitions 
for the different levels of sedation [29]. According to AAP and ASA, there are four 
levels of sedation. These are described in the next sections.  
 
1.5.1. Minimal sedation (anxiolysis) 
Minimal sedation or anxiolysis, is a state of sedation in which the patient obeys verbal 
commands while cognitive and motor functions may be affected. At this level of 
sedation, pulmonary and cardiovascular functions remain normal.  
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1.5.2. Moderate sedation (conscious sedation) 
Conscious sedation can be defined as a medication induced reduction of consciousness 
that still permits purposeful reaction to verbal orders and or tactile stimulation. 
Generally, pulmonary and cardiovascular functions are maintained. There is usually no 
need to protect airway patency because the patient’s automatic ventilation is 
sufficient.  
 
1.5.3. Deep Sedation/Analgesia 
This level of sedation can be defined as a medication induced reduction of 
consciousness from which patients cannot be easily awakened. Patients however react 
purposefully after recurrent or painful stimulation. Often, cardiovascular function 
remains normal, but support of airway patency is often required and the patient’s own 
ventilation may not be enough.  
 
1.5.4. General Anaesthesia 
This is a medication induced loss of consciousness from which patients are not 
awakened by verbal instruction or painful stimuli. Cardiovascular function may be 
affected. In addition, it is necessary to maintain airway patency by positive pressure 
ventilation because of the loss of airway patency. Cravero and Blike (2004) stated 
that qualified anaesthesiologists are the only medical practitioners who should provide 
and/or organise the general anaesthesia intervention plan [6].  Table (1.2) shows the 
ASA definitions of levels of sedation. 
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Table 1. 2: Definitions of levels of sedation from the American Society of 
Anaesthesiologists (ASA)  
 Minimal 
sedation/ 
Anxiolysis 
Moderate 
sedation/ 
Conscious 
sedation 
Deep sedation General 
anaesthesia 
Responsiveness Responds 
normally to 
verbal 
commands 
Purposeful 
response to 
verbal 
commands, 
either alone or 
with light tactile 
stimulation 
Not easily 
aroused, 
however 
purposeful 
response after 
repeated or 
painful 
stimulation 
Unarousable, 
even upon 
painful 
stimulation 
Airway Unaffected No intervention 
needed 
Intervention may 
be needed 
Intervention 
often needed 
Spontaneous 
ventilation 
Unaffected Adequate May be 
insufficient 
(intervention 
may be needed) 
Ventilation often 
required 
Cardiovascular 
function 
Unaffected Usually 
maintained 
Usually 
maintained 
May be impaired 
This table adapted from American Society of Anaesthesiologists (2009)[28]  
 
1.6 Impact of sedation on airway control and respiratory drive 
1.6.1 The Paediatric Airway 
 Anatomical Considerations 
The capacity to evaluate and manage the paediatric airway is considered as the most 
significant aspect of carrying out safe paediatric sedation [31]. Regarding the upper 
airway, it consists of three parts; namely the supraglottic, laryngeal and intrathoracic 
[31, 32].  
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1. Supraglottic: Included in the supraglottic area are pharyngeal structures, which 
refers to the most inadequately maintained and collapsible element of the upper 
airway. This area is the most likely to be affected by sedation [31]. 
2. Glottic (laryngeal): regarding the glottic structures, they comprise the vocal cords, 
subglottic part, and cervical trachea. Laryngospasm represents the most prevalent 
factor causing airway block in this area [31]. 
3. Intrathoracic: This part is composed of both the thoracic trachea and bronchi [31]. 
Differentiating the paediatric airway from the adult airway are a number of 
developmental features, including: the size of the paediatric airway, which is smaller 
in diameter and shorter in length; the young child’s tongue, which is comparatively 
bigger in the oropharynx; the larynx in infants and young children, which is positioned 
more to the anterior; and the relative length, floppiness, and narrowness of the 
epiglottis in infants and young children [33]. In children aged below 10 years, the 
narrowest part of the airway is underneath the glottis at the point of the cricoid 
cartilage [31]. 
Other characteristics predisposing young children to airway obstruction during 
sedation include the small calibre of the paediatric upper airway, the relatively large 
tongue, and the “floppy” and relatively long epiglottis [33]. Similarly, the infant’s 
large occiput puts the head and neck in the flexed position if the patient is positioned 
recumbent, which further aggravates airway blockage [33].  
Whilst in normal respiration, a pressure gradient from the mouth to the airways is 
created through a negative intrapleural pressure produced in the thorax, leading to 
airflow into the lungs [31]. There is a decrease in the extrathoracic airway calibre 
during inhalation, as opposed to the increase in the intrathoracic airway diameter [31]. 
In typical circumstances, there are clinically insignificant changes in the airway 
calibres during respiration [32]. Tightening of the paediatric upper airway may 
considerably increase airway resistance given that resistance is inversely 
proportionate to the fourth power of the radius [32]. A higher-pressure gradient 
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across the airway is needed for elevated airway resistance and the associated 
improved airflow velocity (Bernoulli effect) in order to maintain tidal volume and 
minute ventilation [33]. The normal inspiratory and expiratory impacts are heightened 
on the airway through a larger pressure gradient produced across the airway [33]. As 
a consequence, there appears to be a further collapse of the upper airway resulting 
from the greater negative pressure produced in the pharynx during respiration [32].  
 
 Airway Control 
Pharyngeal Obstruction: A collapsible part positioned between two fairly well-
maintained structures; namely, the nasal passage and the trachea refers to the 
supraglottic area [34]. During the process of sedation or anaesthesia, diaphragmatic 
activity (phrenic nerve) is inhibited to a lesser degree than neuromuscular control of 
the upper airway [35]. As a result, the negative pressures emanating with 
diaphragmatic contraction and the decreased overall tone of the upper airway 
aggravate the reduction in diameter of the pharynx during inspiration, as shown in the 
[34, 35].   
In the process of sedation, reduced pharyngeal tone leads to a narrower anterior-
posterior distance between the posterior pharynx and the soft palate, epiglottis, and, 
to a lesser extent, the base of the tongue [35]. In so doing, the pharyngeal segment 
is used as a “Starling resistor”, a collapsible tube with a calibre which is affected by 
compressions within the lumen of the airway and soft tissue [34, 35]. There appears 
to be an airway obstruction during moderate or deep sedation in the supraglottic 
structures, essentially as a result of the soft palate and epiglottis “leaning back” to the 
posterior pharynx [34, 35]. Despite the fact that it was formerly believed that the 
base of the tongue could be the principal reason of upper airway blockage during 
unconsciousness, it has been shown in MRI studies of the upper airway in sedated 
children that the most likely structures causing pharyngeal obstruction are the soft 
palate and epiglottis [36]. The single most prevalent, serious and negative action 
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taking place during sedation refers to pharyngeal obstruction. There are some basic 
airway exercises, such as a chin lift which usually suffice to release the airway 
obstruction referring to pharyngeal collapse [36].  
Laryngospasm: Another major reason for the obstruction of the upper airway during 
sedation is laryngospasm, which takes place at the level of the glottis [37]. Defining 
laryngospasm, it refers to a glottic musculature spasm and may cause limited or 
complete airway obstruction [35]. There are a number of risk factors associated with 
laryngospasm, including being passively exposed to tobacco smoke, utilisation of an 
airway instrument, being young, higher ASA classification, upper airway secretions, 
airway manipulation, recent upper respiratory infection, and gastroesophageal reflux 
disease [37]. As opposed to pharyngeal obstruction, laryngospasm is not reversed by 
simple airway manoeuvers [35]. There is a stepwise method required for the 
treatment of laryngospasm, which may necessitate positive pressure ventilation, 
enlarging the depth of sedation and in acute cases neuromuscular blockade [37]. 
 
 
 Respiratory Drive 
The breathing process as a basic need comes from within the central respiratory 
centre positioned in the brainstem [38]. The modulation of output from the 
respiratory centre occurs through the interaction of several chemicals, including CO2 
and O2 and mechanical controllers like lung mechanics [39]. Regarding the most 
significant factors of the respiratory drive from the medullary respiratory centre 
include changes in carbon dioxide concentration [38]. There is a free diffusion of 
carbon dioxide across the blood-brain barrier, which leads to a rise in H+ and a 
decline in pH in the cerebral spinal fluid [39]. In addition, while there is a decline in 
pH, there is an increase in neural output from the respiratory centre and ensuing 
surge in minute ventilation (VE), which characteristically rises linearly with increases in 
PCO2 in experimental situations [40]. 
1 General introduction 
 
35 
 
 
Overall, sedative drugs suppress the central respiratory centre and decrease the 
ventilatory response to a particular carbon dioxide level [38, 39]. Sedative drug doses 
that do not result in complete loss of consciousness (e.g., low-dose midazolam) 
frequently shift just the CO2 ventilation response curve to the right while keeping the 
slope of the response [39]. With deeper levels of sedation, as well as the response 
changing to the right, the slope of the CO2 ventilation response curve is also reduced 
[40]. This reaction may take place upon the combination of sedative drugs or utilising 
any sedative that causes unconsciousness [39]. A decreased slope signifies less of a 
rise in ventilator response for any given increase in carbon dioxide [40]. This is an 
instance that may result in acute hypercapnia, hypoxemia, or apnoea [40].  
 
1.7 Sedation for procedures 
Procedural sedation can be defined as a medical technique that involves 
administration of one or more sedative drugs, with or without supplemental analgesia, 
while cardiopulmonary function is conserved [16]. Generally, the purpose of sedation 
can be for diagnostic procedures, for treatment procedures or both. Procedures can be 
subdivided into painless or painful procedures according to the degree of pain which 
they induce [16]. Figure (1.2) illustrates the different types of procedural sedation. 
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Figure 1. 2: Types of procedural sedation  
 
 
1.6.1. Painless (non-invasive) procedures 
These can be defined as diagnostic or treatment techniques which do not need 
insertion of a medical device via a body cavity or cause disruption of body organs 
function.  This type of procedure, for instance, CT scan and MRI can often require a 
high level of child immobilisation [16].  
1.6.2. Painful (Invasive) procedures 
These can be defined as diagnostic or treatment techniques which need insertion of a 
medical device via a body cavity or cause disruption of body organ function.  Painful 
procedures such as liver biopsies and wound care are also often associated with 
anxiety, which reduce the effects of analgesic drugs [41].   
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1.8 Sedation outcome  
1.8.1. Safety issues 
Assessment of the safety of children’s sedation practice has proven difficult due to the 
available prospective studies. Many descriptive studies were conducted to evaluate the 
safety of specific sedative(s) in a variety of settings. The definitions of adverse events 
reported by most of these studies are vague. It is difficult to assess the accurate 
incidence rate of adverse events from the available literature due to the difficulty in 
combining the results from studies which have used different terminology to define 
the same adverse events.  
A retrospective study conducted in the United States to evaluate outcomes of the 
adverse events of sedation in children reported to the American Food and Drug 
Administration from 1969 to 1996, revealed that of the 95 cases of sedation related 
adverse drug events, 51 resulted in death, 9 neurological injuries, 21 increase in 
hospital stay and 14 had no injury [42]. Predisposing factors were (1) outside hospital 
settings, (2) physiologic parameters were monitored inappropriately, (3) resuscitation 
skills were lacking or inadequate, (4) inadequate monitoring before sedation and (5) 
inadequate monitoring after procedural sedation. Increased safety and efficacy of 
sedative drugs can be achieved when children are supervised by knowledgeable 
anaesthesiologists [6]. There are specific standards that should be adhered to these 
specialists. Firstly, these individuals should know how to manage any airway problems 
like airway obstruction.  They should also document any disease that may interfere 
with the sedative procedure, for instance, history of cardiovascular diseases. Thirdly, 
it is important for them to be familiar with details of sedatives such as: doses and side 
effects. Hospitals should be well equipped and should also have a well-organized 
monitoring system [43]. 
Side effects of sedation in the paediatric population may occur as a result of 
medication overdose, other medication errors, inexperienced prescribers, and early 
1 General introduction 
 
38 
 
discharge [44]. Most harmful effects of sedatives are preventable; they are mostly 
caused by provider errors and improper management of adverse events [45].  
 The most serious complication of sedation in children is death, usually resulting from 
the untreated pulmonary depressant effect of the sedative drugs. A prospective study 
evaluating 1140 paediatric patients administered sedatives for diagnostic procedures, 
according to AAP guidelines, showed that about 5.3% developed respiratory side 
effects and one percent had air way obstruction [46]. These complications can occur 
at any level of sedation and with any sedative dose, although high doses are believed 
to be the leading cause for most serious adverse effects [47].  
Adverse events can occur even when clinicians follow current practice guidelines for 
procedural sedation in children [6]. Nevertheless, in order to be able to avoid or even 
to reduce the incidence of sedation adverse events, it is important to ascertain the 
definitions of adverse events. Subsequently, it has been found that there are various 
definitions for medication adverse events such as definitions by the World Health 
Organization (WHO) guideline and the Federal Drug evaluation Agency (FDA)[48, 49]. 
 The definitions by the European Medicines Agency (EMA) and the ICH Harmonised 
Tripartite Guideline are the strongest definitions for drug adverse events. It is 
important to note that the definitions by the EMA will be used later as a base line for 
analysing sedative drugs safety.  
According to the EMA guidelines adverse events have been categorised into serious or 
mild adverse events according to their severity[50]:  
 A serious adverse event is defined as “any untoward medical occurrence that 
at any dose: results in death, is life-threatening, requires inpatient 
hospitalisation or prolongation of existing    hospitalisation, results in persistent 
or significant disability/incapacity, or is a congenital anomaly/birth defect”.  
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 A mild adverse event is defined as “any adverse event that occurred that did 
not need any intervention”. 
The most common adverse events of sedation are airway obstruction, aspiration, 
vomiting and cardiovascular complications [51].   
 Airway obstruction 
One of the most common side effects during moderate or deep sedation is airway 
obstruction which may cause hypoxia. This is characterised by low oxygen levels in 
the blood and tissues. Hypoxia occurs when the oxygen pressure in arterial blood 
(PaO2) is decreased. Hypoxia due to sedation can be classified as mild (SpO2 90-
95%), moderate (SpO2 75-89%), severe (SpO2 40-75%) and extreme hypoxia (SpO2 
<40%) [52]. Severe and extreme hypoxia are capable of causing permanent injury to 
the brain and cardiopulmonary system [53]. 
Airway obstruction may occur due to laryngospasm or pharyngeal obstruction [54], 
and represents approximately 80% of sedative related complications during 
procedural sedation in paediatric patients [42]. 
Although sedatives such as chloral hydrate, ketamine, midazolam and pentobarbital 
can cause airway obstruction, the most serious respiratory airway obstructions are 
often attributable to propofol. Propofol related obstruction accounts for 5 to 15% of 
airway obstruction in children undergoing diagnostic or treatment procedures [55]. It 
can cause unpredictable, irreversible respiratory collapse as well as reduction in 
airway tone and reflexes which may lead to death [56]. A  study by Carvero et al 
(2009) showed that one out of every 65 sedations with propofol was associated with 
laryngospasm and airway obstruction [57]. 
Several factors can worsen airway obstruction in patients administered sedatives, 
among which is the co-administration with other sedatives, especially benzodiazepines 
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(for example administration of chloral hydrate with midazolam). Paediatric patients 
under two years  are more prone to airway obstruction than older children [58]. 
Children with a medical history of bronchiolitis and/ or obstructive sleep apnea also 
have a higher risk. A study by Green and colleagues (2009) showed that 3.9% of 
8,282 paediatric patients receiving ketamine for procedural sedation developed airway 
obstruction. 0.3% developed apnoea and 0.8%, laryngospasm.  They reported that for 
those aged less than two years, overdosing and co-administration with other sedative 
drugs were predictors of more serious respiratory adverse events [58] 
The management of airway obstruction can be accomplished by proper assessment of 
patients for respiratory risk factors such as bronchiolitis before procedures [59]. 
Additionally, during sedation, airway obstruction can be avoided by using simple 
techniques such as suctioning of oral secretions, keeping the head in the right position 
and administering oxygen by  a mask valve ventilation bag [60].  
 
 Aspiration  
Aspiration is another complication of sedation in children and can lead to death [61]. 
Although, the risk is high, the incidence rate is low, especially with conscientious 
patient monitoring [62]. In a study by Warner and colleagues (1999), the risk of 
pulmonary aspiration in paediatric patients with preoperative procedural sedation was 
1 in 8000 patients [63]. Aspiration occurs as a result of muscle tone relaxation in both 
the gastrointestinal tract and oesophagus. This in turn leads to passage of stomach 
contents as well as oesophageal secretions into the distal respiratory airway [64]. A 
variety of risk factors can contribute to the incidence of aspiration during sedation, 
including reflux  and obesity [47].  
In order to avoid the risk of aspiration following sedation, it is important to rule out 
oesophageal reflux during the pre-anaesthetic assessment of the child. Similarly, 
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fasting guidelines should be adhered to; drugs that reduce stomach content or to raise 
pH especially are also important for obese children [65]. Antibiotics are also useful to 
forestall bacterial infection [66].  In patients with risk of aspiration, tracheal intubation 
should be used to protect the airway. A study by Borland et al. reported that of 3300 
cases of paediatric patients receiving preoperative sedation, 52 developed pulmonary 
aspiration; 29 of whom needed tracheal intubation or prolonged hospitalization [67].  
 Vomiting 
Another common adverse effect of sedation is vomiting. Sedatives increase vagal 
tone, thus stimulating the neuromuscular reflex leading to vomiting [6]. Occurrence of 
vomiting during sedation can be fatal, because of its association with aspiration 
pneumonia, and is a major contributor to mortality in sedated paediatric patients [43]. 
Chloral hydrate is associated with a high incidence of vomiting. According to 
Greenberg et al. (1991), of 295 children receiving oral chloral hydrate, 7% developed 
adverse effects with vomiting accounting for most of these effects (4.3%)[68].The risk 
of complications of vomiting worsens in hypovolemic and obese children [69].  Some 
procedures such as dental procedures can themselves cause vomiting independent of 
sedatives. In order to mitigate the effect of these procedures, administration of anti-
emetic medication for instance, ondansetron and continuous suctioning can be 
effective. 
 Cardiovascular complications 
Some sedatives have deleterious cardiovascular effects such as: bradycardia, 
arrhythmias, hypotension, hypertension, and tachycardia [70]. Even cardiovascular 
friendly sedative medications such as etomidate, fentanyl and ketamine can cause 
hypotension, bradycardia and tachycardia [71]. Cardiovascular complications are dose 
and sedation level dependent [46]. Generally, medications in standard normal doses 
are believed to have only minor effects on cardiovascular function, however 
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cardiovascular adverse effects can also happen with normal doses. Arrhythmias have 
been reported in children following administration of chloral hydrate at recommended 
dose [72]. Chloral hydrate induces arrhythmias through direct alteration of the 
pacemaker cells or catecholamine sensitization.  Side effects can also occur from the 
direct effect of drugs on the cardiovascular system leading to myocardial depression. 
Barbiturates, ketamine and propofol are examples of drugs that act this way. 
Concurrent illness and co-administration with other drugs such as furosemide can 
worsen myocardial depression [73].  
Respiratory changes, mainly hypoxia and hemodynamic complications like 
hypervolemia have been shown to be major causes of cardiovascular complications 
[74, 75].  Propofol and dexmedetomidine are the main sedatives associated with 
these effects. In a study of 56 children administered propofol and dexmedetomidine 
as preoperative sedative drugs, Anger and colleagues found that the incidence of 
hypotension was high in both groups (61% versus 32%) [76]. 
Ultimately, the presence of qualified personnel to assess patients before, during and 
after procedural sedation is important in order to avoid complications. According to 
Cravero and Blike (2004) increased safety and efficacy of sedative drugs can be 
achieved when children are supervised by knowledgeable anaesthesiologists. This is 
said to improve the safety of any sedative procedure by 10-fold [6]. There are specific 
standards that should be adhered to these specialists. Firstly, these individuals should 
know how to manage any airway problems like airway obstruction.  They should also 
document any disease that may interfere with the sedative procedure, for instance, 
history of cardiovascular diseases. Thirdly, it is important for them to be familiar with 
details of the sedatives such as doses and side effects. Hospitals should be well 
equipped and should also have a well-organised monitoring system [6]. 
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1.8.2. Effectiveness of sedation 
When sedation is tried for procedures in children, the reported effectiveness of 
different sedatives differs substantially. Assessment of sedation effectiveness is 
evaluated by many clinical studies by measuring two outcomes. The most measured 
outcome is completion of the procedure and the less measured outcome is child, 
parent or anesthesiologist satisfaction [77]. In this context Cravero et al. in his review 
explained that the patient who is administered an oral dose of midazolam for a lumbar 
puncture procedure and cries or screams is often regarded an equal success as a child 
who given brief propofol sedation lies perfectly without crying, although objective 
observers would clearly count one strategy a success and the other a failure [6]. 
Generally for evaluating the value of sedation, two measures must be taken into 
consideration. First, maximise patient’s comfort by providing optimal health care. This 
means that when distraction techniques or minimal sedation become insufficient to 
keep the patient comfortable, additional effective sedation should be applied [78, 79]. 
Secondly, cost-effectiveness of sedation has to be taken into account. The cost of 
procedural sedation includes the time cost of medical staffs required for the providing 
and monitoring of sedative agent or general anesthesia, in addition to the time cost of 
the medical staffs throughout the procedure [80]. The cost strategy also consists of 
the unit cost of medication for sedation and general anesthesia, and other medical 
consumables which are used for administering them. Some strategies include the cost 
effectiveness of sedation resulting complications and the treatment of these 
complications [80]. 
 
1.9 Assessment of sedation level 
It is believed that the best method of sedative assessment is by directly asking 
patients about their comfort. This could however be difficult in young children and ill 
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paediatric patients due to their inability to express their emotions. The large number 
of available sedative drugs, different routes of administration and lack of proven 
information about the best way for sedation evaluation have made the assessment of 
level of sedation very difficult [81].  
There are various methods of assessing level of sedation in paediatrics. Scoring 
systems and neurophysiological method are the two widely used methods. 
1.9.1. Scoring systems 
 Since the introduction of the first scoring scale in 1974, a number of other scales for 
sedation level assessment have been introduced [82]. A systematic review by De 
Jonghe et al (2000) on the use of sedation scoring systems showed that 25 tools for 
sedation assessment were published between 1996 and 1999 [83]. Only three of 
these have been tested and assessed for their validity and consistency. These tools 
are: the sedation agitation scale (SAS), the motor activity assessment scale (MAAS) 
and the Ramsay sedation scale [84]. Scoring systems often evaluate consciousness, 
level of agitation and pain level [85].  
An ideal sedation scoring instrument should be easy to use, precise, safe, and should 
not increase staff workload. The Glasgow Coma Scale (GCS), Ramsay Scoring System 
(RSS), The Observer’s Assessment of Alertness/Sedation (OOA/S), Sedation visual 
analogue scale (VAS) and COMFORT scale are the most commonly used tools for 
sedation level assessment in paediatric patients [84]. 
1.9.2. Neurophysiological methods 
This sedation assessment method is often based on measurement of sedation depth. 
It relies on the hypothesis that ascribes the best indicator of brain function to its 
electrical activity [86]. Examples of neurophysiological assessment tools include: 
electromyography (EMG), electroencephalography (EEG) and evoked potentials.  
1 General introduction 
 
45 
 
1.10 Palatability of oral sedative agents  
1.10.1. Definitions 
Taste can be defined as ‘the sensation of flavour perceived in the mouth on contact 
with a substance’ [87]. Palatable food or drug is considered ‘pleasant to taste’ [87]. 
Specific epithelial cells with unique receptors in the tongue have the ability to detect 
four different modalities of basic taste, namely bitter, sour, salty and sweet [88]. 
Recently, a fifth taste modality called umami – that is, ‘substantial’ or ‘delicious’ – has 
been described [88].    
Children and adults are known to respond to certain tastes differently [89]. Children 
prefer sweet-tasting materials [90]. This preference decreases during late adolescence 
to resemble that of adults [91]. In contrast, dislike of bitterness starts from a very 
young age; thus, bitter tastes are expected to reduce palatability [90]. In addition, 
there are inherited variances in sensitivity to certain tastes [92]. Cultural differences 
may also influence the taste sensation associated with various substances [89]. 
1.10.2. Taste and medication adherence 
While adults may think that the worse a drug tastes, the better it is likely to work, 
children do not seem to have the same view [90]. Palatability has been found to be an 
important feature, after safety and clinical effectiveness, to both children and their 
parents [93]. Many researchers have argued that palatability is an important factor in 
enhancing drug treatment adherence through ensuring successful drug administration 
during the therapeutic course in children. A study by Craig et al. (2009) assessed the 
outcome related to children’s treatment and drug administration; these researchers 
emphasised taste and palatability as the most important barrier to treatment of 
children [94].     
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1.10.3. Assessment of the palatability of drugs in children  
Assessment of palatability of various medications is mainly based on the assessment 
of their taste [90]. Studies of palatability assessment have often been conducted in 
adult patients. However, these results may not be applicable to paediatric patients 
[90]. A prospective study conducted by Matsui et al. (1997) to assess the palatability 
of antibiotic drugs in children and adults showed significant differences between 
children and adults regarding the choice of drug that they considered had the worst 
taste [95]. This emphasises the importance of further well-designed palatability 
assessment studies in children. 
Currently, there are several methods for the assessment of taste perception in 
paediatric patients to measure drug palatability [96]. These range from the simple, 
such as verbal judgments, to the advanced, such as taste sensor systems [97]. 
Assessment of palatability of specific medication by evaluating the time needed for a 
drug to be given and observing the verbal judgments after administration of oral 
medications have been considered the most effective ways to compare various 
flavours [96]. In contrast, it has been found that the assessment of medication tastes 
in children younger than 5 years of age is difficult [98].  
Throughout the literature, standardised visual analogue scales (VASs) such as the 
facial hedonic method are widely used to assess children’s perception to the tastes of 
drugs [99, 100].  
In a systematic literature review of palatability testing of medications in children, 
Davies and Tuleu (2008) reviewed 30 articles published between 1984 and 2008. 
They showed that approximately half of the included articles used a facial hedonic 
scale ranging from 2 to 10 points, with a 5-point scale being the most common [101]. 
In addition, it has been found that facial scales can be applied to assess drug 
palatability in paediatric patients as young as 3 years of age, while VASs are widely 
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used for children aged 6 years and older (Figure 1.3) [100-102]. Parents’ opinions 
regarding the taste and acceptability of oral sedatives have been used to assess the 
palatability of oral medicines in children with developmental disabilities and children 2 
years old and younger using the parents’ reaction to the facial reaction of the child 
based on a modified 10-cm VAS incorporating a 5-point facial scale (1 = really good, 2 
= good, 3 = not sure, 4 = bad, 5 = really bad [101]. Furthermore, it has been found 
that the time a nurse needs to give the drug to a child has been preferred as an 
effective method for measuring the effect of various flavours on the acceptance of 
medications in children younger than 5 years [103]. Open questionnaires can only be 
used for older paediatric patients who are able to clearly articulate their responses. In 
fact, a validated assessment scale is preferred because it provides a standardised 
assessment form to determine the palatability of various medications. Such a 
measurement scale avoids biases that may occur via the use of ranking alone [101]. 
 
Figure 1. 3: A 10-cm visual analogue with a facial hedonic scale  
 
  
 
         This figure retrieved from Matsui (2007) [90]. 
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1.11 Common drugs used for sedation in children  
Some of the most commonly used drugs for sedation in children include sedative-
hypnotics, such as benzodiazepines (e.g. midazolam), barbiturates (e.g. 
pentobarbital) and other drugs such as chloral hydrate and propofol. Since analgesic 
properties are lacking in most sedative-hypnotics they are often used in conjunction 
with opioids, such as fentanyl and morphine for acute cases. Dissociative sedation 
(ketamine) and inhalational sedation (nitrous oxide) account for the other two 
prevalent methods for PS. 
 
1.11.1. Mechanisms of action 
The different pharmacological effects of the sedative drugs are the outcomes of 
interactions at particular receptor locations in the central and peripheral nervous 
systems. One can refer to the receptor kinds and anatomical sites as possibly identical 
in nature or markedly dissimilar; however, the general effects are complementary to 
one another in the sedative-analgesia system [104]. 
The major inhibitory neurotransmitter in the nervous system is Gamma aminobutyric 
acid (GABA) [105]. The discharge of this neurotransmitter comes from the terminals 
of presynaptic neuron cells into the synapse and carries out its activities by being 
attached to its own GABA receptor [105]. This in turn hinders the process of 
transmitting neuronal cells and eventually prevents the distribution of action 
potentials via the Central Nervous System (CNS),  producing sedative effects[105]. An 
influx of chloride (Cl) ions is triggered when GABA opens Cl channels. 
Hyperpolarisation of the neuron  results from the Cl ions influx, which ultimately 
prevents neuronal release [106]. The entry of calcium into the cell reverses the 
hyperpolarisation action [106].  
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There are three kinds of GABA receptors; namely GABA-A, GABA-B and GABA-C 
receptors [105]. GABA-A receptors are acted on by a number of sedative agents, 
while the binding of these receptors can lead to a decrease in neuronal firing 
percentage [105]. Consisting of numerous forms, such as alpha, beta, and gamma, 
the GABA-A receptor subunit is thought to be the functional unit on which 
benzodiazepines and barbiturates function [105].  
 
 Inhalation agents  
 Nitrous oxide (N2O) 
Mild analgesia and anxiolytic effects are produced through inhaling nitrous oxide. It is 
usually used at concentrations that range between 30% and 70% with oxygen making 
up the rest of the combination [107]. There is a rapid onset of action within 30 to 60 
seconds; an optimal impact after about five minutes, and swift recovery upon 
stoppage [107].  
 Mechanism of N2O-induced anxiolysis.  
N2O is likely to act through the benzodiazepine binding site given that its effects are 
stopped by flumazenil. Aminobutyric acid (GABA) activation of its binding site is thus 
facilitated through this action, causing a chloride ion influx [108]. In addition, 
activation of calmodulin (CaM) is caused by the added chloride ion concentration in 
the neuron, which then leads to the enzyme nitric oxide synthase (NOS) being 
triggered [108]. The amino acid L-arginine (L-Arg) is then transformed by NOS into L-
citrulline (L-Cit) and nitric oxide (NO), thus stimulating the enzyme soluble guanylyl 
cyclase and producing the second messenger cyclic guanosine monophosphate (cyclic 
GMP) [108]. The cyclic GMP stimulates a cyclic GMP-dependent protein kinase (PKG), 
which results in the anxiolytic drug effect. 
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 Mechanism of N2O-induced analgesia.  
The neuronal release of endogenous opioid peptide or dynorphins (DYNs) is thought to 
be stimulated by N2O; however, nothing is known with regards to the molecular 
features through which this process is instigated [108]. L-arginine (L-Arg) is taken up 
by the presynaptic nerve terminal, with L-Arg being transformed by the enzyme nitric 
oxide synthase (NOS) into L-citrulline (L-Cit) and nitric oxide (N2O) [108]. It seems 
that NO is included in the stimulated DYNs discharge [108]. While passing the 
synaptic cleft, DYNs activate postsynaptic opioid receptors, which are part of the 7-
transmembrane–spanning, G protein–coupled superfamily of receptors [108].  
It can also be shown that N2O can affect the descending inhibitory pathways. N2O can 
also trigger the discharge of endogenous opioid peptides (EOP), thus initiating opioid 
receptors on -aminobutyric acid (GABA)-ergic pontine nuclei [108]. In the meantime, 
this pathway triggers the descending noradrenergic system in the dorsal horn of the 
spinal cord [108]. This process leads to the direct or indirect inhibition by means of a 
GABA interneuron of the nociceptive processing at the point of the principal afferent 
and second-order neurons that convey sensory signals up the ascending nociceptive 
pathway [108]. 
Nitrous oxide should be administered with oxygen in order to avoid hypoxia [109]. 
During mild or moderately painful invasive procedures, N2O can be given alone or in 
combination with one of the other sedative drugs with a mild sedative effect, such as 
midazolam [110].  It is often used in a 50% concentration (50% N2O and 50% O2) as 
a premixed drug [111]. It can also be given in a 70% concentration and it has been 
found to be effective and safe in children. According to a study by Babl et al (2008), 
the use of high concentrations of  nitrous oxide (70%) as a single sedative agent in 
762  children for procedural sedation was found to be effective and safe [112]. 
Moreover, this drug has mild cardiopulmonary adverse effects even when it is 
combined with a strong sedative such as pentobarbital [113]. A study done by Griffin 
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et al. (1981) failed to indicate any substantial risk of cardiopulmonary depression after 
administering nitrous oxide during 3,000 paediatric invasive procedures [113]. 
 
 Dissociative agent  
 Ketamine  
Ketamine is a dissociative sedative agent derived from phencyclidine compound. It 
has both amnesic and analgesic effects [114]. These effects are often dose 
dependent. For example, its analgesic effect occurs at a low dose; in contrast, its 
sedative effect (dissociative sedation) occurs at a high dose [114]. Ketamine 
selectively depresses the basic operation of the associative cortex and thalamus, while 
improving the activity in the limbic systemic, causing an operational separation 
between the thalamus and the limbic cortex [104]. This process leads to a cataleptic-
like state of unconsciousness, known as dissociative anaesthesia [104]. Involving non-
competitive inhibition of the N-methyl- D-aspartate (NMDA) receptor, a glutamate- 
gated cationic channel selective for calcium appears to be Ketamine’s principle action 
[104, 115]. In terms of this NMDA glutamate receptor subtype, it is part in the 
extended potentiation of synaptic responses linked to the wind-up, central 
sensitisation phenomena [104, 115]. It is also possible that Ketamine would be 
involved with subcategories of endogenous opioid receptors, monoaminergic and 
muscarinic, cholinergic receptors [114].  
Ketamine produces rapid sedation because it has a short half-life of approximately 5 
minutes. It can be administered through various routes; however the intravenous 
route has been clinically proven as the most effective and safest route in a study of 
11,000 paediatric patients [116]. Emergence reactions are one of the major 
drawbacks of ketamine. Emergence phenomena include hallucinations, vivid dreams 
and delirium. Benzodiazepines were found to be effective in prevention of these 
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symptoms [117]. Increased blood pressure, heart rate, and intracranial pressure are 
some of the commonly associated adverse effects. Laryngospasm has been reported 
in a few patients [118]. 
 
 Sedatives with hypnotic effect  
 Chloral hydrate/ triclofos 
Chloral hydrate is a central nervous depressant that has been widely used as 
sedatives in paediatrics for many years [119, 120]. It is a pure sedative-hypnotic drug 
without analgesic properties. In the body, chloral hydrate and triclofos are rapidly 
metabolised and converted to trichlorethanol, which the active metabolite [121]. It 
enhances the action of GABA at GABA (A) receptors, through binding to specific 
receptor locations thereby increasing its inhibitory actions on neurons of central 
nervous system to produce it’s sedation effect [105, 122]. 
Chloral hydrate was introduced for medical use in 1869 by German physician called 
Lieberch [123] and its use in children was begun in 1894. Its effectiveness as a 
sedative drug for non-invasive diagnostic procedures especially CT and MRI has been 
well established with more than 85% success rate recorded [120, 124]. It  is thought 
to be very effective in paediatric patients younger than two years old undergoing non-
invasive procedures [123].  
In the UK chloral hydrate is recommended by National Institute of Health and Care 
Excellence (NICE) guidelines for painless diagnostic imaging procedures in children 
under 15 kg [80]. It produces a relatively mild to moderate sedation effect when 
given orally in doses from 50 to 75 mg/kg [125]. Major drawbacks are the 
unpredictability of its onset of action, prolonged duration of its sedative effect and 
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poor taste [42, 46, 126]. Common AEs are  respiratory complication and vomiting 
[127]. 
Triclofos is a phosphoric ester of trichlorethanol (chloral hydrate active metabolite). It 
was indroduced in UK by Glaxo in 1962 [128]. Its onset of action is about 30 to 45 
minutes [129]. Both chloral hydrate and its active metabolite are effective and safe as 
sedatives and hypnotics [130]. However, triclofos is thought to have a more pleasant 
test and is less of a gastric mucosa irritant than chloral hydrate [129].   
 
 Barbiturates 
A class of sedative recognised for deep sedation, hypnosis, loss of memory, and 
anticonvulsant characteristics but no inherent analgesia is Barbiturate [121]. The 
interaction of barbiturates with the inhibitory neurotransmitter gamma-aminobutyric 
acid (GABA) occurs through attachment to, and instigation of, the GABA-A receptor 
subunit. Increased chloride current conductance can be caused by GABA-A receptor 
initiation, leading to the postsynaptic membrane being hyperpolarised and 
postsynaptic neurons being inhibited [104, 105]. 
It is possible that barbiturates will also imitate the action of GABA resulting in the 
chloride ion channels being directly activated [104, 105]. Excitatory alpha-amino-3-
hydroxy- 5-methyl-4-isoxazole propionic acid (AMPA) subtypes of glutamate receptors 
are also inhibited by Barbiturates [104]. The CNS sedative impacts of barbiturates, 
are therefore dependent on the initiation of inhibitory GABA-A receptors and the 
inhibition of excitatory AMPA receptors [104]. Barbiturates selectively depress 
neurotransmission within the peripheral nervous system by inhibiting the excitatory 
autonomic ganglia and nicotinic cholinergic, acetylcholine receptors [104]. Similarly, 
barbiturates are able to reversibly impair the action of the majority of excitable neural 
tissues, especially suppressing polysynaptic neuron responses [104]. They are also 
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responsible for suppressing the reactions of the reticular activating system in the 
brainstem which ensures the regulation of the level of consciousness, in addition to 
key respirational and cardiac roles [104].  
 
 Secobarbital 
Secobarbital is a barbiturate derivative agent which was previously known as 
quinalbarbitone. It is an intermediate acting agent which is well absorbed from the GI 
tract and its doses for sedation in children range from 7.5 to 10 mg/kg (maximum of 
200 mg) [131]. A study conducted in the UK to evaluate secobarbital safety and 
effectiveness in 40 children with mean age of 32 months showed that adequate 
sedation was achieved in 34 (85%) children [131]. The success rate was better with 
children younger than 5 years (91%), with sedation onset time ranging from 10 to 50 
minutes. The most common reported adverse event was Paradoxical excitement 
[131].  
 
 Pentobarbital 
This is occasionally used in paediatric patients and can be effective for non-invasive 
procedures needing complete immobility [124, 132]. With intravenous titration, 
sedation is evident in 3–5 min with a duration of roughly 30–40 min [68]. 
Pentobarbital is often associated with respiratory depression; however, this unwanted 
effect can be tolerated by healthy paediatric patients [70]. Hemodynamic adverse 
effects are the most common effects of this drug, particularly in hypovolemic 
paediatric patients and those with history of hemodynamic instability [133].   
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 Benzodiazepines 
There are a group of highly lipophilic agents with anxiolytic, amnesic, anti-depressant 
and hypnotic features. As in the case of barbiturates, benzodiazepines enhance the 
action of the inhibitory neurotransmitter GABA by attaching to the GABA-A receptor 
subtype at a particular location different from that of the GABA binding position on the 
receptor [134]. This increases chloride ion channel conductance resulting in a 
hyperpolarised postsynaptic membrane and decreased neuronal excitability. 
Benzodiazepine- receptor binding largely takes place on the postsynaptic nerve 
membranes mostly within the cerebral cortex [104]. As opposed to barbiturates, 
GABA-A receptors are not directly activated by benzodiazepines, which instead 
modulate GABA binding [104]. The attachment of benzodiazepines to distinctly 
different specific GABA-A subunits is considered as to be the mechanism of the 
particularly different pharmacologic properties of the benzodiazepines [104].  
It could be that benzodiazepine-sensitive GABA receptors with alpha-1 subunits are 
the most significant in terms of regulating sleep and are the assumed targets of 
depressant-hypnotic agents and anterograde amnesia [135]. Similarly, 
benzodiazepine-sensitive GABA-A receptors with alpha-2 subunits could be as equally 
essential for the regulation of anxiety and are targets of anxiolytic agents [135]. The 
benzodiazepine antagonist flumazenil attaches to GABA-A receptors and is used 
clinically to quickly antagonise the impact of benzodiazepine overdoses  [105].  
 Midazolam  
Midazolam is the most common benzodiazepine used for procedural sedation. It 
produces anterograde amnesia which is considered as a positive feature of this drug 
[92]. In a randomised double blind study evaluating the effectiveness of midazolam 
and fentanyl as sedative drugs for invasive oncology procedures in paediatric patients; 
72% of children preferred midazolam, while fentanyl was preferred by only 28% (P = 
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0.0278). This was reported to be due to the midazolam amnesic effect [136]. 
Predictable induction time and short duration of action are the most important 
advantages that make it one of the most popular sedative drugs [92].  
It can be administered orally, buccally, intranasally, and rectally. When it is given 
orally, the onset of action starts after 10-30 minutes and lasts for approximately 60 
minutes. The bioavailability of this drug is less than 50% due to the first pass effect of 
the liver [137]. It rapidly crosses the blood brain barrier because of its lipophilicity 
[138]. The volume of distribution of midazolam is large and the elimination half-life, of 
approximately 1.2 hours, is short [139]. The action of intravenous injection is more 
rapid than oral; the effect starts within 30 to 60 seconds and lasts for approximately 
from 15 to 80 minutes [140]. The most common adverse effects reported are gastro 
intestinal upset. In addition, it can lead to paradoxical reactions, hiccups, and 
dyspnoea [141].  
 
 Paraldehyde  
Paraldehyde is one of the oldest sedative drugs; it also possesses hypnotic and 
anticonvulsant properties. It was synthesized by Wildenbusch in 1829 and first used in 
various industrial and medical preparations [142].  Paraldehyde was introduced into 
clinical practice by an Italian physician named Vincenzo Cervello in 1882 [142].  The 
mechanism by which paraldehyde produces its effect is still unclear, however it may 
produce imbalances between facilitatory and inhibitory mechanisms by depressing 
various levels of the central nervous system including the ascending reticular 
activating system [142]. 
Paraldehyde is rapidly absorbed after administration via oral, intramuscular (IM) or 
rectal routes.  It can be given rectally after mixing with olive oil [143]. Caution is 
needed in the administration of paraldehyde as it can melt plastic [143]. However, a 
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plastic syringe will not be affected if the enema solution is drawn up and administered 
within 10 minutes [143]. It produces its action within 10 to 15 minutes after oral 
administration and within 2 to 3 minutes after IM injection. It is widely distributed and 
has a half-life ranging from 8 to 27 hours (7.5 hours). Approximately 80 to 90% of 
the drug is metabolised in the liver to acetaldehyde and approximately 30% is 
excreted in expired air unchanged by the lungs. This gives an unpleasant odour to the 
breath of paraldehyde treated patients. Only trace amounts are excreted in the urine. 
 
 Propofol  
Propofol is an extremely lipid-soluble, ultrashort-acting alkyl phenol agent with clear 
depressant features. In spite of offering no analgesia, propofol has the potential to 
induce a condition of deep sedation, enabling painful procedures to be tolerated [114]. 
It is believed that propofol works through the enhancement of inhibitory GABA 
neurotransmission by reducing the GABA receptor dissociation percentage, hence 
enhancing the conductance of chloride ion channels, hyperpolarisation of the 
postsynaptic cell membrane, and inhibition of neuron initiation. Propofol’s action is 
fairly selective in the modulation of the GABAA receptor [144].  
Following a single intravenous dose, there is a rapid effect within 30 to 45 seconds, 
and quick effect- site equilibration time [104]. As for the effect length, it is short (five 
to 10 minutes), mainly as a result of redistributing into peripheral tissues [104]. 
Because of the wide-ranging inconsistency in the therapeutic window for dosing 
propofol, should be titrated to effect [145].  
The most frequent adverse effect of propofol is profound respiratory depression which 
can be associated with airway obstruction. Cravero and colleagues evaluated the 
incidence of adverse events during children sedated with propofol from 2004 to 2007 
and they found that hypoxia and airway obstruction occurred 154 and 575 times 
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respectively per 10,000 propofol administrations [57]. Another serious adverse event 
of propofol is “propofol infusion syndrome” which can occur due to long term infusion 
of propofol for sedation of critical ill children in intensive care units [146]. This 
syndrome is characterized by the incidence of severe metabolic acidosis and 
rhabdomyolysis i.e the rapid breakdown of muscle tissues accompanied by liver 
enlargement, lipaemia, heart failure and hyperkalemia [146, 147]. 
 
 Alpha-2 Adrenergic Agonists 
These include clonidine and dexmedetomidine and have depressant as well as dose-
dependent analgesic features [148]. It is thought that this analgesia results from an 
agonist interaction with presynaptic alpha-2 Adrenergic receptors positioned on small 
primary afferents, which reduces the transmitter discharge [148]. Furthermore, these 
agonists are believed to interact with postsynaptic alpha2-adrenergic receptors on 
projection neurons[148]. This process results in the hyperpolarisation of the cell by 
enhancing the potassium conductance by Gi coupled potassium (K) channels[148]. 
Apart from their subarachnoid analgesic properties, alpha-2 agonists generate dose- 
dependent sedation at supraspinal position [148]. It is thought that the mechanism of 
sedation is the same as the analgesic activity via postsynaptic alpha-adrenoreceptors 
and inhibitory G proteins [149].  
 Clonidine 
Clonidine is an alpha-2 agonist with sedative, anxiolytic and analgesic properties 
[150]. It inhibits the release of peripheral norepinephrine by stimulation of the 
inhibitory alpha-2 adrenoceptors [151].  
Clonidine is absorbed rapidly after oral administration [150] with a bioavailability of 75 
to 95% [150]. Approximately 20-40% of clonidine is bound to plasma proteins [151].  
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50% of the active drug is metabolised in the liver and excreted in the urine as inactive 
metabolites [150]. The half-life of the drug ranges from 12-33 hours [151].  
Clonidine clearance in neonates is around one-third of that in adults due to immature 
elimination pathways; by one year of age it reaches approximately 82% of adult rate 
[152]. Administration of 2.5 microgram/kg of clonidine by the rectal route in children, 
about 20 minutes prior to induction of anaesthesia has been shown to achieve drug 
plasma concentrations known to be effective in adults [153].   
Intravenous administration of 1 microgram/kg/hour of clonidine with 50 
microgram/kg/hour of midazolam was not associated with substantial changes in 
blood pressure and heart rate and was associated with satisfactory sedation scores 
[154]. Therefore clonidine use as a sedative was found to be cardio-stable when used 
with midazolam in critically ill ventilated infants [155].  
 
 Dexmedetomidine 
Dexmedetomidine is a highly selective α-2 receptor agent with analgesic and hypnotic, 
effects [114]. It has advantages such as: natural sleep stimulation, absence of 
respiratory depression, and cooperative sedation – patients are often able to follow 
simple orders during the procedure [156]. However, intravenous administration of 
dexmedetomidine may lead to cardiovascular complications like bradycardia and 
hypotension [157]. Dexmedetomidene can be administered via the oral, intranasal, 
submucosal and intravenous routes. This drug has been shown to be effective in 
paediatrics patients with autism [158]. According to a recent study by Mason and 
colleagues (2009), dexmedetomidine did not interfere with or impair EEG results 
[159]. Thus it is often useful for sedation prior to EEG in paediatric patients.  
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 Sedatives with analgesic effects 
In terms of this category of medicines, they are largely utilised for invasive processes, 
including dental activities and wound management procedures. In addition, their 
analgesic effects may be improved by combination with other hypnotic or anxiolytic 
agents [160]. The drugs most widely used in children are fentanyl and ketamine.  
 Fentanyl 
This opioid agonist is widely utilised in children in painful procedures. It is a potent 
opioid that has no intrinsic anxiolytic or amnesic characteristics [107]. The opioid 
receptors interact with inhibitory G-proteins, closing N-type voltage-operated calcium 
channels and opening potassium channels leading to hyperpolarisation. In addition, 
they reduce intracellular cyclic adenosine monophosphate (cAMP) by reducing 
adenylate cyclase [161].  
It has a rapid onset of action and high protein binding properties. It reaches peak 
blood concentrations within 4-5 minutes thus it should be administered 4-5 minutes 
before an invasive procedure [131]. Administration of fentanyl in combination with 
other sedative agents provides a synergistic effect resulting in an increased sedative 
effect [160]. Pruritus, vomiting and respiratory depression are the most common 
adverse effects of fentanyl, accounting for 44%, 15-20% and 5% of all adverse effects 
respectively [162]. 
 
1.12 The aims of this thesis 
Because of the increasing use of sedation in paediatric practice, research is needed to 
evaluate its safety and effectiveness in current practice  
The first aim of this thesis was to evaluate, as accurately as possible, the safety and 
clinical effectiveness of some of the most commonly used sedative agents in children. 
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The local hospital’s sedation policy (Derbyshire Children’s Hospital) and the national 
UK NICE guidance were used as a guide [80]. Therefore, systematic reviews of the 
literature on safety and clinical effectiveness of chloral hydrate and midazolam were 
conducted (Chapter 2, 3, and 4). The aims were as follows: 
 To evaluate the effectiveness and the incidence of adverse events reported for 
sedative agent (chloral hydrate and triclofos) during each type of procedural 
sedation including: painless, painful, and treatment procedures (Chapter 2 and 
Chapter 3) 
 To evaluate the effectiveness and the incidence of adverse events of midazolam 
during diagnostic imaging procedures (Chapter 4) 
 
The second aim was to evaluate paraldehyde effectiveness and safety for procedural 
sedation in children. Paraldehyde is part of the local hospital sedation policy, as a 
second line agent. There is very little research available about its use for procedural 
sedation in children, as it is mainly used for treatment of convulsive episodes in 
patients with tetanus and status epilepticus [163].  It was therefore decided to 
conduct a systematic review to evaluate paraldehyde as a sedative agent during 
procedural sedation in paediatric patients (Chapter 5). 
Based on the results from the previous chapters, it was noticed that the palatability of 
oral sedative agents plays a major role in drug acceptance and therefore treatment 
adherence. The subject of palatability was explored further by conducting a literature 
review to assess the palatability of the two most commonly used oral sedative agents 
(chloral hydrate and midazolam) (Chapter 6) and a prospective pilot study was 
performed to assess the palatability of these medicines in a Children’s Hospital setting 
(Chapter 7). 
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 The literature review aimed primarily to evaluate the current published clinical 
evidence concerning the palatability of chloral hydrate and midazolam in children. 
The secondary aim was to review the methodology used in previous studies of 
sedative agents to inform the protocol for the prospective study (Chapter 6). 
 The primary aim of the study was to examine children’s opinions on the taste and 
acceptability of oral chloral hydrate and midazolam (Chapter 7).  
 The secondary aims were as follows: 
 To examine nurses’ and parents’ opinions on the taste and acceptability of 
the given sedative agents.  
 To assess if there could be a relationship between the drug acceptability 
and the success rate of procedural sedation.  
 To assess the requirement of supplemental sedation during procedures. 
 
Due to the fact that I am from the kingdom of Saudi Arabia and will return to work 
there as a pharmacist, the final part of my thesis evaluated the use of sedation in 
children (outside the operating theatre) in the Middle East countries. This was 
achieved through conducting a systematic review of the literature and also assessed 
the use of practical sedation guidelines in these countries (Chapter 8). 
Finally as little information was found in the previous literature review, a survey was 
conducted to evaluate the current practice of sedation in Saudi Arabia. This survey 
aimed to evaluate the views of practitioners on; use of sedation, availability of 
guidelines, the drugs currently being used and the level of practice being undertaken 
(Chapter 9).  
Chapter 10 contains the conclusions of the thesis. 
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CHAPTER TWO 
Systematic Review of Chloral Hydrate for 
Procedural Sedation in Children; An analysis of 
its safety and effectiveness 
Part 2.1.Chloral Hydrate for Painless Procedural 
Sedation 
2.1.1. Introduction  
Paediatric patients undergoing painless diagnostic procedures such as computer 
tomography (CT) scanning are frequently sedated with the aim of reducing anxiety 
and enabling a successful procedure by helping the child to remain still [2, 164]. The 
ideal sedative drug for procedural sedation (PS) would be an agent that has a rapid 
onset of action and a short half-life, allowing easy titration of response and a quick 
recovery time [165]. In addition, it would have few adverse events (AEs). 
Unfortunately it is difficult to find a single sedative agent that possesses all these 
properties [123].  
Several sedative drugs, such as chloral hydrate, nitrous oxide and the 
benzodiazepines, are available for procedural sedation in children.  Chloral hydrate is a 
central nervous depressant that has been widely used as a paediatric sedatives [119, 
120]. Assessment of clinical studies evaluating its safety and effectiveness, 
particularly for painless diagnostic procedures in children is important.  
A systematic literature review was designed to evaluate the clinical effectiveness and 
toxicity of chloral hydrate for painless PS in children (≤18 years). 
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2.1.2. Methods 
A systematic literature search for articles, evaluating chloral hydrate safety and 
clinical effectiveness  in children up to the age of 18 years was electronically 
conducted using four medical databases including: MEDLINE (1948 to January 2012) 
and EMBASE (1980 to January 2012) , COCHRANE (1974 to January 2012) and 
CINAHL (1974 to January 2012). EMBASE, MEDLINE, and COCHRANE library were 
searched separately and then combined to remove duplications. The CINAHL database 
was searched and reviewed manually to remove duplication and relevant articles 
identified.  
The keywords involved in this systematic review were selected based on their 
sensitivity and specificity according to the validated age specific search strategy by 
Hedges Team [166]. Therefore, the most sensitive and specific keywords were as 
following: chloral hydrate AND children OR infant OR pe*diatric* OR neonate OR 
adolescence OR adolescences or adolescent AND sedation. 
All retrieved abstracts were reviewed according to the study inclusion criteria; original 
studies assessing or reporting the safety (AEs) and/or effectiveness of chloral hydrate 
as a sedative agent in children and adolescents from birth up to 18 years, undergoing 
painless procedure(s). All languages were included in this systematic review.  The 
exclusion criteria were: studies that evaluated or reported the use of chloral hydrate 
for other uses rather than painless procedural sedation as well as letters, comments, 
editorials or review articles.  The full articles of all related abstracts were read 
carefully according to the study inclusion and exclusion criteria.  
Articles were classified according to the type of painless PS, according to Sury 
(2004)[16] and all related data including: sample size, study region, study period, 
study design, dose of chloral hydrate, AEs of chloral hydrate, other used sedative drug 
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(s), supplementary dose of sedative drug(s), induction time of sedation, duration of 
sedation, failure rate, success rate were extracted onto a data collection sheet.   
paediatric patients  were grouped into the following age groups: preterm neonates 
(<36 weeks gestation, 0–27 days); full-term neonates (0–27 days, >37 weeks 
gestation); infants and toddlers (28 days to 23 months); children (2–11 years); and 
adolescents (12–17 years)[167].  
The primary endpoint was to evaluate the toxicity of chloral hydrate, while the 
secondary endpoint was to evaluate chloral hydrate clinical effectiveness. According to 
the European Medicines Agency (EMA) [50], AEs were categorised according to their 
severity into serious or mild AEs. A serious AE is defined as “any untoward medical 
occurrence that at any dose: results in death, is life-threatening, requires inpatient 
hospitalisation or prolongation of existing hospitalisation, results in persistent or 
significant disability/incapacity, or is a congenital anomaly/birth defect”. A mild AE is 
defined as “any AE that occurred that did not need any intervention” ([50]). 
Successful procedural sedation was defined as the ability to sedate the child to the 
targeted sedation level and the completion of designated painless diagnostic 
procedures. 
The quality of all included studies was assessed in order to assess bias risk. The 
studies’ quality was assessed by two reviewers (BS and HS) independently. Jadad 
scoring checklists for harm reporting were used to evaluate randomised clinical trials 
(RCTs) [168]. For all RCTs to be considered as good quality, rating should be ≥ 3 out 
of five criteria according to the Jadad scoring checklists. The qualities of prospective 
observational and retrospective studies were assessed using the STROBE checklist 
[169]. Any study with a minimum score of 70% was considered a good quality study.   
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Data from included clinical studies were analysed statistically using SPSS version 22. 
The chi-squared test was used to determine the association between success rates of 
each type of diagnostic procedure. At p<0.05, differences were considered statistically 
significant. Incidences were calculated for AEs, excluding case reports. Incidences 
were calculated by dividing the total number of AEs by the total number of children 
exposed to chloral hydrate. Meta-analysis was not performed due to the heterogeneity 
of the studies. 
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2.1.3. Results 
2.1.3.1. Overview  
Our search strategy identified a total of 1781 articles. After reviewing the abstracts of 
these articles, 1246 articles were excluded because they did not fulfill the inclusion 
criteria (figure 2.1.1). The full texts of the remaining articles (535 articles) were read 
carefully and 69 articles met the study inclusion criteria.  
Figure 2.1. 1: Flow diagram of search and review process 
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The studies were published between 1972 and 2011. The total number of children who 
received chloral hydrate was 15238, the age ranged between birth and 18 years. 
These studies were conducted in 11 different countries, most (40) took place in the 
Americas (38 in United States of America (USA), one in each of Canada and Chile); 19 
in Europe (five in Italy, four in Spain, two in Germany, two in United Kingdom, two in 
Belgium, one in each Greece, one in France, one Norway and one in Turkey); eight in 
Asia (two in Israel, one in each China, Iran, Japan, Jordan, Kingdom of Saudi Arabian 
and in Thailand) and two in Australia. Chloral hydrate was administered orally in the 
majority of the studies (65 studies). The most common study methodology was the 
prospective observational studies (9055 patients), followed by retrospective studies 
(5472 patients). Twenty (29%) of the studies involved infants younger than two years 
(Table 2.1.1).  
The chloral hydrate dose ranged from 25 to 100 mg/kg (median 100 mg/kg maximum 
2g). Procedural sedation indications were CT and/or MRI, EEG, ECG, BAEP and 
pulmonary function test. Oral route (94%) was the most common route of 
administration (Table 2.1.1). 
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Table 2.1. 1: Summary of 69 studies that reported on clinical effectiveness 
and safety of chloral hydrate in children 
Studies’ characteristics No. of studies  No. of children 
Type of study N=69 N=15238 
 Prospective observational 33 9055 
 Retrospective 15 5472 
 Case report 11 16 
 Randomised controlled trial 10 695 
Type of procedure   
 CT and/or MRI  51 10863 
 ECG 6 2272 
 EEG 6 430 
 BAEP 3 1646 
 Pulmonary function test 3 27 
Route of Administration            
 Oral/ dose range (median mg/kg) 65/25 to 100 mg/kg (100) 15184 
 Rectal/dose range (median mg/kg) 4/55 to 77mg/kg (75) 54 
Age groups   
 Preterm neonates 0 0 
 Term neonates 0 0 
 Infants 20 2705 
 Children  7 1933 
 Other patient age groups*                                                                                                42 10600
* Studies involving multiple age groups (the number of patients within each age group was not 
documented)  
BAEP = Brainstem auditory evoked potential, (CT) =Computerised Tomography scan, (ECG) = 
Electrocardiogram test, (EEG) = Electroencephalogram test, (MRI) = Magnetic Resonance Imaging 
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2.1.3.2. Trial quality 
 Ten RCTs compared the effectiveness of chloral hydrate versus other sedatives (Table 
2.1.1). Two studies fulfilled all 5 Jadad scoring criteria. Six studies met >3 criteria or 
more whereas 2 studies met ≤ 2 criteria (Figure 2.1.2, Table 2.1.2). The scores for 
the STROBE checklist for observational studies are illustrated in table (2.1.3). 30 of 
the 48 pooled observational studies were rated with above 70%.  Despite this all 
studies were included in the systematic review to avoid missing any data from these 
articles due to the small number of articles related to each painless procedure. The 
quality scores and selection of paper and abstract were checked by two independent 
reviewers (BS and HS).  
Figure 2.1. 2: Quality assessment criteria of included RCTs 
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Table 2.1. 2:  Quality assessment criteria of included RCTs 
References  Jadad score (out of 5) 
Marti-Bonmati et al. 1995[170] 5 
D'AGOSTINO and TERNDRUP 2000[171] 5 
Malviya et al. 2004[172] 4 
Sury and Fairweather 2006[23] 4 
Layangool et al. 2008[173] 4 
Millichap 1972[174] 3 
Wheeler et al. 2001[175] 3 
Ashrafi et al. 2010[176] 3 
McCarver-May et al. 1996[177] 2 
Thompson et al. 1982[178] 1 
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Table 2.1. 3 Quality assessment criteria of included observational studies 
References STROBE scoring ( out of 22) % 
 
Kannikeswaran et al. 2011[179] 21 95 
Lipshitz et al. 1992[180] 20 91 
Loewy et al. 2005[181] 20 91 
Heistein et al. 2006[182] 20 91 
Manuli and Davies  1993[183] 19 86 
Chung et al. 2000[184] 19 86 
Litman et al. 2010[125] 19 86 
Roach et al. 2010[185] 19 86 
Malviya et al. 1997[46] 18 82 
Thoresen et al.1997[186] 18 82 
Kao et al. 1999[187] 18 82 
Mason et al. 2004[127] 18 82 
Allegaert et al. 2005[188] 18 82 
Avlonitou et al. 2011[189] 18 82 
Strain et al. 1986[132] 17 77 
Pereira  et al. 1993[190] 17 77 
Woolard and Terndrup, 1994[191] 17 77 
Casillas et al. 1995[192] 17 77 
Vade et al. 1995[120] 17 77 
Napoli et al. 1996[193] 17 77 
Rooks et al. 2003[194] 17 77 
Treluyer  et al. 2004[195] 17 77 
Hijazi et al. 2005[196] 17 77 
Wang et al. 2005[197] 17 77 
Cortellazzi et al. 2007[198] 17 77 
Abdul-Baqi 1991[199] 16 73 
Greenberg et al. 1991[68] 16 73 
Ronchera et al. 1992[200] 16 73 
Greenberg et al. 1993[201] 16 73 
Slovis et al. 1993[202] 16 73 
Mallol and Sly 1988[203] 15 68 
Turner et al 1990[204] 15 68 
Ronchera-Oms et al. 1994[205] 15 68 
Malis, Burton 1997[206] 15 68 
Malviya et al. 2000[207] 15 68 
Szmuk et al. 2003[208] 15 68 
Schmalfuss,  2005[209] 15 68 
Hubbard  et al. 1992[210] 14 64 
Merola et al. 1995[211] 14 64 
Beebe et al. 2000[212] 14 64 
Dalal et al. 2006[213] 14 64 
Rumm et al. 1990[119] 13 59 
Temme et al. 1990[214] 10 45 
Filippi et al. 2001[215] 10 45 
Noske and Papadopoulos, 1993[216] 9 41 
Marchi et al. 2004[217] 9 41 
Woodthorpe et al. 2007[218] 9 41 
Eelkema et al. 1977[219] 8 36 
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2.1.3.3. Chloral hydrate effectiveness  
50 studies documented chloral hydrate effectiveness in six painless procedures. 
Eighteen studies described the effectiveness for CT/MRI, 13 studies for MRI, 6 each for 
CT and ECG, 5 for EEG, and one for each BEAP and Pulmonary test. The results will 
now be further explored according to the procedures. 
2.1.3.3.1. CT and/or MRI scans 
Eighteen studies were found. A total of 3854 children aged between 0 and 18 years 
received a median dose of 64 mg/kg, while 19 children with age range from 6 months 
to 6 years received 75 mg/kg rectally. Only 972 children were younger than five years 
old.  
Therapeutic success was achieved in a median of 98% (94% to 100%) of patients. 
Children younger than five years old had a higher success rate, median 99% (98% to 
100%).  
232 (6%) children given chloral hydrate required sedation supplementation such as 
chloral hydrate 25 mg/kg and 2 mg/kg meperidine intramuscularly [46, 214] 
respectively (Table 2.1.4). 
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Table 2.1. 4: RCTs and observational studies for CT/MRI scan 
Reference, 
country  
Study 
design  
Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success rate 
(%) 
Supplementary 
(No.) 
Sedation (min) 
Onset Duration 
D'AGOSTINO 
and TERNDRUP 
2000, USA 
[171] 
Double-blind 
RCT 
2 months-8 
years 
11 
22 
CH  
M 
75 PO 
0.5 PO 
100 
50 
Y (1) 
Y (12) 
NA 
NA 
mean 95 
mean 76 
RUMM, TAKAO 
et al. 1990, 
USA[119] 
Prospective 
study 
2 months- 14 
years 
50 
 
CH  
 
25- 81 PO 87 Y (3) 
 
30 NA 
Temme, 
Anderson et al. 
1990, 
USA[214] 
Prospective 
study 
1 months- 18 
years 
350 
 
CH  
 
50 PO 
 
98 
 
Y (5) 
 
30-60  NA 
Vade, Sukhani 
et al. 1995, 
USA[120] 
Prospective   1- 4 years 191 
 
CH  
 
50-100 PO 
 
99 Y (10) 
 
30 NA 
 
Malis and 
Burton 1997, 
USA[206] 
Prospective 
study 
0- 5 years 31 CH 61 PO 94 NA 
 
NA NA 
Malviya, 
Voepel-Lewis et 
al. 1997, 
USA[46] 
Prospective  
study 
0- 18 years 336 CH Mean 13 PO 
 
77 Y (34) NA NA 
Kao, Adamson 
et al. 1999, 
USA[187] 
Prospective  
study 
2 months– 11 
years 
80 CH 
 
47-100 PO 89 Y (14) 24 NA 
CH: Chloral hydrate, M: Midazolam, PO: Orally, Y: Yes, NA: Not available.
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Table 2.1.4: RCTs and observational studies for CT/MRI scan 
Reference, 
country  
Study 
design  
Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
(No.) 
Sedation (min) 
Onset Duration  
Chung, Hoffer 
et al. 2000, 
USA[184] 
Prospective  
study 
2- 13 months 16 
 
CH 50-100 PO 100 N 19 83 
Malviya, 
Voepel-Lewis 
et al. 2000, 
USA[207] 
Prospective  
study 
0- 18 years 854 
 
CH  
 
62 PO 
 
98 NA 30  NA 
 
Rooks, Chung 
et al. 2003, 
USA[194] 
Prospective  
study 
3- 9 months 358 CH  
 
50 PO 
 
99 
 
NA 16 86 
Szmuk, Kee 
et al. 2003, 
USA[208] 
Prospective  
study 
Mean 5.7 years 26 
 
  
CH  
 
50-100 PO 
 
99 NA 
 
NA NA 
Treluyer, 
Andre et al. 
2004, 
France[195]  
Prospective  
study 
6months- 6years 19 CH 75 PR 83.3 NA 
 
18.6  NA 
Hijazi et al., 
2005, 
KSA[196] 
Prospective  
study 
0-12 years 148 CH 100 PO 
 
79 Y (31) 30 NA 
Schmalfuss 
2005, 
USA[209] 
Prospective  
study 
Mean 28.2 
months 
310 CH 65.2 PO  94 NA 
 
30-60  NA 
CH: Chloral hydrate, PO: Orally, N: No, NA: Not available. 
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Table 2.1.4: RCTs and observational studies for CT/MRI scan 
Reference, 
country  
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
(No.) 
Sedation (min) 
Onset Duration  
Hubbard, 
Markowitz et 
al. 1992, 
USA[210] 
Retrospective  
study 
1 day- 18 years 524 CH 60-75 PO 
 
98 Y (131) 20-30 NA 
Manuli, 
Davies 1993, 
USA[183] 
Retrospective  
study 
1 months-14 
years 
88 
 
CH  
 
50-100 PO 
 
80 NA 28 66 
MEROLA et 
al. 1995, 
USA [211] 
Retrospective  
study 
1 months-17 
years 
131 CH  
 
75 PO 
 
NA 
 
Y (3) NA NA 
Mason, 
Sanborn et 
al. 2004, 
USA[127] 
Retrospective  
study 
6-365 days 
 
331 
 
  
CH  
 
50 PO 
 
98 N 
 
NA NA 
CH: Chloral hydrate
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2.1.3.3.2. MRI procedures 
A total of 5484 children aged between birth and 15 years were treated within 13 
studies. These children received a median dose of 75mg/kg of oral chloral hydrate. 
There were 1930 patients younger than five years, including 1475 (76%) infants 
younger than two years. 448 (8%) children required supplementary sedative drugs, 
only 18 (4%) were children less than two years. Sedation time of chloral hydrate was 
varied (5 to 240 minutes) while the duration of action ranged from 0 to 165 minutes. 
A higher total failure rate of 36% was recorded in patients >5 years old; it did not 
exceed 5% in children aged <5 years old (Table 2.1.5).  
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Table 2.1. 5: RCTs and observational studies for MRI 
Reference, 
country  
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
(No.) 
Sedation (min) 
Onset Duration 
Marti-Bonmati, 
Ronchera-Oms et 
al. 1995, 
Spain[170] 
Double-blind 
RCT 
1.5 months-14 
years 
97 
97 
 
CH  
CH 
70 PO 
100 PO 
64 
87 
Y (14) 
Y (6) 
28 
21  
NA 
NA 
Malviya, 
Voepel‐Lewis et al. 
2004, USA[172] 
Single-blind 
RCT 
2-12 years 35 
35 
CH  
PEN 
75 PO 
2 IV 
97 
81 
Y (13) 
Y (3) 
14-42 22-68 
Sury and 
Fairweather 2006, 
UK[23] 
Double-blind 
RCT 
1- 6 years 50 
48 
  
CH  
TEM+ 
DRO 
50-100 PO 
1+0.25 PO 
100 
80 
Y (14) 
Y (22) 
29 
35 
NA 
NA 
Greenberg, 
Faerber et al. 
1993, USA[201] 
Prospective 
study 
1-11 years 300 CH 100 PO 91 Y (2) 
 
NA NA 
Slovis, Parks et al. 
1993, USA[202] 
Prospective  
study 
0- 8 years 794 CH 50-75 PO 
 
96 Y (35) NA NA 
Ronchera‐Oms, 
Casillas et al. 
1994, Spain[205] 
Prospective  
study 
1 month– 15 
years 
596 CH 
 
64 PO 94 Y (129) 5-240  0-120 
Marchi, Orru et al. 
2004, Italy[217]  
Prospective  
study 
3 months-12 
years 
77 
 
CH 60-80 PO 99 Y (1) 60 NA 
Woodthorpe et al., 
2007, UK [218] 
Prospective  
study 
0- 4years 455 CH 50- 100 PO 97 NA 20-40 45- 60 
CH: Chloral hydrate, PEN= Pentobarbital, TEM+ DRO= Temazepam+ Droperidol 
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Table 2.1.5: RCTs and observational studies for MRI  
Reference, 
country  
Study 
design  
Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
(No.) 
Sedation (min) 
Onset Duration  
Ronchera, 
Martí-Bonmatí 
et al. 1992, 
Spain[200] 
Retrospective 
study 
Mean 42 
months 
172 
 
CH  
 
55 PO 
 
93 NA 30  NA 
 
Beebe, Tran et 
al. 2000, 
USA[212] 
Retrospective 
study 
2 months-14 
years 
448 CH  
 
80- 100 PO 
 
97 
 
NA 69 NA 
Dalal, Murray et 
al. 2006, 
USA[213] 
Retrospective 
study 
16-341 days 102 
 
  
CH  
 
50-100 PO 
 
96 Y (18) 
 
NA NA 
Cortellazzi, 
Lamperti et al. 
2007, 
Italy[198] 
Retrospective 
study 
Mean 30 
months 
888 CH 50-100 PO NA Y (216) 
 
39.1  165 
Litman et al., 
2010, USA[125] 
Retrospective 
study 
0-1 years 1373 CH 50-75 PO 
 
95 NA NA NA 
CH: Chloral hydrate
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2.1.3.3.3. CT scan  
Six studies involving 766 children examined the effectiveness of chloral hydrate. 120 
(16%) of those were under the age of five years. Chloral hydrate was given orally in 
most identified studies (median dose, 80 mg/kg). 
Median success rate was 100% in children younger than five years old, while it was 
97% in the studies that evaluated children aged from birth to 17 years.  64 (8%) 
patients needed median supplementary dose of either chloral hydrate or midazolam 
(50 mg/kg orally or 0.1 mg/kg intravenously) respectively in order to achieve 
therapeutic success. 
Onset of action was variable between studies, ranging from 3 to 135 minutes. 
Duration of action was also highly variable, lasting from zero to 180 minutes (Table 
2.1.6). 
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Table 2.1. 6: RCTs and observational studies for CT scan 
Reference, 
country  
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success rate 
(%) 
Supplementary 
(No.) 
Sedation (min) 
Onset Duration 
Thompson et 
al. 1982, 
USA[178] 
Single-blind 
RCT 
0- 9 years 241 
101 
CH 
AMPS  
80 PO 
0.08 IM 
85 
88 
Y (25) 
Y (10) 
55  
53 
NA 
NA 
McCarver-May 
et al. 1996, 
USA[177] 
Single-blind 
randomised 
cross-over  
Median 
14 days* 
7 
7 
CH  
M 
75 PO 
0.2 IV 
100 
43 
N 
N 
9- 40 
3-15 
15- 55 
15- 55 
Greenberg et 
al. 1991, 
USA[68] 
Prospective 
study 
Mean 2.18 
years 
295 CH  80-100 PO 
 
99 Y (5) 
 
NA 
 
NA 
Pereira et al. 
1993, 
Canada[190] 
Prospective 
study 
0-17 years 110 CH 50-80 PO 97 Y (6) 
 
5-135  0-150  
Strain et al. 
1986, 
USA[132] 
Retrospective 
study 
0-5 years 93 CH 35-75 PO 
 
87 Y (16) 30- 
105  
60- 120 
Noske and 
Papadopoulos 
1993, 
Germany[216] 
Retrospective 
study 
4 months- 4 
years 
20 CH 
 
50-100 PR 100 Y (12) 30 60-180 
AMPS Cocktail=Atropine 0.016 mg, Meperidine 1.0 mg, Promethazine 1.0 mg , Secobarbital 4.0 mg, CH= chloral hydrate, IM=intramuscular, M=midazolam, PO: Orally, PR: 
Per-rectal 
* All children were term new-born infants
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2.1.3.3.4. ECG 
Six studies; five studies were performed in the USA and one in Thailand. 2272 
children received a median dose of 75 mg/kg orally. There were 1867 children under 
five years. The onset of action ranged from 5 to 110 minutes and the duration of 
action ranged from 15 and 240 minutes. The success rate ranged from 89 to 97 % in 
children less than five years and it was 98% in children aged from three weeks to 14 
years old. Supplementary dose(s) of chloral hydrate (25-50 mg/kg) were given to 25 
children (Table 2.1.7).    
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Table 2.1. 7: RCTs and observational studies for ECG 
Reference, 
country  
Study 
design  
Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success rate 
(%) 
Supplementary 
dose/med 
(No.) 
Sedation (min) 
Onset Onset 
Wheeler et al. 
2001, 
USA[175] 
Single-blind 
RCT 
1- 5 years 15 
25 
CH 
M 
75 PO 
0.5 PO 
93  
36 
Y (5) 
Y (13) 
mean 25 
mean 27.3 
mean 25.6  
mean 
21.69 
 
Layangool et 
al. 2008, 
Thailand[173] 
Double-blind  
RCT 
6 months-5 
years 
132 
132 
CH 
M 
 
50 PO 
0.5 PO 
89 
95 
Y (14) 
Y (7) 
25.1 
11.13 
78.9 
40.10 
Lipshitz et al. 
1992, 
USA[180] 
Prospective 
study 
0-36 months 140 CH  51-145  PO 94 Y (6) 
 
5-105  NA 
Napoli et al. 
1996, 
USA[193] 
Prospective 
study 
3 weeks-14 
years 
405 CH 25-125 PO 98 NA  30-60  NA 
Heistein  et al. 
2006, 
USA[182] 
Prospective 
study 
1 month-3 
years 
1095 CH 
 
80 PO NA NA 30-50  NA 
Roach et al. 
2010, 
USA[185] 
Retrospective 
study 
2- 4 years 485 CH 75 PO 97 N 5-110 15-204 
CH= chloral hydrate, M=midazolam, PO: Orally
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Two RCTs compared chloral hydrate success rate with midazolam in children aged from 6 
months to 5 years [173, 175] (figure 2.1.3). The relative risk of procedural success rate 
in the chloral hydrate group was not statistically different from those sedated with 
midazolam (RR 1.52, 95 % CI: 0.5 – 4.63, P=0.46). 
Figure 2.1. 3: The success rate of chloral hydrate versus midazolam 
 
2.1.3.3.5. EEG 
Five studies involving 428 children were identified. The dose of chloral hydrate ranged 
between 50 and 100 mg/kg (median 68.5 mg/kg).  The sedation success rate ranged 
from 50% to 100%. In the studies with the highest success rate, chloral hydrate was 
given at a higher median dose of 100 mg/kg versus 69 mg /kg in all others. The average 
induction time for sedation using chloral hydrate was from 10 to 150 minutes, while the 
average duration of sedation was between 15 and 240 minutes. 18 children required 
sedative supplementary dose(s). In the two randomised controlled trials chloral hydrate 
was compared with either triclofos or melatonin. The procedural success rate of chloral 
hydrate was compared with triclofos and it was higher, 88% and 84%. 100% success 
was seen with both chloral hydrate and melatonin but, a higher amount of 
supplementary sedation was seen with melatonin[174, 176] (Table 2.1.8). 
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Table 2.1. 8: RCTs and observational studies for EEG 
Reference, 
country  
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success rate 
(%) 
Supplementary 
(No.) 
Sedation (min) 
Onset Duration 
Ashrafi et al. 
2010, 
Iran[176] 
Single-blind 
RCT 
1-64 months 174 
174 
CH 
ME 
50 PO 
2-6 mg PO 
100 
100 
Y (6) 
Y (20) 
10-150 
5-210 
15-240  
15-240 
Milichap 1972, 
USA[174] 
Double-blind 
RCT 
4-14 years 34 
37 
CH 
TRI  
100 PO 
15/Ib PO 
88 
84 
NA 
NA 
mean 
37.3 
mean 37.3 
Loewy et al. 
2005, 
USA[181] 
Prospective 
study 
1month- 
5years 
24 CH  60 PO 50 Y (12) 
 
mean 32
  
mean 226 
Thoresen et 
al.1997, 
Norway[186] 
Prospective 
study 
1.5-13.5 
years 
13 CH 55-77 PR NA NA  20-30min mean 164.5 
Wang et al. 
2005, 
China[197] 
Prospective 
study 
1 months-12 
years 
183 CH 
 
100 PO 100 NA NA 
 
NA 
ME=Melatonin, TRI=Triclofos, CH: Chloral hydrate, PO: Orally, PR: Per-rectal
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2.1.3.3.6. BAEP procedure 
There was one prospective study conducted in Greece to evaluate the effectiveness of 
chloral hydrate in 1586 children aged from birth to 14 years[189]. The dose was 40 
mg/kg.  The success rate in infants aged six months or younger was 100% compared 
to 72% in children older than six months. The onset of sedation time ranged from 15 
to 30 minutes and the duration required between 34 and 49 minutes.  
2.1.3.3.7. Pulmonary function test 
One prospective observational study was conducted in Australia to evaluate chloral 
hydrate effectiveness in ten infants aged from 7 to 33 weeks, mean, 17.4 
weeks[203]. Chloral hydrate was given orally in a dose range of 70 to 100 mg/kg. The 
mean onset of action was 28 minutes; however the duration of action was ranged 
between 15 and 240 minutes. All diagnostic procedures were completed successfully. 
 In Summary 
Summing up the results of chloral hydrate effectiveness, Table (2.1.9) compares 
effectiveness in all painless diagnostic procedures. 
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Table 2.1. 9: Sedation success rates for all painless procedures  
Type of painless 
procedures 
Chloral hydrate dose 
(median dose mg/kg) 
Success rate 
(median success %) 
Pulmonary function test 70 to 100 mg/kg 
(85 mg/kg) 
100% 
CT 35 to 100 mg/kg 
(77.5 mg/kg ) 
84 to 100% 
(98%) 
CT/MRI 25 to 100 mg/kg 
(64 mg/kg ) 
77 to 100% 
(98%) 
MRI 50 to 100 mg/kg 
(75 mg/kg ) 
64 to 100% 
(96%) 
Electrocardiogram (ECG) 25 to 100 mg/kg 
(75 mg/kg) 
89 to 98 % 
(94%) 
Electroencephalograph 
(EEG) 
55 to 100 mg/kg 
(68.5 mg/kg) 
50 to 100% 
(94%) 
Brainstem auditory evoked 
potential (BAEP) 
40 mg/kg 
 
72 to 100% 
(86%) 
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2.1.3.4. Chloral hydrate safety 
Fifty four studies explored the safety of chloral hydrate. The total number of children 
exposed to chloral hydrate was 14439, and there were 1,951 reported AEs. This gave 
an estimated risk of an AE as 13.5 in every 100 patients, or one AE in every seven 
children receiving chloral hydrate. The most frequently occurring AEs were hypoxia, 
vomiting, hyper activity, restlessness and motor imbalance (Table 2.1.10). 
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Table 2.1. 10: Reported AEs from 54 studies 
Body system AEs Frequency  Incidence (%)(AEs 
cases/14439) 
Respiratory system Hypoxia 774 5.3 
Airway obstruction 39 0.3 
Respiratory depression 28 0.2 
Wheezing  1 0.01 
Respiratory arrest  1 0.01 
Apnoea 4 0.03 
Central nervous system Vomiting  430 2.9 
Hyperactivity 210 1.45 
Motor imbalance 93 0.64 
Emesis  52 0.36 
Restlessness 52 0.36 
Prolonged sedation 43 0.3 
Paradoxical reaction 38 0.26 
Ataxia  34 0.24 
Drowsiness 23 0.16 
Excessive sedation 23 0.16 
Nervousness 8 0.06 
Dizziness 8 0.06 
Mental confusion  8 0.06 
Seizure 3 0.02 
Cardiovascular  system Bradycardia  16 0.11 
Agitation  10 0.07 
Hypotension  5 0.03 
Tachycardia  1 0.01 
Others Skin rash  14 0.1 
Cough 3 0.02 
Salivation  3 0.02 
Hiccup 2 0.01 
Abdominal pain 1 0.01 
Urticaria 1 0.01 
Not specified 23 0.16 
 
Total 1,951 13.5 
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There were 847 reported respiratory complications which represent greater than 40% 
of all reported AEs. Hypoxia was the most common and accounted for more than 90% 
of all respiratory AEs. Four hundred and ninety three cases/14439 patients (3.4%) of 
hypoxia were mild (SpO2 90-95%), whereas 281 cases/14439 patients (1.9%) were 
moderate (SpO2 <90%) and one case/14439 patients (0.007%) was severe.  There 
were no discontinuation of any painless procedures as a result of hypoxia, and all 
cases improved after administration of oxygen supplement. Other respiratory 
complications were: airway obstruction and respiratory depression, which were 
reported for 39/14439 patients (0.3%) and 28/14439 patients (0.2%) cases 
respectively. These complications were resolved by using simple manoeuvres, such as 
giving oxygen supplementation and airway opening. There were no medication related 
deaths reported, however, 16 children needed medical interventions due to chloral 
hydrate toxicity (Tables 2.1.12, 2.1.16,2.1.18, 2.1.19).  
In this review, all studies that identified chloral hydrate AEs have been subdivided 
according to the type of diagnostic procedures. Eighteen studies evaluated the safety 
of chloral hydrate as a sedative drug for CT and/or MRI, 15 studies for MRI, 5 studies 
for CT, 6 ECG, 5 EEG, 3 BAEP, and 2 Pulmonary function test . 
2.1.3.4.1. CT/MRI  
18 studies involving patients who were administered chloral hydrate for CT and/or MRI 
were identified [46, 119, 120, 127, 171, 183, 184, 187, 191, 194, 196, 202, 206-209, 
211, 214]. Data was not separated for each procedure, a total of 4249 children, aged 
from birth to 18 years. The dose of chloral hydrate was from 25 to 100 mg/kg, 
median 64 mg/kg. 405 AEs were documented. The overall estimated risk of AEs is 9.5 
in 100 paediatric patients. There were no deaths due to chloral hydrate AEs, however, 
one infant with pulmonary stenosis and tricuspid atresia developed severe hypoxia 
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(SpO2< 85%) and required medical intervention, oxygen supplement and airway 
support[120].  
There were no studies that specially evaluated chloral hydrate safety in children with 
developmental disabilities. Table (2.1.11) shows the frequency and incidence risk of 
AEs (%) children population of the most common AEs of chloral hydrate according to 
the age groups.  
Table 2.1. 11: Most common reported AEs 
  
AEs 
Frequency number of AEs cases/total number of children exposed to 
chloral hydrate (incidence %)/Age groups-(number of children) 
<2 years 
(354) 
<5 years 
(558) 
Mixed 
(3337) 
Total of AEs 
Hypoxia  Mild  10 (2.8) 30 (5.4) 18 (0.5) 58 (1.4%) 
Moderate  - - - - 
Severe  - 1 (0.2) - 1 (0.02%) 
Vomiting  - 9 (1.6) 41 (1.2) 50 (1.2%) 
Hypotension  4 (1.1) 4 (0.7) - 8 (0.19%) 
Hyperactivity  2 (0.6) - 29 (0.9) 31 (0.73%) 
Emesis  1 (0.3) 9 (1.6) - 10 (0.24%) 
Motor imbalance - - 84 (2.5) 84 (1.98%) 
Paradoxical reaction  - - 13 (0.4) 13 (0.31%) 
  
4 patients developed severe AEs. One prospective study reported one case of severe 
hypoxia that developed following administration of 50mg/kg chloral hydrate and 
resolved by oxygen therapy and changing head position[120].  
One case series reported one case of overdose and two cases of accidental 
intravenous administration[220]. Ingestion of 219 mg/kg of chloral hydrate resulted in 
lethargy and transient bigeminy in a child aged 3 years old whereas, IV administration 
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of chloral hydrate in two children aged 15 months and 3 years old resulted in CNS AEs 
and local effects in the site of injection (Table 2.1.12). 
Table 2.1. 12: Chloral hydrate serious AEs for CT/MRI  
Reference, 
country 
Patient age Dose of CH AEs Treatment Hospital 
stay/ days  
Vade, 
Sukhani et al. 
1995[120] 
<1 year 50 mg/kg Severe 
hypoxia 
Oxygen 
therapy,  
Head 
repositioning 
manipulation 
NA 
Sing et al. 
1996, 
USA[220] 
3 years 219 mg/kg 
PO 
Lethargy, 
Transient 
bigeminy 
Intubation, 
O2 therapy  
Y (2 days) 
15 months 88 mg/kg IV* Cyanosis, 
Skin 
sloughing at 
the site of 
injection 
 
O2 therapy 
  
Y (2 days) 
3 years 39 mg/kg IV* Lethargy, 
Skin 
sloughing at 
the site of 
injection 
O2 therapy Y (>2 days) 
*Medication errors 
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2.1.3.4.2. MRI 
15 studies involving 5034 children reported AEs of chloral hydrate for MRI, patients 
range from birth to 15 years (mean 34 months) [23, 125, 170, 172, 179, 192, 198, 
200, 201, 205, 212, 213, 215, 217, 218]. A median oral chloral hydrate dose of 100 
mg/kg was administered and 810 AEs were reported. The estimated risk of AEs is 
16.1 in 100 children.  
In one case report study by Rowert et al. (1997) a 9 days old infant developed apnoea 
immediately after receiving oral doses of chloral hydrate (70 mg/kg) [221]. This led to 
the stopping of the MRI. Table (2.1.13) illustrates the frequency and incidence risk of 
AEs per 100 children population of the most common AEs of chloral hydrate according 
to the age groups.  
Table 2.1. 13: Most common reported AEs  
 
AEs 
Frequency number of AEs cases/total number of children exposed 
to chloral hydrate (incidence %)/Age groups-(number of 
children) 
<2 years 
(1475) 
<5 years 
(1490) 
Mixed* 
(2069) 
Total of AEs 
Hypoxia  Mild  35 (2.4) 29 (1.9) 270 (13) 334 (6.6%) 
Moderate  273 (18.5) - - 273 (5.4%) 
Severe - - - - 
Bradycardia  3 (0.2) - - 3 (0.06%) 
Airway obstruction  2 (0.1) 19 (1.3) 21 (1.0) 42 (0.8%) 
Vomiting  2 (0.1) 24 (1.6) 68 (3.3) 94 (1.9%) 
Hypotension     1 (0.07) - - 1 (0.02%) 
Tachycardia     1 (0.07) - - 1 (0.02%) 
Drowsiness  - 15 (1.0) - 15 (0.3%) 
Hyperactivity  - - 15 (0.7) 15 (0.3%) 
Motor imbalance  - - 9 (0.4) 9 (0.18) 
Ataxia  - - 8 (0.4) 8 (0.16%) 
Dizziness  - - 3 (0.1) 3 (0.06%) 
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There were 892 children (1 to 10 years old) with developmental disabilities and they 
experienced 74 AEs/892 patients (8.3% children). These included; hypoxia 33/892 
patients (3.7%), airway obstruction 21/892 patients (2.4%), ataxia 8/892 patients 
(0.9%), hyperactivity 7/892 patients (0.8%), dizziness 3/892 patients (0.3%) and 
vomiting 2/892 patients (0.2%) children.  
Two studies reported 273 children experiencing moderate hypoxia, oxygen saturation 
(SpO2) level of <90%  [125, 198]. Chloral hydrate was given orally during these 
studies in doses ranging from 50-100 mg/kg (median 63 mg/kg). The median age of 
the children with moderate hypoxia was 18 months or less (it was not possible to 
calculate the median exactly as individual ages were not given). There was no 
discontinuation of any MRI procedures as a result of moderate hypoxia. 269 of the 
273 cases of moderate hypoxia responded to supplemental oxygen therapy. For the 
remaining 4 children the authors did not mention the medical interventions which 
were given (Table 2.1.14).  
Table 2.1. 14: Summary of the 273 children who developed moderate hypoxia 
References Study 
design 
No. of pt. 
receiving 
chloral 
hydrate 
No. of pt. 
with 
moderate 
hypoxia 
Age* Drug 
(doses) 
Monitoring 
device(s) and 
intervention(s) 
Cortellazzi, 
Lamperti et 
al. 2007, 
Italy[198] 
Retrospective 
study 
888 4 Mean 30 
months 
50-100 PO  Continuously 
monitored  of 
SpO2 and PECO2 
 Not mentioned  
 
Litman et 
al, USA 
[125] 
Retrospective 
study 
1373 269 0-1 years, 
mean 5 
months 
50-75 PO 
 
 Pulse Oximetry 
 Supplemental 
oxygen therapy 
  
* Individual data about the age of each patient was not given 
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2.1.3.4.3. CT scan 
Five studies looked at the safety of chloral hydrate during CT [68, 177, 190, 216, 
219]. These involved 785 children from birth to 17 years old, mean age 18 months. 
27 AEs with an overall estimated risk of 3.4 in 100 patients were reported. Vomiting 
accounted for the majority of the total events (14 cases/785 patients representing 
incidence of 1.8%). Other common AEs were moderate hypoxia (8 cases/785 patients, 
1%) and hyper activity (5 cases/785 patients, 0.6%) children. There were 20 children 
under the age of two years, 12 of them experienced AEs with hypoxia the most 
common AEs in this age group, with 5 cases/20 patients (25%) reported. Other AEs 
include; vomiting 4 cases/20 patients (20%) and hyper activity 3 cases/20 patients 
(15%) children. The median dose was 80 mg/kg. All doses were given orally except in 
one instance when it was administered rectally. The effect of chloral hydrate in 
children with developmental disabilities was not assessed in any studies. 
Two studies reported 8 children experiencing moderate hypoxia [177, 190]. Chloral 
hydrate was given orally in doses ranging from 50-100 mg/kg (median 80 mg/kg). 
The mean age of the children with moderate hypoxia was 13 months. This is similar to 
the mean age of children in all the studies, which was 18 months or less (Table 
2.1.15).  
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Table 2.1. 15: Summary of the 8 children who developed moderate hypoxia 
References Study 
design  
No. of pt. 
receiving 
chloral 
hydrate        
No. of pt. 
with 
moderate 
hypoxia 
Age  Drug 
(doses) 
Monitoring 
device(s) and 
intervention(s) 
Pereira et al. 
1993[190] 
Prospective 
study 
110 4 0.1-6 
years, 
mean 
1.1 
years* 
50-80 
mg/kg 
PO 
 Pulse Oximetry 
 Supplemental 
oxygen therapy 
 Changing in the 
position of the 
neck 
 Suctioning of the 
oral secretion  
McCarver-
May et al., 
1996[177] 
Double blind 
Cross-over 
design 
7 4  Median 
14 days 
* 
75 
mg/kg 
PO  
 Continuously 
monitored  of 
hemoglobin 
oxygen saturation 
 Supplemental 
oxygen therapy 
 Administration of 
albuterol 
nebulization (in 
one patient) 
  
* Individual data about the age of each patient was not given 
 
Seven children developed serious AEs. These children had an age range from 28 days 
to 66 months (median, 13 months). The dose of chloral hydrate given ranged between 
10 and 667mg/kg. In 2 cases, toxicities were due to medication errors (Table 2.1.16).
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Table 2.1. 16: Chloral hydrate serious AEs for CT scan 
Reference, 
country 
Patient age Dose of CH AEs Treatment Hospital 
stay/ days  
Farber 1985, 
Israel[222] 
18 months 100mg/kg  Severe 
dyspnea, 
Tachycardia,  
Tachypnea 
severe, 
Severe 
laryngeal 
Oedema, 
Respiratory 
acidosis 
Hydrocortisone 
(IV), Racemic 
adrenalin 
(INH) 
N 
Abel 1987, 
Germany[223] 
40 weeks 10 mg/kg Respiratory 
arrest  
Immediate 
resuscitation, 
O2 therapy  
NA 
Greengerg 
and Faerber 
1990, 
USA[224] 
13 months 
 
100mg/kg 
 
Respiratory 
failure, 
severe 
hypoxia, 
respiratory 
acidosis, 
hypercapnia  
Intubation,  
O2 therapy 
NA 
66 months 100 mg/kg Respiratory 
failure 
Intubation,  
O2 therapy 
Y (>2 days) 
Kirimi et al. 
2002, 
Turkey[225]  
28 days 250 mg/kg* Respiratory 
distress,  
Excessive 
salivation, 
Respiratory 
depression, 
Severe 
hypoxia 
IV fluid 
O2 therapy 
Y (>1 day) 
Andereola et 
al.2006, Italy 
[226] 
16 months 75 mg/kg Cyanosis,  
Excessive 
salivation 
Generalized 
clonic  
seizures, 
Respiratory 
depression, 
Severe 
hypoxia  
Intubation,  
O2 therapy, 
Lorazepam 
0.05 mg/kg 
IV, 
Thiopental 3.5 
mg/kg 
Y (5 days) 
Dogan-Duyar 
et al. 2009, 
Belgium[227] 
3 months 667 mg/kg* Tachycardia,  
Dyspnea, 
 
Intubation,  
O2 therapy, 
IV fluid 
Y (>7days) 
*Medication errors, Inh=Inhalation, IV= Intravenous 
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A summary of the most common AEs associated with chloral hydrate PS for CT, MRI 
and CT and/or MRI is shown in the following table. 
Table 2.1. 17: Summary of CT/MRI AEs  
 
Body system 
 
AEs 
Frequency number of AEs cases/total number of 
children exposed to chloral hydrate (incidence %) / 
painless procedure 
CT MRI CT/MRI 
Respiratory 
system 
 
Hypoxia  8 (1.0%) 607 (12.1%) 59 (1.39%) 
Airway obstruction   42 (0.8%)  
Central nervous 
system 
 
Vomiting  14 (1.8%) 94 (1.9%) 50 (1.2%) 
Hyperactivity  5 (0.6%) 15 (0.3%) 31 (0.73%) 
Drowsiness   15 (0.3%)  
Motor imbalance  9 (0.18) 84 (1.98%) 
Paradoxical reaction    13 (0.31%) 
Emesis    10 (0.24%) 
Ataxia   8 (0.16%)  
Dizziness   3 (0.06%)  
Cardiovascular  
system 
 
Bradycardia   3 (0.06%)  
Hypotension   1 (0.02%) 8 (0.19%) 
Tachycardia   1 (0.02%)  
 
2.1.3.4.4. ECG  
Six studies were found [173, 175, 180, 182, 185, 193]. The total number of children 
was 2272, aged from birth to 14 years old. All studies stated that chloral hydrate was 
given orally, with median dose of 75 mg/kg.  
There were 302 documented AEs/2272 patients (13.3% of patients). The most 
frequent was hypoxia in 98 cases/2272 patients (4.3%), followed by vomiting 55 
cases/2272 patients (2.4%), emesis 41 cases/2272 patients (1.8%), prolonged 
sedation 36 cases/2272 patients (1.6%), paradoxical reaction 25 cases/2272 patients 
(1.1%), and ataxia 24 cases/2272 patients (1.1%). 
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2.1.3.4.5. EEG  
Five studies were published from 1972 to 2010 [174, 176, 181, 186, 197]. These 
studies reported on 428 patients aged from one month to 14 years. The studies were 
conducted in China, Iran, Israel, Norway and the USA. Chloral hydrate dose ranged 
from 55 to 100 mg/kg, median 80 mg/kg. All doses were given orally except in one 
administered rectally. Only two patients (out of a total of 428 children) experienced 
six (1.4%) mild to moderate AEs. They were both less than 5 years old. Ataxia and 
dizziness was seen in both patients (2 cases/428 patients, 0.4%) and cough and 
urticarial rash in one each. There were no discontinuations of EEG due to AEs.  The 
Chloral hydrate median dose was 80 mg/kg.  
One  case report detailed two children who developed a cough and urticaria of the 
whole body 30 minutes after receiving 500mg of chloral hydrate rectally [228] (Table 
2.1.18). 
Table 2.1. 18: Chloral hydrate serious AEs for EEG 
Reference, 
country 
Patient 
age 
Dose of CH AEs Treatment Hospital stay/ 
days  
Yamada et 
al. 2002, 
Japan[228] 
2 years 500 mg PR Cough, 
Urticaria  
Hydroxyzine, 
Hydrocortisone   
NA 
4 years 500 mg PR Cough, 
Urticaria  
β2 stimulant 
Inh. 
NA 
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2.1.3.4.6. BAEP  
Chloral hydrate safety was evaluated by three prospective observational studies 
including 1646 children [188, 189, 199]. The dose of chloral hydrate ranged from 30 
to 40 mg/kg, median 40 mg/kg. There were 396 AEs/1646 patients (24% children) 
Vomiting was the most common 217 cases/1646 patients (13.2%). The second was 
hyper activity 152 cases/1646 patients (9.2%), followed by bradycardia 13 
cases/1646 patients (0.8%), skin rash 10 cases/1646 patients (0.6%) and apnoea 4 
cases/1646 patients (0.2%) children. All AEs were mild and self-resolved. 
There was only one prospective study which identified chloral hydrate safety in 26 
children with age younger than two years (mean 33.1 weeks)[188]. The only AE 
reported was bradycardia in which occurred in 13 of the 26 children (50%).    
 
2.1.3.4.7. Pulmonary function test 
Two studies evaluated chloral hydrate toxicity in 25 infants (< 2 years)[203, 204]. 
Chloral hydrate dose was ranged from 50 to 100 mg/kg, median 70 mg/kg. There 
were two AEs which developed in two infants, both of which were mild hypoxia, 2 
cases/25 patients (8.0%).  
A Case report described two male infants aged 20 months and 24 months who were 
given oral chloral hydrate for lung function test in doses of 80 mg/kg[229]. 
Subsequently, one infant developed severe obstructive apnoea, while the other 
developed severe hypoxia. Both of them required medical interventions and 
hospitalisation (Table 2.1.19). 
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Table 2.1. 19: Chloral hydrate serious AEs for pulmonary function test 
Reference, 
country 
Patient age Dose of CH AEs Treatment Hospital 
stay/ days  
Biban et al. 
1993, 
Italy[229] 
20 months 80mg/kg PO Severe 
obstructive 
apnoea, 
Severe 
hypoxia 
 
Intubation , 
O2 therapy 
Y (>3 days) 
24 months 80mg/kg PO Severe 
obstructive 
apnea, 
Severe 
hypoxia 
O2 therapy Y (NA) 
 
Summary of chloral hydrate AES has been shown in table (2.1.20). 
Table 2.1. 20: Summary of all Reported AEs   
Type of painless procedures Chloral hydrate dose 
(median dose mg/kg) 
Frequency (incidence %) 
Brainstem auditory evoked 
potential (BAEP) 
30 to 40 mg/kg 
(40 mg/kg) 
396 AEs/1646 patients (24) 
MRI 50 to 100 mg/kg 
(100 mg/kg ) 
810 AEs/5034 patients (16.1) 
Electrocardiogram (ECG) 25 to 100 mg/kg 
(75 mg/kg) 
302 AEs/2272 patients (13.3) 
CT/MRI 50 to 100 mg/kg 
(64 mg/kg ) 
405 AEs/4249 patients (9.5) 
Pulmonary function test 50 to 100 mg/kg 
(70 mg/kg ) 
2 AEs/25 patients (8) 
CT          50 to 100 mg/kg 
(80 mg/kg) 
27 AEs/785 patients (3.4) 
Electroencephalograph (EEG) 55 to 100 mg/kg 
(80 mg/kg) 
6 AEs/428 patients (1.4) 
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2.1.4.  Discussion 
The systematic literature review in this study focused on the safety and effectiveness 
of chloral hydrate for painless PS in paediatric patients. 
This review showed a variable rate of success across various procedures, ranging 
between 50% and 100%. The success rate for CT scanning and pulmonary function 
test was higher than for MRI and ECG (Table 2.1.17). Some studies reported a 100% 
success rate for pulmonary function test and CT scanning (median 98%) The success 
rate for MRI was from 64 to 100% (median 96%). This finding was consistent with 
studies results of Vade et al. (1995) and Mallol et al. (1988) which reported higher 
sedation success for CT and pulmonary testing than MRI[120, 203]. In the current 
review, the median dose of chloral hydrate for MRI (75mg/kg) was higher than for 
(BAEP; 40 mg/kg). This may be because MRI procedures are usually longer, very 
noisy and need complete sedation for the child to remain still enough. This systematic 
review corroborated previous studies in which the patients required higher doses of 
chloral hydrate for MRI procedures than for CT [120, 201]. 
The success rate for sedation in painless diagnostic procedures can be increased by 
supplemental dose(s) of other sedatives, such as midazolam (0.05 mg/kg 
intravenous) or by an additional dose of chloral hydrate (25 mg/kg oral)[213, 217]. 
The current review showed that supplemental sedative drug(s) were required more 
during MRI (8%) than they were for a CT scan (4%). Similarly, Kao et al. (1999) 
reported that an additional dose of chloral hydrate increased the success rate of the 
procedure from 89% to 98%[187].  
The induction time of sedation was highly variable between procedures and ranging 
between 3 and 240 minutes. The duration of procedural sedation was also highly 
variable; the shortest was 10 minutes, and the longest was 240 minutes. This may be 
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due to the longer half-life of chloral hydrate, which may lead to an unpredictably long 
recovery time[179, 201]. 
With regard to the safety of chloral hydrate, this review demonstrated a high rate of 
AEs during BAEP 396 AEs/1646 patients (24%) followed by, MRI 810 AEs/5034 
patients  (16.1%) and ECG 302 AEs/2272 patients (13.3%) (Table 2.1.20). This could 
be because these painless diagnostic procedures require a longer period and this may 
lead to administration of high chloral hydrate dose[170]. The higher median chloral 
hydrate dose of 100mg/kg for MRI compared with 80mg/kg for CT scan supports this 
reason. It may also be explained by the use of supplemental sedative dose (s) during 
the procedure. Treluyer et al. (2004) described a better safety profile of chloral 
hydrate for CT scanning when compared to MRI[195]. In addition, the variable rate of 
AEs may be explained by the use of supplemental sedatives during the procedure. 
Vade et al. (1995) recorded no failure of treatment in children aged 1 to 4 years who 
received chloral hydrate in combination with hydroxyzine, but reported a 3% failure 
rate in infants aged less than 1 year who were not given supplementary sedation 
[120].  
This systematic review confirmed that the most common AEs attributed to chloral 
hydrate were vomiting and respiratory complications. The types of AEs were similar, 
irrespective of the type of painless diagnostic procedure. Hypoxia was the most 
commonly reported AE in paediatric patients undergoing sedation prior to painless 
diagnostic procedures (774 cases/14439 patients, 5.3%), but in most cases (493 
cases / 774 cases, 64%), it was mild and self-limiting. 
The current review noted 16 serious AEs that required medical intervention and 
hospitalisation; most of them were respiratory complications [120, 220, 226-228].  
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This review showed that the incidence of hypoxia was high in infants younger than 
two years (2 cases/ 25 patients, 8%). This result corresponds with those obtained in 
various other studies. Litman et al. (2010) reported that the risk of hypoxia was 
directly associated with younger age and tended to be higher in infants with mean age 
58.7 days (3.1%) than infants with mean age 152 days (1.7%) (p<0.0001)[125]. In a 
study of paediatric patients undergoing CT and MRI imaging, Malviya et al. (1997) 
found that infants younger than 12 months of age had more respiratory AEs (mainly 
hypoxia) than children aged from 25 months to 12 years (p<0.0001)[46]. 
 The literature review for this study found few studies that evaluated the safety of 
chloral hydrate sedation specifically for paediatric patients with developmental 
disabilities. The incidence of AEs in children with developmental disabilities (74 
AEs/892 patients, 8.3%) in this systematic review was comparable with the 7.6% 
reported by Cortelazzi et al. (2007)[198]. This may have been due to the difficulty of 
sedating children who were hyperactive or displayed exaggerated reactions to unusual 
environments[230, 231]. Consequently, they may have required supplemental 
sedation or a higher dose than typically developing children[231].  
This review indicated that children with developmental disabilities are more likely to 
develop hypoxia than others, 3.7% (33 cases/892 patients) versus 1.7% (70 
cases/4142 patients) in children without developmental disabilities older than two 
years old. Kannikeswaran et al. (2009) found that children with developmental 
disabilities were 3.2 times more likely to develop hypoxia than children without 
developmental disabilities were (P < 0.01)[231] 
Vomiting was the second most frequently reported AE in this review, with a risk of 
2.9% (430 cases/14439 patients) across all painless procedures. Vomiting often leads 
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to complications such as aspiration pneumonia during PS [232]. The emetic effect of 
sedatives, especially opioids, is well-recognised[112]. 
Vomiting may occur due to the unpleasant taste of chloral hydrate. Children may 
refuse to swallow the drug, while some that swallow it do not retain[127, 170]. 
Fasting before PS reduces the incidence of vomiting[233]. Antiemetic drugs such as 
metoclopramide and ondansetron can mitigate the problem[232]. Most of the 
vomiting noted in this review was not severe and did not warrant medical 
intervention.  
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2.1.5. Limitations 
Our systematic review was limited by the number of clinical studies. The relatively 
small number of studies of each procedure may limit the generalisability of the 
results. Similarly, the comparisons between patients with BAEP, CT and pulmonary 
test sedation and those with EEG, ECG and MRI sedation may be inadequate because 
of the relatively small number of studies and patients. Additionally, studies that were 
determined to have poor quality were not excluded from this systematic review, which 
may have introduced bias. 
The difficulty of calculating the safety data was compounded by the heterogeneous 
reporting styles of the authors. Many did not use standard definitions of AEs and the 
effectiveness of chloral hydrate. Follow-up was generally poor; only a few studies 
included post-discharge data. Hence, it may be difficult to know how the patients 
reacted to the drugs after they left the hospital. Information on events after discharge 
would have enriched this systematic review.  
 
2.1.6. Conclusions 
Chloral hydrate has been used extensively as a sedative for painless diagnostic 
procedures. It is effective as a sedative agent for painless diagnostic procedures with 
success rates up to 100%, particularly in shorter procedures such as CT scanning. 
Hypoxia is a significant problem with chloral hydrate use. Monitoring children during 
sedation, especially infants, is important, and a practitioner who is confident in 
resuscitation should conduct the sedation. 
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Part 2.2. Chloral Hydrate for Painful Procedural 
Sedation 
 
2.2.1. Introduction  
Painful procedures, such as some forms of dental procedures, can make children 
anxious. For many children, procedures that are essential for diagnosis and treatment 
are worse than the disease itself [234]. Additionally, the memory of an unpleasant or 
painful event may cause negative behaviour towards future procedures [234]. 
Therefore, children undergoing painful procedures need sedation to reduce anxiety, 
control pain and decrease movement. The NICE guidelines recommend midazolam or 
nitrous oxide for painful procedures [80]. However, chloral hydrate is frequently used 
around the world as an oral sedative for painful procedures in paediatric patients [78]. 
Several studies have investigated the effectiveness and safety of chloral hydrate for 
these procedures [235]. In part 2.1 of this chapter, a systematic literature review 
showed chloral hydrate to be effective and relatively safe for children undergoing 
painless procedures. In this part, the effectiveness and safety are assessed for painful 
procedures. 
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2.2.2. Methods 
This was identical to the systematic literature review described in part 1 of this 
chapter.  
2.2.3. Results 
1781 related abstracts were found. After screening the abstract for irrelevant articles 
and duplications, 535 articles were identified. The full texts of these articles were read 
carefully and 49 studies that met the inclusion criteria were included (Figure 2.2.1). 
These studies were divided according to the type of painful procedures into six 
categories. Accordingly, the results will be explored based on type of procedure. 
Figure 2.2. 1: Flow diagram of search and review process. 
 
                                                                                                            
                                                                                  
Cochrane 
44 
 
 
MEDLINE 
  463 
 
CINAHL 
92 
 
EMBASE 
1182 
 
1781 Articles 
 
535 Articles 
 
1246 Removed after 
screening abstract for 
irrelevant articles and 
duplications 
373 Duplicate citations 
208 Non-humans 
224 Abstracts not 
meeting      inclusion 
criteria 
257 Review article 
112 Letters 
40   Editorials 
32   Conference abstract 
 
486 Original articles not 
meeting inclusion criteria  
 
49 Included 
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2.2.3.1. Characteristics of the studies 
There were 26 RCTs and 17 prospective observational studies (Table 2.2.1).  The 
largest number of children were involved in prospective studies (853 children), 
followed by 677 children in RCTs. Twenty nine (59%) of the studies involved children 
aged up to five years old (Table 2.2.1).  Studies were conducted in twelve different 
countries; 33 in the USA, three in Brazil, two in each Mexico, the UK and Turkey, and 
one in each of Australia, Canada, Ceylon, Chile, Finland, Singapore, and Taiwan. 
 Chloral hydrate was only administered via the oral route. The dose ranged from 25 to 
100 mg/kg  
Table 2.2. 1: Summary of 49 studies that reported on clinical effectiveness 
and safety of chloral hydrate in paediatrics  
Characteristics of studies Number of studies Number of children 
Type of study N=49 N=1789 
 Randomised controlled trial 26  677 
 Prospective observational study 17 853 
 Retrospective 3  253 
 Case report  3 6 
Type of procedure   
 Dental procedures 34 957 
 Minor surgery and sleep induction 8 323 
 Ophthalmic examination 4 373 
 MCUG 1 18 
 Nasofibroscopy test 1 100 
 SCE (Blood taking)  1 18 
Route of Administration            
 Oral 49 1789 
Age groups   
 Preterm neonates 0 0 
 Term neonates 0 0 
 Infants 5 32 
 Children  29 1267 
Other patient age groups*                                                                                                15 490
* Studies involving multiple age groups (the number of patients within each age group was not 
documented). MCUG=Micturating cystourethrogram imaging procedure, SCE= Sister chromatid assay 
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2.2.3.2. Trial quality 
The scores for the Jadad scoring checklist for quality assessment of the RCTs are 
shown in figure 2.2.2. Fifteen of the 26 RCTS scored ≥3 and so were considered to be 
of high methodical quality. Level of agreement was calculated and there was a 
substantial agreement between the two blinded assessors (0.93) [236]. The scores for 
the STROBE checklist for observational studies are illustrated in Table (2.2.2). Fifteen 
of the eleven pooled observational studies were rated with above 70%. All studies 
were included in the systematic review to avoid missing any data from these articles 
due to the small number of articles related to each painless procedure. The quality 
scoring and selection of papers and abstracts was checked by two independent 
reviewers (BS and HS).  
 
Figure 2.2. 2: Quality assessment criteria of included RCTs 
  
 
2.2 Chloral Hydrate painful Procedural Sedation 
 
111 
 
Table 2.2. 2: Quality assessment criteria of included observational studies 
References STROBE scoring ( out of 34) % 
Needleman et al. 1995[237] 20 91% 
Costa et al. 2012[238] 20 91% 
Castro et al. 1994[239] 18 82% 
Fishbaugh et al. 1997[240] 18 82% 
Patrocínio et al. 2001[241] 18 82% 
Ikbal et al. 2004[242] 18 82% 
Nathan and West  1987[243] 17 77% 
Fox et al. 1989[244] 17 77% 
Lopez et al. 1995[245] 17 77% 
Ong et al. 1996[246] 17 77% 
Litman et al. 1998[247] 17 77% 
Chowdhury and Vargas et al. 2005[235] 17 77% 
Iwasaki et al. 1989[248] 16 73% 
Binder and Leake 1991[249] 16 73% 
Sams et al. 1991[250] 16 73% 
Wright et al. 1986[251] 15 68% 
Jaafar and Kazi 1992[252] 15 68% 
Duncan et al. 1994[253] 15 68% 
Campbell et al. 1998[254] 13 59% 
Mueller et al. 1985[255] 13 59% 
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2.2.3.3. Chloral hydrate Effectiveness 
34 articles evaluated the clinical effectiveness of chloral hydrate (22 for dental 
procedures, 6 for Minor surgery and sleep induction, 3 for ophthalmic examination, 
and 1 for each MCUG, Nasofibroscopy test, and SCE). The study results will be further 
described according to these categories. 
2.2.3.3.1. Dental procedure  
22 studies (14 RCTs, 5 prospective studies, and 3 retrospective studies) evaluated 
chloral hydrate effectiveness during dental procedures (Table 2.2.3). These studies 
included 704 children with ages that ranged from 1 to 17 years. Chloral hydrate was 
given in most studies in combination with other sedative and analgesic agents 
including: hydroxyzine, meperidine, nitrous oxide and promethazine and 
acetaminophen. Chloral hydrate was given via the oral route in all studies. Total doses 
of chloral hydrate ranged between 20 mg/kg and 75 mg/kg, median 75 mg/kg max. 
2gm.  
The induction time was varied and it was ranged from 30 to 60 minutes. The success 
rate of dental procedures was highly varied between studies. It was 100% in some 
studies [126, 240, 254, 256-260], while it ranged from 40% to 53% in others[258, 
261]. There were 29 (4%) patients that required supplemental dose(s) of sedation. 
There were 521 children younger than five years who received chloral hydrate in an 
oral dose ranging between 25 to 75 mg/kg. The success rate, in this group of children, 
varied between 53% and 100%. 
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Table 2.2. 3: RCTs and observational studies for dental procedures 
Reference, 
country  
Study 
design  
Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
dose/med (No.) 
Sedation (min) 
Onset Duration 
Barr et al. 1977, 
USA[259] 
Double-
blind RCT 
1- 17 
years 
21 
21 
CH 
P 
40 PO 
 
100 
100 
NA 
NA 
30 
NA 
NA 
NA 
Moore et al. 1984, 
USA[260] 
Double-
blind RCT 
2- 5 years 45 
15 
CH 
P 
20,40,60 
PO 
100 
100 
N 
N 
NA 
NA 
NA 
NA 
Houpt et al. 1989, 
USA[262] 
Double-
blind RCT 
19- 41 
months 
19 
19 
CH 
P 
50 PO 84 
63 
NA 45 
NA 
NA 
NA 
Houpt et al. 1984, 
USA[258] 
Single-blind 
RCT 
21- 46 
months 
17 
17 
CH 
CH 
50 PO 
75 PO 
53 
84 
      Y (17) 
N 
45 
45 
NA 
NA 
Houpt et al. 1985, 
USA[263] 
Double-
blind RCT 
15- 45 
months 
21 
21 
CH 
CH+PRO 
50 PO 
50 PO+ 25 
PO 
72 
89 
NA 
NA 
 
45 
45 
NA 
NA 
Moody et al. 
1985, USA[261] 
Single-blind 
RCT 
27-74 
months 
10 
10 
10 
CH 
CH 
CH+HYD 
 
50 PO 
50 PR 
30 PO+ 25 
PO 
40 
70 
70 
NA NA 
 
NA 
Badalaty et al. 
1990, USA[264] 
Double-
blind RCT 
20- 48 
months 
30 
30 
CH 
D 
50 PO 
0.3, 0.6 
PO 
60 
73, 93 
N 
N 
45 
>45 
NA 
NA 
CH=Chloral hydrate, D=Diazepam, HYD=Hydroxyzine, P=Placebo, PRO=Promethazine. 
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Table 2.2.3: RCTs and observational studies for dental procedures 
Reference, 
country  
Study 
design  
Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
dose/med 
(No.) 
Sedation (min) 
Onset Duration 
Meyer et al. 1990, 
USA[126] 
Single-
blind RCT 
21- 74 
months 
20 
20 
CH 
TR 
40 PO 
0.02 PO 
100 
100 
NA 
NA 
30 
NA 
NA 
NA 
Tsinidou et al. 1992, 
UK[265] 
Double-
blind RCT 
20- 60 
months 
20 
20 
CH+HYD 
TEM 
50+25 PO 
0.3 PO 
70 
65 
N 
N 
NA 
NA 
NA 
NA 
Sams et al. 1993, 
USA[266] 
Double-
blind RCT 
18- 48 
months 
13 
11 
CH+PRO 
MEP+PRO 
50+1 PO 
1+1 PO 
100 
100 
NA 
NA 
NA 
NA 
NA 
NA 
Haas et al. 1996, 
Canada[257] 
Double-
blind RCT 
3.6- 10.8 
years 
23 
23 
CH 
M 
50 PO 
0.6 PO 
100 
100 
NA 
NA 
NA 
NA 
NA 
NA 
Reeves et al. 1996, 
USA[267] 
Double-
blind RCT 
27- 73 
months 
20 
20 
CH+HYD 
M+ACE 
50+25 PO 
0.5+10 PO 
100 
95 
N 
N 
NA 
NA 
NA 
NA 
Avalos-Arenas et al. 
1998, Mexico[256] 
Double-
blind RCT 
Mean age 
Gp1 27.7 
months 
Gp2 29.2 
months 
20 
20 
CH+P 
CH+HYD 
 
70 PO 
70+2 PO 
100 
100 
NA 
NA 
60 
45 
 
Mean 78 
Mean 70 
Dallman et al. 2001, 
USA[268] 
Double-
blind RCT 
26- 58 
months 
31 
31 
CH+PRO 
M 
62.5+12.5 
PO 
0.2 PO 
71 
68 
NA 
NA 
NA 
NA 
NA 
NA 
ACE=Acetaminophen, MEP=Meperidine, P=Placebo, TR= Triazolam, PRO=Promethazine, HYD=Hydroxyzine, TEM:Temazepam, M:Midazolam 
2.2 Chloral Hydrate painful Procedural Sedation 
 
115 
 
Table 2.2.3: RCTs observational studies for dental procedures 
Reference, 
country  
Study 
design  
Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
dose/med (No.) 
Sedation (min) 
Onset Duration 
Litman et al. 
1998, USA[247] 
Prospective 
study 
1-9 
years  
32 
32 
32 
CH 
CH+N2O 
CH+ N2O 
70 PO 
70+30% 
70+50% 
82 
98 
98 
Y (8) 
Y (2) 
Y (2) 
NA 
NA 
NA 
NA 
Duncan et al. 
1994, USA[253] 
Prospective 
study 
13-50 
months 
50 
 
CH 
 
75 PO 85 N 30-45 NA 
Fishbaugh et al. 
1997, USA[240] 
Prospective 
study 
22- 48 
months 
30 CH 
 
50 PO 
 
100 NA NA 
NA 
NA 
NA 
Nathan, West 
1987, USA[243] 
Prospective 
study 
18- 60 
months 
44 
90 
CH+HYD 
CH+HYD+MEP 
50-70+25 
PO 
50-
70+25+20-
30 PO 
31 
76 
NA 
NA 
NA 
NA 
NA 
NA 
Campbell et al. 
1998, USA[254] 
Prospective 
study 
3-5 
years  
5 
5 
5 
CH 
K 
K 
50 PO 
2 IM 
3 IM 
100 
100 
100 
NA 
Y (3) 
Y (5) 
43.8 
16.6 
15.2 
NA 
NA 
NA 
Needleman et 
al. 1995, 
USA[237] 
Retrospective 
study 
mean 
2.6 
years 
113 
296 
CH 
CH+HYD 
55 PO 
55+1 PO 
72 
75 
NA 
NA 
Mean 
66.6 
Mean 
66.6 
 
NA 
NA 
Sams et al. 
1991, USA[250] 
Retrospective 
study 
20- 20 
months 
71 
41 
CH+PRO 
MEP 
53.3 +1 PO 
1+1 PO 
66 
54 
NA 
NA 
NA 
NA 
NA 
NA 
Chowdhury and 
Vargas et al. 
2005, USA[235] 
Retrospective 
study 
24- 60 
months 
69 
47 
CH+HYD+MEP 
CH+N2O 
25+1+1 PO 
50+50% PO 
90 
70 
NA 
NA 
45 
25 
NA 
NA 
CH=Chloral hydrate,
 
N2O=Nitrous oxide, K=Ketamine, MEP=Meperidine, HYD=Hydroxyzine, P=Placebo, PRO=Promethazine. 
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 Randomised controlled trials 
14 RCTs compared the effectiveness of chloral hydrate versus other sedative agents in 
paediatric patients undergoing dental procedures (Table 2.2.3). These RCTs have 
been placed in three groups: 
• Studies comparing chloral hydrate effectiveness with a placebo 
• Studies comparing effectiveness of different doses of chloral hydrate 
• Studies comparing chloral hydrate effectiveness with different sedative agents. 
1. Studies comparing chloral hydrate effectiveness with a placebo 
Three studies compared the effectiveness of oral chloral hydrate with placebo[259, 
260, 262] (Table 2.2.3). Two studies found that there was no statistically significant 
difference in success rate between chloral hydrate and placebo groups, and all 
children completed dental procedures (Figure 2.2.3)[259, 260]. In contrast, the other 
study (Houpt et al. 1989) chloral hydrate was statistically more successful than than 
placebo(P < 0.05), (84% in CH groups compared to 63% in placebo)[262].  
Considering all 3 studies together, the relative risk of procedural success rate in the 
chloral hydrate group was not statistically different from those receiving placebo (RR 
1.03, 95 % CI: 0.89 - 1.2, P=0.67)(Figure 2.2.3). 
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Figure 2.2. 3: Comparison of Chloral hydrate versus placebo 
     Placebo    Chloral hydrate 
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2. Studies comparing effectiveness of different doses of chloral hydrate 
One study  compared at the effect of low dose of CH (50 mg/kg) versus high dose (75 
mg/kg)[258]. Children in higher dose of CH group had a statistically significantly high 
success rate compared to those in low dose CH groups (P < 0.05) (Table 2.2.3). 
3. Studies comparing chloral hydrate effectiveness with different sedative 
agents 
 Chloral hydrate/hydroxyzine (CH/H) 
Five studies compared CH/H with other sedative agents [126, 256, 261, 265, 267] 
(Table 2.2.3). In Avalos-Arenas (1998) study children were given CH (70 mg/kg)/H (2 
mg/kg) or CH (70 mg/kg) alone[256]. All children completed their dental treatment 
procedures.  
Tsinidou (1992) looked at the effectiveness of oral CH (40 mg/kg)/H (25 mg) 
compared to oral hydroxyzine (0.3 mg/kg) in children aged between 20 and 60 
months. The procedural success rate was slightly higher in the CH/H group but not 
statistically significant (70% vs 65%) respectively[265]. 
Meyer (1990) looked at the effectiveness of chloral hydrate (40 mg/kg, 
PO)/hydroxyzine (25mg, PO) compared to triazolam (0.02 mg/kg) in children aged 
between 21 and 74 months[126]. All children completed their dental treatment 
procedures[126]. 
Moody (1985) compared rectal CH (50 mg/kg) with either oral CH (30 mg/kg)/H (25 
mg) or oral CH (50 mg/kg) alone,  sedation was more effective with rectal CH and oral 
CH/H groups compared to oral CH alone (70%, 70% vs 40%) respectively[261].  
Reeves et al. (1996) found that the success rate of procedures was higher in patients 
who received CH (50 mg/kg)/ H (25 mg) compared to patients who received 
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midazolam (0.5mg/kg)/acetaminophen (10mg/ kg), but this was not statistically 
significant[267].    
 Chloral hydrate/promethazine (CH/PRO) 
Three studies compared CH/P effectiveness to other agents [263, 266, 268] (Table 
2.2.3).  
Dallman et al. 2001 compared the effectiveness of CH (62.5 mg/kg)/PRO (12.5 
mg/kg) to midazolam (0.2 mg/kg) and found it was relatively similar[268]. While 
Houpt et al. (1985) found that CH (50 mg /kg)/ PRO (25 mg) was more effective than 
CH (75 mg/kg) with procedural success rate 89%vs 72% respectively[263]. In a study 
carried out by Sams et al. (1993) children aged from 18 to 48 months were given CH 
(50 mg/kg)/PRO (1mg/kg) or meperidine (1mg/kg)/PRO (1mg/ kg)[266]. They found 
that the procedural success rate was similar between the two groups as all patients 
completed their procedures. 
 Chloral hydrate/diazepam (CH/D) 
One study conducted by Badalaty et al. (1990) compared the effectiveness of CH (50 
mg/k) to diazepam (0.3 and 0.6 mg/kg) and they found that diazepam at 0.3 or 0.6 
mg/kg was more effective than chloral hydrate (73%, 93% and 60%, respectively). 
 Chloral hydrate/midazolam (CH/M) 
Hass et al. (1996) compared the effectiveness of CH (50 mg/kg) to midazolam (0.6 
mg/kg) and found the procedural success rate was similar between the two groups as 
all patients completed their procedures 
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2.2.3.3.2. Minor surgery and sleep induction 
Six studies evaluated chloral hydrate effectiveness in 318 children aged from 6 
months to 12 years. Chloral hydrate was given orally in a dose range from 25 to 75 
mg/kg (median 50 mg/kg). Sedation time ranged between 20 and 70 minutes, while 
duration of sedation ranged from 20 to 60 minutes. The failure rate varied between 
studies. It was zero in some studies[239, 245] (Castro et al. 1994 and Lopez et al. 
1995), but up to 30% in another [246]. There were two (0.6%) children who required 
supplemental doses of chloral hydrate.  
There were 75 children younger than five years. Chloral hydrate dose ranged from 40 
to 50 mg/kg (median 45 mg/kg) orally. All sedation was completed with 100% 
procedure success rate. 
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Table 2.2. 4: RCTs for Minor surgery 
Reference, country  Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
dose/med 
(No.) 
Sedation (min) 
Onset Duration 
Saarnivaara et al. 
1988, Finland[269] 
Double-blind RCT 1-8 
years 
126  
122 
CH 
M 
25, 50 or 75 PO 
0.4, 0.5 or 0.6 
PO 
NA 
 
NA 
NA 
NA 
NA 
21-35 
21-35 
Ong et al. 1996, 
Singapore[246] 
Single-blind RCT 1-12 
years 
25 
27 
31 
29 
CH 
M 
TRI 
Pro 
P 
40 PO 
0.2 PO 
3 PO 
1 PO 
70 
42 
55 
39 
32 
NA 
 
NA 
 
NA 
 
Anderson et al. 1990, 
Australia [270] 
Double-blind RCT 6- 47 
months 
43 
43 
CH 
D 
40 PO 
0.25 PO 
100 
100 
NA 
 
70 
84 
30 
27 
Binder and Leake 
1991, USA[249] 
Prospective 
observational 
study 
1-10 
years 
42 CH 
 
25-50 PO 
 
95 Y (2) 20-60 20-60 
 
Castro et al. 1994, 
Brazil[239] 
Prospective 
observational 
study 
1- 12 
years 
50 CH 50 PO 
 
100 N 
 
NA 
NA 
NA 
NA 
Lopez et al. 1995, 
Chile[245] 
Prospective 
observational 
study 
1- 5 
years 
32 
27 
CH 
M 
50 PO 
1 PO 
100 
66 
NA 
 
Mean 
21.8 
Mean 
117.5 
NA 
NA 
CH=Chloral hydrate, D= Diazepam, ALP= Alprazolam, Pro= Prometazine, P=Placebo, TRI=Trimeprazine, CH: Chloral hydrate, M: Midazolam 
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2.2.3.3.3. Ophthalmic examination 
Chloral hydrate effectiveness was identified in three studies. The total number of 
children was 372 and their ages were ranged from birth to five years. The dose of 
chloral hydrate ranged from 80 to 100 mg/kg, median 100 mg/kg. Chloral hydrate 
induction time was between 20 and 45 minutes, with average duration from 30 
minutes to two hours. The effectiveness of chloral hydrate was found to be high with 
success rates ranging from 88 to 100%. Supplementary dose(s) of sedation were not 
given during procedures in two studies[251, 252] while in the other study, data was 
not available[244]. 
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Table 2.2. 5: RCTs for Ophthalmic examination 
Reference, 
country  
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success rate 
(%) 
Supplementary 
dose/med 
(No.) 
Sedation (min) 
Onset Duration 
Jaafar, Kazi 1993, 
USA[252] 
Prospective 
study 
0- 5 years 60 CH 100 PO 
 
100 N 20-45 30-150 
Fox et al. 1990, 
USA[244] 
Prospective 
study 
1 month-5 years 302 CH 80- 100 PO 
 
88 NA NA 
 
NA 
 
Wright et al. 
1986, USA[251] 
Prospective 
study 
4- 21 months 10 CH 80- 100 PO 100 N NA 
 
NA 
 
CH= Chloral hydrate 
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2.2.3.3.4. MCUG procedure 
One RCT evaluated chloral hydrate effectiveness[271]. This study was published in 
2005 and it compared oral chloral hydrate 25 mg/kg with oral midazolam 0.6 mg/kg. 
The total number of children was 18, aged from 6 months to 15 years. Sedation time 
ranged between 10 and 20 minutes (median 16 minutes) and the duration time 
ranged from 20 to 35 minutes (median 28 minutes). The success rate was 100% in 
chloral hydrate group, while it was 94% in midazolam group.  
2.2.3.3.5. Nasofibroscopy test 
One study was published in 2001[241]. This prospective observational study was 
conducted in Brazil. The total number of children was 100 with the age ranging from 
one to four years. Chloral hydrate at a dose of 100 mg/kg was administered orally. 
The mean sedation time was 40 minutes. All patients completed their procedures 
successfully. 
2.2.3.3.6. SCE assay (blood taking) 
One prospective observational study was found from Turkey [242]. The total number 
of infants was 18, aged from 31 to 55 days. In this study chloral hydrate was 
administered via oral route in a dose of 50 mg/kg. The success rate was 100%.  
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 Summary of chloral hydrate clinical effectiveness 
We found 34 articles evaluating the effectiveness of chloral hydrate for painful 
procedural sedation (PS). The following table illustrates the success rates per type of 
painful procedures (Table 2.2.6). 
Table 2.2. 6: Success rate (%) of all types of painful procedures 
Type of procedures Chloral hydrate  dose 
Range (median dose) 
Success rate 
Range (median success) 
Minor surgery, sleep induction 25 to 75 mg/kg  
(50 mg/kg) 
70 to 100% 
(100%) 
Ophthalmic examination 80 to 100 mg/kg  
(100 mg/kg) 
88 to 100% 
(100%) 
MCUG procedure 25 mg/kg 100% 
Nasofibroscopy test 100 mg/kg 100% 
SCE assay (blood taking) 50 mg/kg 100% 
Dental procedure 20 to 75 mg/kg  
(50 mg/kg ) 
40 to 100% 
(84%) 
 
2.2 Chloral Hydrate painful Procedural Sedation 
 
126 
 
2.2.3.4. Chloral hydrate safety 
Forty six studies evaluated chloral hydrate safety for six different painful procedures 
including dental procedures, minor surgery and sleep induction, ophthalmic 
examination, MCUG, Nasofibroscopy test, and SCE. There were a total of 1810 
children exposed to chloral hydrate with estimated risk of 17.3 in every 100 patients, 
or one AE in every six children receiving chloral hydrate. Hypoxia was the most 
frequently occurring AE followed by vomiting, and restlessness (Table 2.2.7).  
All studies were subdivided according to the type of painful procedure. Thirty four 
studies evaluated chloral hydrate safety for dental procedures, six for minor surgery 
and sleep induction, three for ophthalmic examination, and one each for MCUG, 
Nasofibroscopy test, and SCE. 
 
Table 2.2. 7: Reported AEs for all painful procedures  
Body system Adverse effects Frequency Incidence (%)(AEs 
cases/1810) 
Respiratory system Hypoxia 95 5.2 
Increased Respiratory rate  24 1.3 
Airway obstruction 12 0.7 
Decreased Respiratory rate 4 0.2 
Central nervous system Vomiting  59 3.3 
Restlessness  39 2.2 
Anxiety  15 0.8 
Irritability  15 0.8 
Drowsiness  11 0.6 
Dizziness  6 0.3 
Ataxia  1 0.1 
Cardiovascular  system Increased heart rate 6 0.3 
Others Excessive sleep  19 1.0 
Fever  4 0.4 
Hiccup 1 0.1 
sickness 1 0.1 
Visual disturbance  1 0.1 
Total 313 17.3 
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2.2.3.4.1. Dental procedures 
28 studies reported AEs while 6 studies had none [257, 264, 267, 272-274]. 984 
children received chloral hydrate (median dose 75 mg/kg) for dental procedures out of 
1699 participants. The mean age of these children was 38 months (3 studies did not 
give the mean age [235, 255, 259]). There were 236 AEs (Table 2.2.8). The 
estimated risk of experiencing an AEs was 24%, or approximately one AE in every 
four children receiving chloral hydrate.  
Table 2.2. 8: Reported AEs for dental procedures 
Body system Adverse effects Frequency Incidence (%)(AEs 
cases/984) 
Respiratory system Hypoxia 94 9.6 
Increased Respiratory rate  24 2.4 
Airway obstruction 12 1.2 
Decreased Respiratory rate 4 0.4 
Central nervous system Vomiting  42 4.3 
Irritability  15 1.5 
Anxiety  6 0.6 
Dizziness  6 0.6 
Ataxia  1 0.1 
Cardiovascular  system Increased heart rate 6 0.6 
Others Excessive sleep  19 1.9 
Fever  4 0.4 
Hiccup 1 0.1 
sickness 1 0.1 
Visual disturbance  1 0.1 
Total 236 24 
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Hypoxia was most common and accounted for almost 40% of all AEs. Sixty five 
cases/984 patients (6.6%) of hypoxia were mild (SpO2 90-95%), whereas 29 
cases/984 patients (3%) were moderate (SpO2, 85-89%).  There was no 
discontinuation of the dental procedure due to hypoxia. Other respiratory 
complications were: increased respiratory rate, airway obstruction and decreased 
respiratory rate which were reported for 24, 12 and 4 cases respectively (Table 
2.2.8).  
Seven studies reported children (29) experiencing moderate hypoxia, oxygen 
saturation (SpO2) level of <90%  [248, 250, 255, 256, 265, 275, 276]. Chloral 
hydrate was given orally during these studies in doses ranging from 50- 100 mg/kg 
(median 50 mg/kg). 13 children received chloral hydrate only, whereas 16 also 
received other sedative agents [promethazine (10), hydroxyzine (4), and nitrous 
oxide (2)]. The median age of the children with moderate hypoxia was 36 months or 
less (it was not possible to calculate the median exactly as individual ages were not 
always given). This is similar to the mean age of children in all the studies, which was 
38 months.   
Most studies gave detailed information about monitoring and management of 
moderate hypoxia, six studies used a pulse oximetry to monitor oxygen saturation 
levels [248, 250, 255, 256, 265, 275]. 28 of the 29 cases of moderate hypoxia 
responded to changes in the position of the head and neck. One 25 month old female 
however failed to respond to changes in the head position, but the authors did not 
mention the further medical intervention which was given [248] (Table 2.2.9). 
The second most common AE was vomiting, developed by 42 cases/984 patients 
(4.3%) children. All cases of vomiting were mild and resolved without requiring 
medical intervention. 
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Table 2.2. 9: Summary of the 29 children who developed moderate hypoxia 
References Study 
design  
NO. of 
children 
Age (months) Drug (doses) Monitoring device(s)  
 
Mueller et al. 
1985 [255] 
Prospective 
study 
2  24- 72 * CH 100 mg/kg+ 
50%N2O 
 Pulse Oximetry 
  
Iwasakiet al. 
1989 [248] 
Prospective 
study 
5 < 36 
(4 children) 
CH 75 mg/mg  Pulse Oximetry, 
Capnography 
 
25 CH 75 mg/mg  Pulse Oximetry, 
Capnography 
 
Sams et al. 
1991[250] 
Retrospectiv
e population 
based study 
10 24 CH/P (mg) 
800/12.5 
 Pulse Oximetry 
  
24 CH/P (mg) 
636/12.5 
29 CH/P (mg) 
700/15.0 
29 CH/P (mg) 
700/15.0 
31 CH/P (mg) 
600/12.5 
31 CH/P (mg) 
750/12.5 
36 CH/P (mg) 
750/12.5 
39 CH/P (mg) 
715/7.15 
40 CH/P (mg) 
570/12.5 
59 CH/P (mg) 
820/12.5 
Tsinidou et al. 
1992 [265] 
Double blind 
Cross-over 
design 
3 20- 60 * CH/H (mg/kg) 
50/25 for each 
patient  
 Pulse Oximetry 
  
Avalos-Arenas et 
al. 1998 [256] 
Double blind 
RCT 
6 21- 36 * CH (mg/kg) 
70 for each patient 
 Pulse Oximetry, 
precordial 
stethoscope, 
sphygmomanometer 
 
Meyer et al. 2004 
[275] 
Double blind 
Cross-over 
design 
2 32- 63 * CH (mg/kg) 
50 for each patient 
 Capnography, Pulse 
Oximetry, precordial 
stethoscope 
 
Torres-Pérez et 
al. 2007 [276] 
Single blind 
RCT 
1 12- 120 * CH/H (mg/kg) 
50/1.5 
 NA 
 
* Individual data about the age of each patient was not given, CH-chloral hydrate, P-promethazine,  
H- hydroxyzine.  
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2.2.3.4.2. Minor surgery 
Six studies evaluated chloral hydrate toxicity in 318 children [239, 245, 246, 249, 269, 
270]. A total of 61 adverse events with an incidence rate of 19.2 per 100 children 
were documented. The chloral hydrate dose ranged from 25 to 75 mg/kg (median 
dose 50 mg/kg). The most common AEs were restlessness 39 cases/318 patients 
(12.3%) followed by; drowsness 11 cases/318 patients (3.5%), anxiety 9 cases/318 
patients (2.8%) and vomiting 2 cases/318 patients (0.6%) children. 
A Case of corrosive burns of the upper respiratory airway was described in an 18 
months infant male a few minutes after administration of oral chloral hydrate[277]. 
Immediate tracheal intubation and medical interventions was given. Hospitalisation for 
24 hours was required.  
2.2.3.4.3. Ophthalmic examination 
AEs were evaluated in three prospective observational studies [244, 251, 252]. The 
total number of children was 372 and the total number of AEs was 16 events (4.3%). 
Vomiting occurred in 15 cases/372 patients (4%) patients, whereas mild hypoxia was 
seen in one cases/372 patients (0.3%) patient. There were no procedural sedation 
discontinuations due to AEs. This review also identified one case report for an 8 
months infant male who developed severe oropharyngeal and oesophageal burn after 
a chloral hydrate overdose (8 gm instead of 0.4 gm) as a medication error [278]. 
Immediate intubation was carried out to support his airway and ventilation. 
Additionally 40 mg intravenous corticosteroid was given every six hours and the 
patient was followed up for approximately one year.  
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2.2.3.4.4. MCUG 
One RCT by Akil et al. (2005) evaluated chloral hydrate safety in 18 children aged 
from 6 months to 15 years old[271]. This study compared oral chloral hydrate 25 
mg/kg with oral midazolam 0.6 mg/kg. AEs were not observed in any of the children. 
2.2.3.4.5. Nasofibroscopy  
One prospective study was found [241]. The total number of children was 100 aged 
from 1 to 4 years old. Chloral hydrate was given orally at dose of 100 mg/kg. There 
were no AEs reported.   
2.2.3.4.6. SCE assay 
One prospective observational study evaluated chloral hydrate AEs[242]. Chloral 
hydrate was given orally to 18 infants aged from 31 to 55 days. AEs were not 
reported.  
Summary of chloral hydrate AES has been shown in table (2.2.10). 
Table 2.2. 10: Summary of all Reported AEs  
Type of painless procedures Chloral hydrate dose 
(median dose mg/kg) 
Frequency (incidence %) 
Dental procedures 50 to 100 mg/kg 
(75 mg/kg) 
236 AEs/984 patients (24) 
Minor surgery 25 to 75 mg/kg 
(50 mg/kg ) 
61 AEs/318 patients (19.2) 
Ophthalmic examination 80 to 100 mg/kg  
(100 mg/kg) 
16 AEs/372 patients (4.3) 
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2.2.4. Discussion: 
Chloral hydrate effectiveness was highest in ophthalmic examinations (median 100%) 
and lowest in dental procedures (median 84%). It has been documented that the 
success rate depends on the dose administered [237]. Houpt et al. (1985) reported 
that 75 mg/kg of chloral hydrate was superior to 50 mg/kg for controlling the 
behaviour of paediatric patients in dental treatment [258]. In this review, the median 
dose of chloral hydrate was higher in ophthalmic examinations than in dental 
procedures (100 mg/kg versus 75 mg/kg respectively).  
The current review indicated that the number of children who needed supplemental 
sedatives was higher during dental procedures compared to other procedures. This 
could have been due to the longer time for these procedures [258]. 
With regard to the safety of chloral hydrate, our systematic review revealed a high 
incidence of AEs (313 AEs/1810 patients, 17.3%) in painful procedures. Hypoxia and 
vomiting were the most common AEs across most studies that evaluated the safety of 
chloral hydrate. AEs were highest during dental procedures (236 AEs/984 patients, 
24%) and minor surgery (61 AEs/318 patients, 19%).  
Hypoxia was the most frequently reported AE in this systematic review. Almost 1 in 19 
children experienced hypoxia. In 1/3 of these cases, the hypoxia was moderate, with 
saturation of peripheral oxygen (SpO2) reduced to <90%, requiring intervention.  
Hypoxia was also the most frequent complication reported with other sedatives used 
for children undergoing painful procedures. For example, all 20 children who received 
alphaprodine in a clinical trial developed hypoxia [255]. Another study of midazolam 
reported hypoxia in 1 in eight children [235].   
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Vomiting was the second most common AE and was experienced by 3.3% of children 
(59 cases/1810 patients). All cases were self-limiting. Generally, chloral hydrate is 
known to cause gastric irritation and emetic stimulation [243, 258, 263]. The 
unpleasant taste of chloral hydrate may also cause vomiting or even prevent the child 
from swallowing the drug [70]. Additionally, some dental procedures may stimulate 
the gag reflex, which can lead to vomiting [279]. 
This systematic review found that the incidence of AEs following administration of 
chloral hydrate for painful procedures was higher than for painless procedures 
313AEs/1810 patients (17.3%) versus 1,951AEs/14439 patients (13.5%). 
In this systematic review, two serious AEs were found. The first case was an 18-
month-old male who developed corrosive burns on his upper airway after receiving 
chloral hydrate. The other was a 9-year-old female who developed supraventricular 
tachycardia 7 hours after a dose of 600 mg of oral chloral hydrate. Both cases 
required medical intervention and hospitalisation [277, 280]. 
2.2.5. Limitations 
This systematic review has several limitations. First, only a small number of studies 
evaluated chloral hydrate safety and effectiveness during painful procedures such as 
micturating cystourethrogram or nasofibroscopy. This may limit the generalisability of 
the results. Another important limitation is that the methods for measuring outcomes 
and the definitions of safety and effectiveness differed between studies. The statistical 
analysis methods also varied. Additionally, the majority of the studies focused on 
patients aged from 1 to six years. Consequently, it was difficult to locate robust data 
about chloral hydrate safety and effectiveness in the other age groups.  
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2.2.6. Conclusions 
Chloral hydrate for painful procedures seems to have good effectiveness if it is used in 
relatively high doses (from 50 mg/kg to 75 mg/kg). Moderate hypoxia was the most 
serious reported AE. This underscores the importance of monitoring the respiratory 
system during sedation and that sedation should be conducted by a practitioner who 
is confident in resuscitation 
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Part 2.3. Chloral Hydrate for treatment uses 
 
2.3.1. Introduction 
Chloral hydrate has less frequently been used for medical treatment such as 
treatment of neonatal abstinence syndrome [213]. It is important to note that its uses 
depend on its ability to induce sedative and hypnotic effects through binding to GABAA 
receptors in the brain[123].   
It is used for the treatment of several disorders, such as insomnia (short-term), 
agitation and cluster seizures in neonates[281]. Prolonged use may lead to a higher 
incidence of AES for example, hepatic toxicity. Martinbiancho et al. (2009) reported 
that 22.7% (78) of children who were given chloral hydrate for prolonged sedation 
experienced AEs. When given chloral hydrate for 6 days, 10.5% (24) of children 
developed AEs, and when given it for longer, 47% (54) of children developed 
AEs[282]. Hypoxia was the most common AEs (64.6%), followed by 
hypotension[282]. In fact, there is a lack of data on chloral hydrate safety and clinical 
effectiveness for prolonged sedation. 
The aim of this systematic review is to evaluate the clinical effectiveness and safety of 
chloral hydrate for treatment uses in paediatric patients. 
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2.3.2. Methods 
The search strategy and the key words are as discussed in the earlier part of chapter 
2.  
2.3.3. Results  
1781 related abstracts were found. After screening the abstract for irrelevant articles 
and duplications, 135 articles were identified. The full texts of these articles were read 
carefully and 17 studies that met the inclusion criteria were included (Figure 2.3.1). 
Figure 2.3. 1: Flow chart of study 
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Characteristics of the studies 
17 studies were identified, 11 studies for treatment of agitation, 4 for neonatal 
diseases and 2 for neurological disorders (Table 2.3.1). 
The largest group of studies was case reports (9), followed by prospective and 
retrospective studies (Table 2.3.1). Six were conducted in the USA, four in the UK, 
three in Canada, and one in each Czech Republic, Turkey, Germany, and Japan.  
Chloral hydrate was given orally in 15 studies in doses that ranged from 20 mg to 
100mg/kg, while it was given rectally in 2 studies in doses from 34 to 63 mg/kg.   
Table 2.3. 1: Summary of 17 studies that reported on clinical effectiveness 
and safety of chloral hydrate for treatment use in children 
Studies’ characteristics Number of studies  Number of children 
 
Type of study N=17 N=517 
 Case report 9 11 
 Prospective observational 3 368 
 Retrospective 3 109 
 Randomised controlled trial 2 29 
Type of treatment procedure   
 Agitation  11 445 
 Neonatal diseases*  4 48 
 Treatment of neurological disorders**  2 24 
Route of Administration           
 
 
 
 Oral 15 494 
 Rectal 2 23 
Age groups   
 Preterm neonates 1 1 
 Term neonates 3 49 
 Infants 7 13 
 Children 3 24 
 Other patient age groups*** 4 430 
* Neonatal diseases include: Hyaline membrane disease (HMD), neonatal abstinence syndrome, cluster seizures in 
benign convulsions and treatment of cryptogenic ohtahara syndrome 
** Neurological disorders include: clustering seizure and treatment of refractory epilepsy 
*** Studies involving multiple age groups (the number of patients within each age group was not documented) 
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2.3.3.1. Trial quality 
After the application of the Jadad scoring checklists, no study fulfilled all 5 criteria. 
Two studies met ≤ 2 criteria (Table 2.3.2). The scores for the STROBE checklist for 
observational studies are illustrated in table (Table 2.3.3). 5 of the 6 identified studies 
were rated above 70%.   
Table 2.3. 2:  Quality assessment criteria of included RCTs 
References  Jadad score (out of 5) 
Reimche L. et al., 1989[283] 2 
Kuaemko 1972[284] 3 
 
Table 2.3. 3: Quality assessment criteria of included observational studies 
References STROBE scoring ( out of 22) % 
 
Martinbiancho et al., 2009[282] 17 77 
Esmaeili et al., 2010[285] 17 77 
Lambert et al., 1990[286] 16 73 
Hindmarsh et al., 1991[287] 16 73 
Enoki et al., 2007[288] 16 73 
Mayers et al., 1992[289] 15 68 
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2.3.3.2. Chloral hydrate Effectiveness 
Six studies evaluated chloral hydrate effectiveness for treatment uses. Three reported 
use for seizures treatment. One retrospective study that evaluated the effectiveness 
of chloral hydrate for treatment of cluster seizures in 22 children, aged between 3 and 
39 months was conducted in Japan[288]. The dose of chloral hydrate ranged from 
33.8 to 62.5 mg/kg (mean 48.7 mg/kg) PR. The success rate was 86% (seizures 
completely ceased) after a single dose of chloral hydrate. 
One case report identified the use of chloral hydrate for refractory epilepsy 
treatment[290]. There were two patients reported (4 days and 6 years old). The 
patients were given 30mg/kg of oral chloral hydrate every 3 and every 4 hours 
respectively. The seizures completely ceased after 48 and 24 hours respectively. 
Another case study reported a 5 weeks old patient was treated with 58 mg/kg/day of 
oral chloral hydrate. 24 hours after treatment initiation all seizures ceased 
completely[291].   
Two studies reported use for neonatal disease treatment. One retrospective study 
involved 29 neonate patients with abstinence syndrome (median gestational age was 
38.5 weeks), conducted in Germany[285]. Chloral hydrate was administered orally in 
a dose from 30 to 50 mg/kg. All children were treated successfully and discharged 
after median 32 days (range, 14 to 56 days). Another RCT compared chloral hydrate 
effectiveness (80mg PO every 6 hrs for 24 hrs) to diazepam (1mg PO every 6hrs for 
24 hrs) in 17 neonates (average gestational age was 40 weeks) treated for cerebral 
irritation[284]. All neonates in both groups were treated successfully within 4 days. 
One study reported use for agitation treatment. This was a prospective observational 
study that evaluated chloral hydrate effectiveness in 19 neonatal patients with 
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agitation. All cases of agitation were controlled within 30 min following a chloral 
hydrate dose (50mg/kg oral)[289].   
A summary of the data regarding chloral hydrate effectiveness of all treatment uses 
are compared in the following table.  
Table 2.3. 4: Chloral hydrate sedation success rates of all treatment uses 
Type of  treatment uses No. of patients Chloral hydrate dose  
(mg/kg) 
Success 
rate 
Treatment of agitation  19 50 mg/kg 100% 
Treatment of neonatal 
diseases 
29 30 to 50 mg/kg  100% 
Treatment of cerebral 
irritation  
17 80 mg/kg 100% 
Treatment of neurological 
diseases 
22 33.8 to 62.5 mg/kg  86% 
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2.3.3.3. Chloral hydrate safety 
15 studies evaluated chloral hydrate safety for treatment uses. One study reported 
use for seizure treatment. This was a retrospective study of 22 children aged from 3 
to 39 months which reported no AEs [288]. 
Two studies evaluating the safety of chloral hydrate in 46 neonates for neonatal 
disease treatment reported 13 AEs in 17 neonates (Nine cases of vomiting and four of 
drowsiness) [284, 285].  
Five studies reviewed the safety of chloral hydrate in 438 patients for the treatment of 
agitation [282, 283, 286, 287, 289]. There were 81 AEs with an incidence rate of 
18.5%. Mild hypoxia occurred with the highest frequency in 71 children (71 cases/438 
patients, 16.2%), while the other AEs was bradycardia 5 cases/438 patients (1.1%), 
diarrhoea 4 cases/438 patients (0.91%) and hypotension in 1 case/438 patients 
(0.2%). There were no severe AEs or death. 
There were seven case reports of 8 children experiencing chloral hydrate toxicity 
[292-298]. All children required medical interventions and hospitalisation. Five 
children required intubation for respiratory failure/hypoxia (Table 2.3.3). 
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Table 2.3. 5: Chloral hydrate serious AEs for treatment of agitation from case reports/series  
Reference, 
country 
Patient 
age 
Dose of CH AEs Treatment Hospital stay/ 
days  
Granoff et al. 
1971,  USA[292] 
22 
months 
250 mg PO Acute airway obstruction, 
cyanosis 
Intubation,  
O2 therapy 
Y (> 12 hours) 
 
 
Watts et al. 1975,  
UK[298] 
20 weeks 200-400 mg/24 hrs. Hyperamino aciduria, 
Hypermethioninemia 
Discontinuation of chloral 
hydrate   
Y (NA) 
 
 
 
Laptoo and 
Rosenfeld 1983, 
USA[293] 
2 days  30 mg/kg PO   
After 4 hrs. an additional doses (40, 45 
and 50 mg/kg) over 12 hours were 
given 
 
Respiratory failure  Intubation,  
O2 therapy 
Y (4 weeks) 
Hartley et al. 
1989, USA[294] 
2.5 
months 
30 mg/kg PRN (2- 6 doses/day) Severe bronchospasm 
developed after 2 weeks 
Oxygen therapy,  
Discontinuation of chloral 
hydrate   
 
Y (NA) 
3 months 20 mg/kg every 6 hrs. Severe bronchospasm 
developed after 1 weeks 
Oxygen therapy,  
Discontinuation of chloral 
hydrate   
 
Y (NA) 
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Table 2.3.3: Chloral hydrate serious AEs for treatment of agitation from case reports/series  
Reference, 
country 
Patient 
age 
Dose of CH AEs Treatment Hospital stay/ 
days  
Anyebuno, 
Rosenfeld 1990, 
USA[295] 
14 days 44 mg/kg every 6 hrs. and after 17 
days the dose increased to 50 mg/kg 
every 6 hrs. 
 
Respiratory depression 
after 21 days 
Discontinuation of chloral 
hydrate,   
Intubation,  
O2 therapy   
Y (2 weeks) 
Goldsmith 1993, 
USA[297] 
35 weeks 20 mg/kg every 6 hrs. After 4 days  infant 
developed   renal failure, 
respiratory depression, 
hypotension 
Intubation,  
O2 therapy, 
Dopamine and 
dobutamine drip, 
Furosemide IV  
 
Y (NA) 
Cecen et al. 2009, 
Turkey[296]  
4 months 50mg/kg chloral hydrate rectally, then 
after 5 min another dose of 50mg/kg 
was given orally 
 
Tachycardia,  
Dyspnea, 
Respiratory insufficiency, 
cyanosis 
Intubation,  
O2 therapy, 
Steroid and adrenaline 
inh. 
Y (7days) 
Inh=Inhalation, IV= Intravenous 
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2.3.4. Discussion  
Over the last 100 years, chloral hydrate has been used to treat some diseases such as 
insomnia and agitation in both children and adults.  
The most frequent use reported in this review was the treatment of agitation due to 
mechanical ventilation (445 (86.2%)). This might be because a sedation agent such 
as chloral hydrate is used to optimise ventilation [15, 299]. 
The incidence of AEs was higher in children who were given chloral hydrate for 
treatment of agitation than in neonates with 81 AEs in 438 paediatric patients 
compared to 13 AEs in 17 neonates. This might be because most children who were 
treated for agitation were under mechanical ventilation in the intensive care unit 
therefore they are very unwell and AEs are usually more frequent in this group, due to 
the use of high numbers of drugs and the possibility for drug interactions[300]. 
Hypoxia was reported as the most common AE. The higher incidence of hypoxia may 
be explained by the use of sedative drugs for long periods of time. Prolonged sedation 
was identified as a risk factor for AES [2], but it is not clear whether it resulted from 
the drug. Oxygen desaturation may have been related to insufficient mechanical 
ventilation and not directly to chloral hydrate AEs [282]. It is important to note that 
hypoxia was self-limiting in most of the evaluated cases.  
The low incidence rate of other reported AEs may be due to inaccurate documentation 
of the safety data and the difficulty of knowing how the patients reacted to the drugs 
during prolonged sedation. Gastrointestinal AEs were the second most frequently 
reported AEs, including vomiting and diarrhoea, and most of these followed 
administration for treatment of agitation. Life-threatening hypoxia and respiratory 
2.3 Chloral Hydrate for treatment uses 
 
145 
 
depression were reported in 8 children. No chloral hydrate-related deaths were 
reported. 
The success rate of chloral hydrate was high across all treatment procedures, ranging 
from 86% to 100%. Interestingly, all cases of agitation were treated successfully. This 
might be attributed to the multiple doses used for agitation on mechanical 
ventilation[213]. Correspondingly, in a study by Koa et al. (1999), the success rate 
increased from 89% to 98% following an additional dose of chloral hydrate[187]. 
Some limitations of this systematic review must be taken into account when reporting 
the results. The small number of studies that evaluated chloral hydrate safety and 
effectiveness for treatment in children limited the generalisability of the result. AEs 
may have been under-reported due to the difficulty of identifying the clinical outcomes 
in children under prolonged sedation in some studies. Additionally, many studies did 
not use a standardised definition of AE and effectiveness.  
2.3.5. Conclusions 
This systematic review evaluated the clinical use and safety of chloral hydrate for 
treatment in paediatric patients. It has been found that chloral hydrate was effective 
in most cases in which the success rate ranged as high as 100%. However, hypoxia 
was a common AE, mainly in children who were treated for agitation due to 
mechanical ventilation. These results are limited by the small number of patients and 
the non-uniformity of systems for reporting outcomes. Further clinical studies with 
larger numbers of children and constant reporting of outcomes are needed to confirm 
our findings. 
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CHAPTER THREE 
Systematic Review of Triclofos for Procedural 
Sedation in Children: 
An analysis of its safety and effectiveness 
 
3.1. Introduction 
The safety and effectiveness of chloral hydrate in children was assessed in Chapter 2 
and it was shown that chloral hydrate seems to be effective, but has a relatively high 
incidence of AEs. In this chapter, the safety and effectiveness of chloral hydrate active 
metabolite (triclofos) is assessed further. In the UK triclofos is no longer available as it 
was removed from the market in 2010 because tricofos has not been widely studied 
as a sedative agent for PS in children compared to chloral hydrate [301]. However, it 
still used in other countries such as India [301].  
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3.2.  Aims  
The aims of this systematic literature review are to evaluate the effectiveness and 
safety of triclofos for procedural sedation (PS) in children. 
3.3. Methods 
MEDLINE (1948–January 2012), EMBASE (1980–January 2012), COCHRANE (1974- 
January 2012) and CINAHL (1974- January 2012) were searched. EMBASE, MEDLINE, 
and COCHRANE library were searched separately and then combined together to 
remove duplications. CINAHL was searched manually to identify relevant articles and 
to remove duplication. All languages were included in this systematic review. 
This search was conducted using combinations of the following search terms: 
“triclofos” and “children or infant or pe*diatric* or neonate or adolescence or 
adolescences or adolescent” and “sedation” [166]. 
The search was limited to the studies that assessed triclofos safety and/or 
effectiveness in children, up to 18 years, undergoing PS. 
Exclusion Criteria were: 
 Patients older than 18 years. 
 Not used for sedation or treatment. 
 Not used for diagnostic procedure. 
 Any letter or review article; however, references were checked.  
The population of the study was defined as children and adolescents 18 years and 
younger. Age was grouped as preterm neonates (<36 weeks gestation, 0–27 days), 
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full-term neonates (0–27 days, >37 weeks gestation), infants (28 days–23 months), 
children (2–11 years) and adolescents (12–17 years)[167]. 
3.3.1. Data extraction 
The following data were extracted from each study: 
• Sample size. 
• Study region. 
• Study design. 
• Dose of triclofos.  
• AEs of triclofos. 
• Other used sedative drug (s). 
• Supplementary dose of sedative drug(s). 
• Induction time of sedation. 
• Duration of sedation. 
• Success rate. 
Data was extracted onto a data collection sheet.  AEs were categorised according to 
their severity into mild or serious AEs. Subsequently, these AEs were analysed for 
each children group to detect their incidence. Data were analysed statistically using 
SPSS version 22. Incidences were calculated for AEs, excluding case reports. Due to 
the heterogeneity between the studies it was not possible to perform statistical meta-
analysis.  
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Trial quality was assessed by two reviewers (BS and HS) independently. Jadad scoring 
checklists for harm reporting were used to evaluate RCTs [168]. Studies with a 
minimum score of ≥ 3 were considered as good quality. The STROBE checklist  was 
used to evaluate the qualities of prospective observational and retrospective studies 
[169]. Any study with a minimum score of 70% was considered as good quality.   
 
3.4. Results 
140 clinical studies were identified after searching through EMBASE, MEDLINE, 
COCHRANE, and CINAHL data bases. After limitation to humans, the remaining articles 
were 114.  Out of these articles, 19 articles were excluded because of duplication. The 
abstracts of the remaining articles were then reviewed according to the inclusion and 
exclusion criteria. After reviewing 95 abstracts, 54 articles were obtained as full text. 
Only 17 articles fulfilled our inclusion criteria (Figure 3.1). The included studies were 
then categorised according to the type of diagnostic or treatment procedure [16].  
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Figure 3. 1: Flow chart of triclofos 
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All 17 studies were published between 1972 and 2012. The majority (10) were RCTs. 
There were 4 prospective studies and 3 case reports. The studies were conducted in 6 
different countries including: India (6), the UK (5), Japan (2), the USA (2), Finland 
(1), and Israel (1). The total number of children who were given triclofos was 688, 
aged from birth to 15 years. Five (29%) of the studies involved infants only. The 
largest group of children who received triclofos was in RCTs (543 children) (Table 
3.1).  
Triclofos was administered as a sedative for either painless or painful PS. It was given 
via the oral route in all studies, the dose ranged from 10 to 80 mg/kg. 
Table 3. 1: Summary of 17 studies that reported on clinical effectiveness and 
safety of triclofos for painless and painful procedures in paediatrics 
Studies’ characteristics Number of studies  Number of children 
Type of study N=17 N=688 
 Randomised controlled trial 10 543 
 Prospective observational 4 142 
 Case report 3 3 
Type of procedures  
 
 
 
 Painless procedures 5 170 
 Painful procedures 12 518 
Route of Administration           
 
 
 
 Oral 17 688 
Age groups  
 
 
 
 Preterm neonates 0 0 
 Term neonates 0 0 
 Infants 5 86 
 Children 4 185 
 Other patient age groups* 8 417 
*Including paediatric studies for which the age group was not stated or mixed ages. 
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A 96% agreement level between the two assessors was reached. No RCT study fulfilled 
all 5 Jadad criteria. Seven studies met ≥3 criteria whereas 3 studies met ≤ 2 criteria 
(Table 3.2). With regard to the observational studies, only one study was rated less 
than 70% (Table 3.3). All studies were included in the systematic review to avoid 
missing any data from these articles due to the small number of publications identified 
for each painless and painful procedure. The quality scoring and selection of papers 
and abstracts was checked by two independent reviewers (BS and HS). 
Table 3. 2: Quality assessment criteria of RCTs. 
References  Jadad score (out of 5) 
Parameswari et al., 2010 [302] 4 
Millichap ,1972 [174] 3 
Gupta et al., 1972 [128] 3 
BOYD, 1973 [303] 3 
Page,  1990 [304] 3 
Singh et al., 2003 [305] 3 
Shabbir et al., 2011 [301] 3 
Lindgren et al., 1980 [306] 2 
Sharma et al., 1992 [307]  2 
Bhatnagar et al., 2012 [308] 1 
 
Table 3. 3: Quality assessment criteria of observational studies. 
References STROBE scoring ( out of 22) % 
 
Jackson et al, 1991[130] 17 77 
Stocks et al, 1994[309] 17 77 
Rabbette et al., 1991[310] 16 73 
Udani et al. 1965[311] 15 68 
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3.4.1. Painless procedures 
Five studies identified recruited 170 children aged from 5 weeks to 14 years. They 
were conducted in 4 different countries (2 in the UK, and one in each India, Japan, 
and the USA). Triclofos effectiveness and safety were evaluated for 5 different 
painless procedures (Table 3.4) 
Table 3. 4: Types of painless procedures 
Painless procedure Number of studies 
CT 1 
EEG 1 
Measurement of Hearing-Breuer inflation (HBR) 1 
Hypnotic test (psychological test to assess mental state) 1 
Lung plethysmography study 1 
Total number 5 
 
One randomised double-blind study was published in 1972 [174]. This study 
compared the safety and effectiveness of oral triclofos with oral chloral hydrate for 
EEG. 37 children, aged from 4 to 14 years, received (33 mg/kg) triclofos orally and 34 
children (22 mg/kg) chloral hydrate orally. The mean time of sedation induction was 
similar for triclofos, 36.6 minutes and chloral 37.3 minutes respectively. Sedation was 
successful in 31 patients (84%) given triclofos and 30 patients (88%) with chloral 
hydrate. 12 AEs (12/37 patients, 32.4 %) were documented during triclofos sedation. 
The most frequent AEs for triclofos were drowsiness 5 cases/37 patients (13.5%), 
followed by: ataxia 3 cases/37 patients (8.1%), dizziness 3 cases/37 patients (8.1%) 
and grogginess 1 cases/37 patients (2.7%) children.  
One prospective observational study was conducted in the UK to evaluate safety and 
effectiveness for Hearing-Breuer inflation (HBR) test in 33 infants aged from 4 to 6 
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weeks [310]. Triclofos was administered orally in doses of 75 mg/kg. Only one infant 
(3%) failed to sleep following sedation. 
One prospective study conducted in India evaluated triclofos safety and effectiveness 
for hypnotic test (induce sleep) in 50 paediatric patients aged from 3 months to 12 
years [312]. The dose of triclofos was between 22 and 44 mg/kg (maximum 66-88 
mg/kg) orally. Mean sedation time was 60 minutes. The only AE was vomiting which 
occurred in one child. 49 (98%) were successfully sedated. 
A prospective study conducted in the UK, assessed the lung plethysmography in 49 
infants, aged 5 to 8 weeks [309]. The dose of triclofos was 75 mg/kg orally. The 
plethysmography study was done successfully for all 49 infants (100%). There was no 
incidence of any AE. 
There was one case report of a 28 weeks old male who developed pedalling-like 
movements after receiving a dose of 80 mg/kg orally for a CT scan [313].This AE 
lasted for approximately two hours. Medical interventions were not required.  
The following tables (3.5, 3.6) summarise the AEs and clinical effectiveness data of 
triclofos (PS). 
Table 3. 5: Triclofos sedation success rates 
Type of procedure  No. of patients Triclofos dose  Success rate (%) 
Lung plethysmography study  49 75 mg/kg 100 
Hypnotic test (induce sleep)  50 22 to 44 mg/kg 98 
Hearing-Breuer inflation (HBR) 33 75 mg/kg 97 
Electroencephalogram (EEG) 37 33 mg/kg 84 
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Table 3. 6: Triclofos sedation AEs. 
Type of procedure Triclofos dose  Frequency Incidence   of AEs     (%) 
Electroencephalogram (EEG)  33 mg/kg 12 12/37 patients (32.4%) 
Hypnotic test  22 to 44 mg/kg 1 1/50 patients (2%) 
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3.4.2. Painful procedures 
There were 12 studies involving 518 children aged between 0 and 15 years old. Three 
studies were conducted in India, the USA, and the UK, and one in each Finland, Israel, 
and Japan (Table 3.7). The majority were RCTs 
Table 3. 7: Summary of 12 studies that reported on clinical effectiveness and 
safety of triclofos for painful procedures in paediatrics 
Studies’ characteristics Number of studies  Number of children 
Type of study N=12 N=518 
 Randomised controlled trial 9 506 
 Prospective observational 1 10 
 Case report 2 2 
Type of procedures  
 
 
 
 Dental  4 123 
 Minor surgery 8 395 
Route of Administration           
 
 
 
 Oral 12 518 
Age groups  
 
 
 
 Preterm neonates 0 0 
 Term neonates 0 0 
 Infants 2 2 
 Children 4 185 
 Other patient age groups* 6 331 
*Including paediatric studies for which the age group was not stated or mixed ages. 
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3.4.2.1. Triclofos effectiveness 
Four RCTs were identified for dental procedures (Table 3.8), all performed in India. 
The total number of children was 123, with age ranging from 15 months to 9 years. 
Triclofos was given in combination with other sedative agents (promethazine) in one 
study [307]. Triclofos was given via the oral route in doses that ranged from 70 to 75 
mg/kg (median 70 mg/kg). The success rate ranged between 76 and 100%, median 
99% (Table 3.8). 
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Table 3. 8: RCTs for dental procedures  
Reference, 
country   
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
dose/med 
(No.) 
Sedation (min) 
Onset Duration  
Sharma et al., 
1992, India  
[307] 
Cross-over 
study 
36- 60 
months 
21 
22 
TRI 
TRI+PRO 
75 PO 
59+1 PO 
76 
86 
NA 
NA 
NA 
NA 
NA 
NA 
Singh et al., 
2003, India  
[305]  
Double-blind 
RCT 
15- 45 
months 
30 
30 
30 
TRI 
M 
PRO  
70 PO 
0.5 PO 
1.2 PO 
100 
100 
100 
NA 
NA 
Mean 35 
Mean 19 
Mean 37 
Mean 131 
Mean 93 
Mean 143 
Shabbir et al., 
2011, India  
[301]  
Cross-over 
study 
3- 9 years 12 
12 
TRI 
M 
70 
0.5 
98 
100 
N 
N 
NA 
NA 
NA 
NA 
Bhatnagar et 
al., 2012, 
India   [308] 
Single-blind 
RCT 
3- 9 years 60 TRI 
M 
TR 
Z 
70 PO 
0.5 PO 
2 PO 
0.4 PO 
100 
100 
100 
100 
NA 
NA 
NA 
NA 
NA 
NA 
 HYD=Hydroxyzine, M=Midazolam, MEP= Meperidine, PRO= Promethazine, TR= Tramadol, TRI=Triclofos, Z=
 
Zolpidem 
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A total of five studies were identified involving administration before anaesthesia 
minor for surgery. All were published between 1972 and 2010. The studies were 
performed in four different countries; two in the UK and one in each; Finland, India 
and the USA. The total number of children involved was 383, in children from birth to 
fifteen years. The success rate ranged from 50 to 98%, median 80% (Table 3.9).  
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Table 3. 9: RCTs for minor surgery 
Reference, 
country   
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
dose/med 
(No.) 
Sedation (min) 
Onset Duration  
Gupta et al., 
1972, UK  [128] 
Double-blind RCT/ 
preoperative 
sedation 
2- 13 
years 
95 
95 
TRI 
TRI+ 
HY 
75 PO 
75+ 0.035 PO 
80 
80 
NA 
NA 
NA 
NA 
NA 
NA 
 BOYD and 
MANFORD, 
1973, UK [303] 
Double-blind RCT/ 
preoperative 
sedation 
2-9 years 99 
101 
TRI 
D  
71 PO 
0.2 PO 
90 
81 
NA 
NA 
NA 
NA 
NA 
NA 
Lindgren et al., 
1980, 
Finland[306]   
Double-blind RCT/ 
Otolaryngological 
surgery 
0-15 years 41 
87 
TRI 
D+F  
70 PO 
0.25+0.02 PO 
50 
100 
NA 
NA 
NA 
NA 
NA 
NA 
Page and 
Morgan-
Hughes,1990, 
USA  [304] 
Double-blind 
RCT/day-case 
surgery 
1- 5 years 128 
135 
TRI 
P 
70 PO 
 
98 
98.5 
NA 
NA 
90 
NA 
NA 
NA 
Parameswari et 
al.,2010, India 
[302] 
Double-blind 
RCT/elective 
surgery 
1-10 years 20 
20 
TRI 
M 
75 PO 
0.5 PO 
65 
20 
NA 
NA 
90 
NA 
30 
NA 
 D=Diazepam, F= Flunitrazepam, HY= Hyoscine, P=Placebo, TRI=Triclofos, M=Midazolam
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3.4.2.2. Triclofos safety 
Two RCTs evaluated Triclofos safety for dental procedures [305, 307]. The total 
number of children was 51 aged from 15 to 60 months. Triclofos was given in a 
median dose of 72.5 mg/kg. Only one patient developed vomiting (1/51 patients, 
2%).  
Six studies evaluated triclofos toxicity for minor surgery [128, 130, 302-304, 306]. 
They included 393 children aged from 0 to 15 years. Triclofos was given orally, 70 to 
100 mg/kg (median 75 mg/kg). 120 AEs with the incidence rate of 30.5% (120 
AEs/393 children). Vomiting was the most frequent AE occurring in 60/393 patients 
(15%) followed by; mild hypoxia in 48/393 patients (12%) and restlessness in 12/393 
patients (3%) patients. 
There were two case reports of male infants aged two months and ten months who 
received oral triclofos for sleep induction [314, 315], doses were 1800 mg and 
120mg/kg respectively (medication errors). After six hours the first infant developed 
deep coma, severe hypothermia, hypotension and lack of tendon reflexes. He was 
admitted to the hospital and was given intravenous fluids and was monitored for more 
than four days until he became stable. Another 10 months infant developed cyanosis 
due to upper airway obstruction following oral administration of triclofos. He required 
medical interventions (oxygen supplementation) and hospitalisation. 
Table 3.10 and table 3.11 summarise triclofos safety and effectiveness data in 
children undergoing painful procedures.  
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Table 3. 10: Triclofos sedation success rates of all painful procedures 
Type of painless procedures Triclofos dose range mg/kg 
(median)  
Success rate 
(median) 
Dental procedure  70 to 75 mg/kg  
(70 mg/kg) 
76 to 100% 
(99%) 
Minor surgery and sleep induction 70 to 75 mg/kg  
(71 mg/kg) 
50 to 98% 
(80%) 
 
Table 3. 11: Sedation AES all painful procedures 
Type of procedure 
(No. of patients) 
No. of patients Triclofos dose range 
mg/kg (median) 
Frequency Incidence   of 
AEs        (%) 
Minor surgery and 
sleep induction 
393 70 to 100 mg/kg  
(75mg/kg) 
120 120 /393 patients 
(30.5%)  
Dental procedure 51 70 to 75 mg/kg  
(72.5 mg/kg) 
1 1/51 patients (2%)  
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3.5. Discussion 
Triclofos (trichloroethanol) is an active metabolite of chloral hydrate. However, its use 
is limited in some countries for instance; in the UK, triclofos is not among the sedation 
agents commonly used in the NHS [80]. The present systematic review suggests that 
triclofos can be an effective and safe sedative agent for children and young people 
undergoing certain diagnostic or treatment procedures. 
The systematic literature review in this study yielded 17 articles. Surprisingly, these 
indicated that triclofos was used more frequently for painful therapeutic procedures 
than painless diagnostic procedures (71% and 29% respectively). This finding 
contrasts with various guidelines that recommend the use of triclofos as a sedative 
agent only for painless treatment or diagnostic procedures [316]. 
Approximately 1 in 5 children (21.9%) experienced an AE with triclofos. The incidence 
of AEs was significantly higher following triclofos administration for painful procedures, 
particularly sleep induction before minor surgery, compared with painless procedures 
(27.3% (121/444) versus 7.7% (13/169)). This result agrees well with the findings 
obtained by Boyd and Manford (1973) who found a high incidence of AEs after 
triclofos (PS) for children aged from two to nine years undergoing ear, nose and 
throat (ENT) surgery [303]. This was thought be due to the administration of 
intravenous barbiturate medication such as thiopentone and methohexitone for 
induction and/or procedure itself such as dental treatment procedures [303, 306]. 
Additionally, these results were comparable with those reported for chloral hydrate in 
Chapter 2, in which the incidence of AEs was higher in painful procedures than it was 
in painless procedures (17.3% (313 AEs/1810 patients) versus 13.5% (1,951 
AEs/14439 patient) respectively).   
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 According to this systematic review the types of AEs were different according to the 
type of diagnostic or treatment procedure. The most commonly reported AE was 
vomiting with the incidence rate of 10% (62/613) children. This AE was higher with 
painful procedures (minor surgical procedure) compared with painless procedures 
(hypnotic test) 15% (60/393) versus 2% (1/50) respectively. In a prospective study 
of ear, nose and throat (ENT) surgical procedures, vomiting was more common in the 
post-operative period in children receiving triclofos (55.5%) versus (52.5%) in 
diazepam group [303]. It seemed unlikely that the triclofos premedication was a 
causal factor since they found that the nature of the vomitus in almost every case was 
altered blood. Most of the vomiting documented in this review was not severe and did 
not warrant medical intervention. 
The second most commonly reported AE revealed in this review was hypoxia, with a 
risk of 7.8% (48/613). This AE was reported only in healthy children undergoing 
painful procedures (minor surgery; 12% (48/393)). This result agrees with those 
obtained in other studies. In a study of children undergoing triclofos PS for sleep 
induction prior to elective surgery, Jackson and colleagues (1991) found that 
administration of triclofos in doses up to 100 mg/kg led to development of mild 
hypoxia (approximately 70% infant) [130]. All hypoxia cases were mild (SpO2 90-
95%) and did not required medical intervention. 
In our systematic literature search, only two serious AEs were found. These AEs were 
due to administration in over dose (1800 mg and 120mg/kg) to two male infants aged 
two and ten months respectively [314, 315]. Hypotension and lack of tendon reflexes 
occurred with the first infant, while cyanosis developed in the second infant. Both 
cases required medical interventions and hospitalisation. One AE (pedalling like 
movements) was developed after administration of a dose of 80 mg/kg of chloral 
hydrate to a 28 weeks old infant[313]. Medical interventions were not needed. 
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The success rate of painless PS compared with painful procedures was found to be 
higher (ranged from 84% to 100% versus 50 to 100%). This might be because the 
painful dental treatment procedures required a longer duration of time to be 
completed  or because of inadequate analgesia [307, 317].  
3.6. Limitations 
The results of this systematic review must be construed with caution because of a 
number of limitations. Few studies had the clear objective of determining the clinical 
effectiveness of triclofos as a sedative in either painless or painful procedures. The 
assessment of outcomes was inconsistent. As well, the statistical methods in the 
various studies were diverse. Some of the findings were limited by the number of 
children. Finally, the rarity of noted AEs might be due to inadequate reporting. 
3.7. Conclusions 
The systematic review suggests that triclofos seems to have a good sedative effect 
mainly with short painless PS. Vomiting and hypoxia AES were the most commonly 
reported AEs. However, these findings are limited by low patient numbers and the 
non-uniformity of outcomes reporting system(s). 
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CHAPTER FOUR 
Paraldehyde Safety and Clinical Effectiveness 
for Procedural Sedation in Children: A 
Systematic Review 
4.1. Introduction 
Several classes of drugs have been used for providing comfort to children during 
various procedures. In the UK, drugs used for procedural sedation (PS) in children 
include: Chloral hydrate, Fentanyl, Ketamine, Midazolam, Morphine, Nitrous oxide, 
Opioids, Propofol and Sevoflurane [318]. In previous chapters chloral hydrate and 
triclofos safety and effectiveness for PS in children were studied. This chapter 
discusses an additional drug, paraldehyde.  
Currently, in many countries, the use of paraldehyde is limited to the treatment of 
convulsive episodes in patients with tetanus and status epilepticus [163]. However, in 
some countries, such as the UK, paraldehyde is still used for PS in children as a part 
of the local hospital’s sedation policy (e.g. Derbyshire Children’s Hospital). Moreover, 
there are concerns about its adverse events (AEs), including respiratory depression 
and cardiovascular collapse, especially when given in high dose(s). Paraldehyde is still 
used as an add on agent in the sedation protocol of the Royal Derby Children’s 
Hospital, therefore, we found that evaluating the literature about its safety and 
effectiveness is very important.  
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4.2. Methods 
A systematic literature review was conducted to identify studies evaluating the 
efficacy and safety of paraldehyde in paediatric patients aged 18 years and younger. 
The following databases were searched separately and then combined together to 
remove duplications: MEDLINE, EMBASE, International Pharmaceutical Abstracts (IPA) 
and PubMed. 
All articles published between 1948 and August 2013 were considered. All languages 
were included in this systematic literature review.  
Selection of the keywords in this systematic review was based on their sensitivity and 
specificity according to validated age specific search strategy by Hedges Team [166]. 
Thus it has been found that the most sensitive and specific keywords were as 
following: paraldehyde and children or infant or pe*diatric* or neonate or adolescence 
or adolescences or adolescent and sedation (combined with the Boolean operator 
“OR”). 
Inclusion criteria were original studies assessing the safety and clinical effectiveness 
of paraldehyde as a sedative medication in children, up to the age of 18 years, 
undergoing diagnostic and/or treatment PS.  
Exclusion Criteria were: 
• Patients who are older than 18 years. 
• Paraldehyde not used for sedation. 
• Any comment, editorial or review article. 
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Data extracted from each article included the publication year, study period, study 
region, study design, number of children exposed, age of children exposed, dose of 
paraldehyde, route of administration, induction time of sedation, duration of sedation, 
success rate and AES data.  
Assessment of trial quality for each paper was made in order to reduce the risk of 
bias. The STROBE checklist was used to score both prospective observational studies 
and retrospective study [169]. Any study with a minimum score of 70% was 
considered a good quality study. All studies were included in the systematic review to 
avoid missing any data from these articles due to the small number of articles found 
which assessed paraldehyde safety and effectiveness for PS. The quality and selection 
of papers and abstracts were checked by two independent reviewers (BS and HS). 
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4.3. Results 
The initial search revealed 445 references. 266 articles remained after limitation to 
human and removing the duplication was applied (Figure 4.1), and after reviewing the 
titles and abstracts of these articles, 234 articles did not fulfil the inclusion criteria. 32 
articles were read, but 27 did not meet the inclusion criteria, leaving only 5 articles 
figure (4.1) and table (4.2). 
Three of the 5 included studies were rated above 70%.  All studies were included in 
the systematic review. Meta-analysis was not performed due to the heterogeneity of 
the studies. The scores for the STROBE checklist for observational studies are 
illustrated in table 4.1.  
Table 4. 1: Quality assessment criteria of included observational studies 
References STROBE scoring ( out of 22) % 
 
Palomo et al. 1988[319] 19 86 
Keengwe et al. 1999[320] 18 82 
Adenipekun et al. 1997[321] 17 77 
Dearlove ,2007[322] 15 68 
Sammons et al. 2011[323] 14 64 
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Figure 4. 1: Flow chart of study 
 
 
 
 
 
 
 
 
 
 
 
 
PubMed 
78 
 
 
MEDLINE 
 91 
 
IPA 
14 
 
EMBASE 
262 
 
445 Articles 
 
32 Articles 
 
413 Removed after 
screening abstract for 
irrelevant articles and 
duplications 
173 Abstracts not 
meeting      inclusion 
criteria 
107 Duplicate 
citations 
72 Non-humans 
58 Review article 
3 Surveys 
 
27 Original articles not 
meeting inclusion 
criteria  
criteria 
5 Included 
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Table 4. 2: Characteristics of the five selected studies  
Study/ Country Type of study No. of 
children 
Paraldehyde 
group 
Age No. (%) of AEs  
Palomo et al., 
1988/Spain [319] 
Prospective 
observational 
8 8 18 months to 4 years 2 (25%) vomiting   
Adenipekun et al., 
1997/Nigeria [321] 
Retrospective 84 Not specified 1 month to 6 years 35 (85.4%) injection cellulitis,  
3 (7.3) paresis of lower limb,  
2 (5%) sterile abscesses,  
1 (2.4%) aspiration pneumonia 
Keengwe et al., 
1999/UK [320]  
Prospective 
observational 
1857 Not specified 5 months to 19 years Not specified 
Dearlove and 
Corcoran, 2007/UK 
[322] 
Prospective 
observational 
4643 Not specified Not specified Not specified 
Sammons et 
al.,2011/UK [323]  
Prospective 
observational 
audit 
297 149 (0.5%)  Median 2 years  Not specified   
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The five studies identified were published from 1988 to 2011. The majority (4) were 
prospective observational studies. They were performed in three different countries 
(Nigeria, Spain and the UK) (Table 4.1). 
The first study was published in 1988 by Palomo et al. to evaluate the efficacy and 
safety of paraldehyde when administered rectally to eight paediatric patients, aged 
from 18 months to 4 years undergoing audiometric tests [319]. The dose of 
paraldehyde ranged between 0.15 ml/kg and 0.5 ml/kg.  Effective sedation was 
achieved in 6 (75%) of the children, while two children (25%) failed (there was no 
relation between the paraldehyde dose and sedation duration).  The onset of action 
was reached within 5 to 15 minutes and the duration of sedation was from 4 to 8 
hours.  The only reported adverse event was vomiting, occurring in 2 cases/8 children 
(25%) of the patients.   
A retrospective study evaluated the occurrence of complications following sedation of 
children undergoing radiotherapy [321]. The authors reviewed the records of 84 
children aged from one month to six years. The doses of sedative agents were 25mg 
to 50mg chlorpromazine, 6.25mg to 12.5mg promethazine, I.M paraldehyde and I.V 
diazepam. Complications were observed in 41 children (41/84, 49%). Tolerance was 
distinguished by the third week of paraldehyde daily I.M injection which led to an 
increase in the dose or addition of diazepam I.V. Reported AEs included  injection 
cellulitis 35 (35/41, 85.4%), paresis of lower limb 3 (3/41, 7.3), sterile abscesses 2 
(2/41, 5%), and aspiration pneumonia 1 (1/41, 2.4%). The authors did not mention 
how many children received paraldehyde alone or in combination with other drugs. 
The following year (1999), Keengwe and colleagues conducted a prospective 
observational study to assess the efficacy and safety of their structured sedation 
program [320]. A total of 1857 children aged between 5 months and 19 years 
undergoing MRI scans received either oral sedation that consisted of chloral hydrate 
4 Paraldehyde for procedural sedation in children 
 
173 
 
90 mg/kg (maximum 2g) orally with or without rectal paraldehyde 0.3 ml/kg (in 
children ≥6 years). All MRI scan requests for paediatric patients who failed oral PS, as 
well as those diverted for general anaesthesia from the beginning, were allocated to 
undergo the MRI scan with either general anaesthesia or intravenous sedation after 
reassessment by a consultant anaesthetist. Sedation was accomplished in 93.1% of 
the children given oral sedation.  
The only adverse events were reported in oral chloral hydrate group alone in which 
two paediatric patients developed severe respiratory depression necessitating 12 to 18 
hours monitoring in the hospital following scanning. No data was given regarding the 
number of patients receiving paraldehyde.  
From 2002 to 2006, the efficacy and safety of the structural sedation programme of 
Manchester children’s hospitals for MRI examination in paediatric patients were 
evaluated  [322]. 4165 children underwent PS. For those <20 kg the agents 
prescribed were 100 mg/kg up to maximum dose of 2 gm of chloral hydrate with or 
without 0.3 ml/kg paraldehyde. For those >20 kg quinalbarbital 10mg/kg up to 200 
mg orally was prescribed. Additionally, there were 478 children who underwent 
general anaesthetics due to sedation failure or general anaesthesia referral. The total 
failure rate was 11% (478 of 4165 children). There were five AEs which were 
respiratory complications due to PS. Only, one AE developed after general anaesthesia 
(not specified by authors).  Numbers, safety and/or clinical effectiveness data for 
those that received paraldehyde sedation were not specified as a separate group.  
Another observational study evaluated the safety and clinical effectiveness of both 
sedation and anaesthesia for neuroimaging procedure in children from 2000 to 2004 
at the University hospital of Nottingham [323]. The population consisted of 297 
patients (median of 2 years of age) given sedation for neuroimaging. The sedation 
regimen included- Chloral hydrate 50 to 100 mg/kg to a maximum of 2 g, with or 
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without rectal paraldehyde 0.3 ml/kg for children younger than four years and 
Quinalbarbitone 7.5 to 10 mg/kg to nearest 25 mg to a maximum of 200 mg, with or 
without rectal paraldehyde 0.3 ml/kg for children older than four years. Chloral 
hydrate was given as the first drug to 64%, quinalbarbitone to 35%, paraldehyde to 
0.5% and midazolam to 0.5%. A second drug was administered in 16% cases. 
Successful sedation was achieved in 92% of the children, with median duration time 
of three hours and 9 minutes. 1.5 % cases failed to achieve sedation. Vomiting 
occurred in 36% of the paediatric patients and 20% were given supplemental oxygen 
throughout the neuroimaging scan. Additionally, one serious adverse event occurred, 
the child required oxygen therapy and hospitalisation.  In another group 111 
paediatric patients, with median age of 5 years, were given general anaesthesia for 
neuroimaging procedure, all were completed successfully. Vomiting was developed by 
one child after awakening from general anaesthesia and two children developed 
nausea. Median duration time for general anaesthesia was one hour and 30 minutes. 
The authors concluded that general anaesthesia is more convenient and better 
tolerated than (PS) for paediatric neuroimaging. No separate data was given for the 
patients receiving paraldehyde. 
4.4. Discussion 
The aim of this systematic literature review was to evaluate paraldehyde safety and 
clinical effectiveness in order to develop evidence based for its use as sedative agent 
in children. However this systematic review could not find any studies evaluating 
and/or comparing the safety and /or clinical effectiveness of paraldehyde with other 
available sedative dugs commonly used for (PS) in children.  
The major problem associated with assessing the safety and clinical effectiveness of 
paraldehyde sedation is the small number of studies, their poor quality and limited 
data available within them. In Palomo and colleagues (1988), the data is from only 
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eight subjects, which is too small to evaluate safety, however this was the only study 
that clearly aimed to evaluate use and safety in children [319]. It found only two 
cases of vomiting that were self-limiting and required no therapeutic intervention.  
The number of children who received paraldehyde, alone or in combination with other 
sedative agents, and the number and severity of AEs were not mentioned in 2 of the 
reviewed studies [320, 322]. The studies by Sammons et al. (2011) and Dearlove 
(2007) evaluated the safety and efficacy of their institutional (PS) guidelines [322, 
323]. Paraldehyde was used as a second-line agent and was not separately described. 
With respect to secondary outcomes, none of the studies that evaluated the 
effectiveness of paraldehyde used the Ramsey Sedation Scale (RSS) or another 
precise measurement system. Palomo et al. (1988) concluded that sedation was 
effective in 3/4 of the children, however, the study did not describe the exact dose of 
rectal paraldehyde [319]. 
The trial by Keengwe and colleagues (1999) compared the efficacy of oral sedation, 
intravenous sedation and general anaesthesia, but no data was given about clinical 
effectiveness of paraldehyde sedation alone or as a second line sedative [320].  
We do not feel that there is any evidence in the literature that currently supports the 
use of paraldehyde as a first or second line agent for sedation in children. 
4.5.  Limitations 
Our systematic literature review is limited by the small number of studies that 
evaluated the outcomes. The data were pooled from only 3 studies that evaluated the 
AEs and successful PS of paraldehyde. Accordingly, our results regarding safety and 
clinical effectiveness can only be considered preliminary. 
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4.6. Conclusions 
This systematic review was carried out to evaluate paraldehyde safety and clinical 
effectiveness for paediatric (PS). The data were limited and available in only 5 studies, 
and the evidence for the use of paraldehyde in (PS) in children remains questionable. 
This highlights the importance of further large and well-designed studies to confirm its 
future use. 
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CHAPTER FIVE 
Midazolam for Sedation of Children during 
Imaging Procedures: A Systematic Review 
5.1. Introduction 
Several sedatives are available for procedural sedation (PS) in children[254]. The 
choice of drug depends on practice, guidelines and physician comfort[324]. Midazolam 
belongs to a class of benzodiazepines named imidazobenzodiazepines[12]. Clinically, 
midazolam is primarily used as premedication or as a sedative for minor procedures 
because it has a relatively rapid onset of action and short half-life [325]. It also has 
anticonvulsant and muscle relaxant characteristics [326]. 
Midazolam is extensively used for sedation in children word-wide.  In this chapter I 
will describe a systematic literature review of studies evaluating midazolam 
effectiveness and safety as a sedative agent in children undergoing imaging 
procedures. We focused on its use for imaging procedures because midazolam is the 
recommended drug at the Royal Derby Hospital for imaging diagnostic procedures in 
children over 15 kg. However, a local hospital audit study (unpublished) conducted at 
the hospital evaluating the effectiveness of midazolam during imaging procedures in 
20 children suggests that midazolam does not work (only 40% of children completed 
their procedures after sedation was supplemented with paraldehyde, while no children 
on midazolam alone completed their procedures).  
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5.2. Method  
This systematic literature review was conducted using MEDLINE (1948– September 
2014), EMBASE (1980– September 2014), International Pharmaceutical Abstracts 
(IPA) (1970- September 2014), and PubMed (until September 2014).   
In order to select the most specific and sensitive key words for the search strategy, an 
initial search for related terms was conducted. These terms were used by previous 
review studies by Lourenço-Matharu et al. in 2012 and Morão et al. in 2011 [327, 
328]. Our search terms were also selected according to a validated age-specific search 
strategy developed by the Hedges Team [166]. These terms included: midazolam and 
children or infant or pe*diatric* or neonate or adolescence or adolescences or 
adolescent and Hypnotics or Sedatives or Anti-Anxiety Agents or Conscious sedation 
or Preanesthetic medication or preanaesthetic medication or sedat$ or Anxiety or 
anxiety or anxious or fear$ or fright$ or stress$ or distress$ or phobi$ or 
uncooperative or un-cooperative or unco-operative. 
All studies, irrespective of language, which evaluated midazolam safety or adverse 
events and clinical effectiveness, were included. Letters, comments, editorials, notes, 
review articles, studies involving patients older than 18 years and studies that did not 
use midazolam for PS during imaging were excluded. 
All selected abstracts were double-checked to ensure that they satisfied the inclusion 
and exclusion criteria. The included articles were read carefully, and the following data 
was extracted from each study: sample size, study region, study period, study design, 
dose of midazolam, adverse drug events of midazolam, other sedative drug(s) used, 
supplementary dose of sedative drug(s), induction time of sedation, duration of 
sedation, failure rate and success rate. The children were grouped by age: less than 2 
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years, from 2 through 11 years, and from 12 through 18 years, according to the 
guidelines of the International Conference of Harmonization (ICH) [167]. 
 Outcome measures 
1. Evaluating the incidence of AEs in children who received midazolam.  
2. Evaluating success rate of imaging procedures. 
AEs were categorised as either serious or mild, according to the European Medicines 
Agency guideline [50] 
 A serious AE is defined as “any untoward medical occurrence that, at any dose, 
results in death (or) is life-threatening, (or) requires inpatient hospitalisation or 
prolongation of existing hospitalisation (or) results in persistent or significant 
disability/incapacity, or is a congenital anomaly/birth defect”. 
 A mild AE is defined as “any AE that occurred that did not need any 
intervention”.  
Hypoxia was regarded as mild when the value of arterial haemoglobin oxygen 
saturation (SpO2) fell to between 90 and 95%, moderate between 85 and 89%, and 
severe when less than 85%[120]. Successful PS was defined as the ability to sedate 
the child to the target sedation level and the ability to achieve the imaging 
procedure[262]. 
All studies were assessed for risk of bias. The Cochrane collaboration’s tool was used 
to evaluate randomized controlled studies (RCTs) [329]. Prospective observational 
studies, and retrospective studies were assessed using the STROBE checklist [169]. 
Any study with a minimum score of 70% was considered to be of good quality. 
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Data from included studies were analysed statistically using SPSS version 22. 
Incidence was calculated by dividing the number of AEs by the number of children 
exposed to midazolam, excluding case reports. The clinical efficacy was calculated as 
the weighted mean difference of the number of children whose procedures were 
completed successfully with midazolam compared to placebo or other sedative agents. 
Fisher’s exact test was used to compare sedative supplementations between imaging 
procedures. The differences between imaging procedures was considered significant at 
P<0.05. Meta-analysis was not performed due to the heterogeneity of the studies. 
5.3. Results 
The total number of articles identified after searching EMBASE, MEDLINE, IPA, and 
PubMed databases was 4402. After removing duplications and to include only humans, 
2903 articles remained (Figure 5.1). During the initial screening of article titles and 
abstracts, 948 articles were removed, leaving 1955 articles. The inclusion and 
exclusion criteria were applied to these, resulting in 29 studies, including 17 RCTs, 10 
prospective observational studies, 1 retrospective study and 1 case report (Figure 3.1 
and Table 3.1).  
The final 29 studies were performed in 12 countries and included 6342 children (Table 
5.1), who were aged between 0 and 18 years (mean 45 months). The doses given are 
shown in Table 5.2. 
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Figure 5. 1: Flow chart of study 
PubMed 
379 
 
 
MEDLINE 
 1279 
 
IPA 
125 
 
EMBASE 
2619 
 
4402 Articles 
 
1955 Articles 
 
2447 Removed after 
screening abstract for 
irrelevant articles and 
duplications 
1749 Original articles 
not meeting inclusion 
criteria  
100 Review 
72 Survey 
5 Letters 
 
29 Included 
 
1040 Duplicate 
citations 
621 Abstracts not 
meeting      inclusion 
criteria 
459 Non-humans 
116 letters 
95 Conference 
abstracts 
47 Surveys 
43 Notes 
26 Editorials 
 
5 Midazolam for sedation of children during imaging procedures 
 
182 
 
Table 5. 1: Summary of 29 studies that reported on clinical effectiveness and 
safety of midazolam for imaging procedures in paediatrics 
Study characteristics Number of studies  Number of children 
Type of study N=29 N=6342 
 Randomised controlled trial 17 1269 
 Prospective observational 10 4704 
 Retrospective 1 367 
 Case report 1 2 
Type of imaging procedure 
 
 
 
 
 CT, MRI 19 5576 
 MCUG, VCUG 6 271 
 ECG 2 162 
 EEG 1 100 
 Gamma camera examination 1 233 
Route of Administration    
 
 
 
 
 Oral 12 1225 
 Intravenous infusion 6 3556 
 Intranasal 4 579 
 Intravenous bolus  3 376 
 Rectal 3 130 
 Not reported 1 476 
Age groups 
 
 
 
 
 Preterm neonates 0 0 
 Term neonates 2 9 
 Infants 0 0 
 Children 5 341 
 Other patient age groups* 22 5992 
MCUG= micturating cystourethrogram, VCUG= voiding cystourethrogram  
*Including paediatric studies for which the age group was mixed or not stated. 
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Table 5. 2: Routes of drug administration and ranges of midazolam doses 
Routes of drug administration Range of doses (median) 
By mouth 0.5 to 0.6 mg⁄ kg (0.5 mg/kg) 
Intranasal 0.15 to 0.5 mg⁄ kg (0.3 mg/kg) 
Intravenous bolus 0.1 to 0.6 mg⁄ kg (0.16 mg/kg) 
Intravenous infusion  
LD* 0.02 to 0.2 mg/kg  (0.2 mg/kg) 
MD** 0.15 to 0.6 mg/kg (0.3 mg/kg) 
Per rectal 0.3 to 1 mg⁄ kg (0.3 mg/kg) 
*LD= loading dose, **MD= maintenance dose 
 
 
Using the Cochrane risk of bias criteria for quality assessment five RCTs were rated 
high-risk in their blinding of participants and personnel [177, 271, 330-332]. The 
assessment of incomplete outcome was inadequately described in 5 RCTs [330-334]. 
The risk of bias in the blinding of outcome assessment was high in 4 RCTs [177, 330, 
331, 335]. Three RCTs were rated high risk in selective reporting bias [177, 332, 334] 
(Figure 5.2). Nine of the 11 observational studies were rated as meeting 70% of the 
criteria or higher. The remaining two were rated 68% [3, 336] (Table 5.3). All studies 
were included in the systematic review in order to avoid missing any data due to the 
small number of articles identified for each imaging procedure.  
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Figure 5. 2: Cochrane risk of bias criteria for quality assessment of RCT 
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Coventry et al. 1991 
       
   McCarver-May et al. 1996 
       
D'agostino, Ternderup 2000 
       
Moro-Sutherland et al. 2000 
       
            Wheeler et al. 2001 
       
 Stokland et al. 2003 
       
         Akil et al. 2005 
       
    Keidan et al. 2005 
       
   Koroglu et al. 2005 
       
     Cengiz et al. 2006 
       
        Herd et al. 2006 
       
    Yildirim et al. 2006 
       
Layangool et al. 2008 
       
   Gemma et al. 2009 
       
         Jain et al. 2010 
       
Thevaraja et al. 2012 
       
   Chokshi et al. 2013 
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Table 5. 3: Quality assessment criteria of included observational studies 
References STROBE scoring ( out of 22) % 
 
Singh et al. 2009[337] 19 86 
Ashrafi et al. 2013[338] 18 82 
Elder, 1995[339] 18 82 
Szczepaniak et al. 2004[340] 18 82 
Solvis et al. 1993[202] 17 77 
Ljung, 1996[341] 16 73 
Malviya et al. 2000[207] 16 73 
Mekitarian et al. 2013[342] 16 73 
Koroglu et al. 2005[331] 16 73 
Doganay et al. 2001[336] 15 68 
Alp et al. 2002[3] 15 68 
 
5.3.1. Midazolam Effectiveness  
All included studies were classified according to five types of imaging procedure (Table 
5.1). The measures of effectiveness in this systematic review included procedural 
success, induction time of sedation, and duration of sedation, as reported by the 
original investigators.  
Twenty three articles evaluated the clinical effectiveness of midazolam for imaging 
procedure sedation: 8 computed tomography (CT), 6 magnetic resonance imaging 
(MRI), 6 micturating urethrograms (MCUG) or voiding urethrograms (VCUG), 2 
electrocardiograms (ECG), and 1 electroencephalogram (EEG).  
5.3.3.1. CT scanning  
Eight studies (5 RCTs and 3 prospective studies) evaluated midazolam effectiveness 
for CT scanning in 650 children (Table 5.4). 
The success rate of midazolam procedural sedation was variable and ranged from 
19% in one study to 100% (median 69%). Fifty four patients (8.3%) required 
supplementary dose(s) of either midazolam 0.2mg/kg, pentobarbital 2.5 to 5 mg/kg 
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(mean 3.75 mg/kg), or ketamine/lignocaine 5 mg/kg +2 mg/kg. The onset of sedation 
for the intravenous route ranged from 3 to 15 minutes and for the rectal route ranged 
from 16 to 20 minutes. The duration of sedation for the intravenous route ranged 
from 4.8 to 55 minutes, for the oral route ranged from 4.1 to 76 minutes and for the 
rectal route ranged from 66 to 157 minutes (Table 5.3).  
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Table 5. 4: RCTs and observational studies for CT scanning 
Reference, 
country  
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
dose/med 
(No.) 
Sedation (min) 
Onset Duration 
Coventry et al. 
1991, UK[343] 
Double-blind RCT 5 months-5 
years 
15 
15 
M 
M 
0.3 PR 
0.6 PR 
87 
80 
Y (5) 
Y (5) 
16 
10 
157 
NA 
McCarver-May et 
al. 1996, USA[177] 
Single-blind 
randomised cross-
over  
Median 
14 days 
7 
7 
M 
CH 
0.2 IV 
75 PO 
43 
100 
N 
N 
3-15 
9-40 
15- 55 
15- 55 
D'Agostino & 
Terndrup 2000, 
USA[171] 
Double-blind RCT 2 months–8 
years 
22 
11 
M 
CH 
0.5 PO 
75 PO 
50 
100 
Y (12) 
Y (1) 
NA 
NA 
76 
95 
Morp-Sutherland 
et al. 2000, 
USA[333] 
Single-blind RCT 6 months-6 
years 
26 
29 
M 
PEN 
0.2 IV 
infusion 
5 IV infusion 
19 
97 
Y (16) 
N 
NA 
6 
NA 
86 
Jain et al. 2010, 
India[344] 
Double-blind RCT 1-5 years 29 
31 
32 
M 
M+K 
P 
0.5 PO 
0.25 PO+ 1 
PO 
100 
100 
100 
NA 
NA 
NA 
NA 
NA 
NA 
4.1 
4.5 
5.2 
Doganay et al. 
2001, Turkey[336] 
Prospective 
observational study 
1-18 years 30 M 
0.35 PR 100 NA NA NA 
Alp et al. 2002, 
Turkey[3] 
Prospective 
observational study 
2- 78 months 20 
30 
20 
M 
T 
C 
1 PR 
50, 35, 25 
PR 
0.1 ml/kg 
IM 
36.6 
39 
24.4 
NA 20 
15 
22 
66 
94 
118 
Singh et al. 2009, 
India[337] 
Prospective 
observational study 
6 months-6 
years 
516 M 0.2 IV 
infusion 
98 Y (16) 5.9 4.8 
CH= chloral hydrate, IV= intravenous, K= ketamine, M= midazolam, P= placebo, PEN= pentobarbital, PO= Orally, PR= per rectum (by rectum), 
T=Thiopental, C=Cocktail 
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5.3.3.2. MRI  
Three RCTs and two prospective observational studies evaluated midazolam in 143 
children aged from 1 to 18years during MRI (Table 5.5). The success rate varied from 
0 to 100% (median 67%). Success was lower after a single dose (20%) and increased 
significantly (up to 100%) after supplemental IV boluses of 0.5 mg/kg propofol[331, 
335]. 35 children (24.5%) required supplementary sedatives (midazolam 0.2 mg/kg 
or propofol 0.5 mg/kg) to complete the procedures. The onset of sedation varied from 
15 to 43 minutes and the duration of action ranged from 2.5 to 118 minutes.   
Patients receiving CT scans were less likely to require supplemental doses of sedative 
compared to those receiving MRI (RR= 27.6, 14% CI: 33-53.15, P=0.0001).  
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Table 5. 5: RCTs and observational studies for MRI 
Reference, 
country  
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate (%) 
Supplementary 
dose/med (No.) 
Sedation (min) 
Onset Duration 
Koroglu et al. 
2005, 
Turkey[331] 
Single-blind RCT 1-7 
years 
40 
40 
M 
Dext 
0.6 IV infusion 
0.5 µg IV 
infusion 
97.5 
97.5 
Y (30) 
Y (8) 
35 
19 
25 
24 
Cengiz et al. 
2006, 
Turkey[345]  
Double-blind RCT  
1-7 
years 
48 
48 
M + P 
M + 
Diph  
0.5 PO 
0.5 + 1.25 PO 
59 
82 
NA 
NA 
15- 30 
15- 43 
15-43 
14-45 
Gemma et al. 
2009, Italy[335] 
Single-blind RCT 
3-7 
years 
5 
7 
M  
Pro  
0.6 IV infusion 
4 IV infusion 
100 
100 
Y (5) 
Y (5) 
NA 
NA 
2.5-15 
2-15 
Doganay et al. 
2001, 
Turkey[336] 
Prospective 
observational study 
1-18 
years 
30 M 0.35 PR 67 NA NA NA 
 
Alp et al. 2002, 
Turkey[3] 
Prospective 
observational study 
2- 78 
months 
20 
30 
20 
M 
T 
C 
1 PR 
50, 35, 25 PR 
0.1 ml/kg IM 
 
0 
76.5 
23.5 
NA 20 
15 
22 
66 
94 
118 
 
IV= intravenous, K= ketamine, M= midazolam, P= placebo, PEN= pentobarbital, PO= orally, PR= per rectum (by rectum), Diph=
 
Diphenhydramine,  
Dext= Dexmedetomidine 
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 RCTs comparing effectiveness to other agents in CT and MRI 
Seven RCTs compared midazolam effectiveness with other sedative agents for CT 
and/or MRI (Tables 5.4 and 5.5). In 4 RCTs, midazolam was less effective than the 
comparator [171, 177, 333, 345]. 
Coventry et al. (1991) compared midazolam in different doses and found that 
midazolam given rectally as the sole agent during CT scanning was effective in 
approximately half of the children[343]. After supplementary doses of ketamine 5 
mg/kg or lignocaine 2 mg/kg, midazolam 0.3 mg/kg and 0.6mg /kg produced 
adequate sedation for the procedure to be completed in 87% and 80% of the children 
respectively. The authors found that midazolam 0.3 mg/kg and 0.6mg/kg were not 
different in effectiveness for sedation for CT.  
In a crossover study by McCarver-May et al. (1996) 7 infants (median 14 days) 
undergoing CT scanning were successfully sedated with a single dose of oral chloral 
hydrate 75 mg/kg. After 48 hours these same 7 infants underwent a second episode 
of imaging and instead received IV midazolam 0.2 mg/kg; only three were 
successfully sedated with a single dose (p=0.04)[177]. Another study by D'Agostino 
and Terndrup found that oral midazolam 0.5 mg/kg was ineffective in 11 of 22 
children (50%) undergoing MRI and CT scanning[171].  The authors discussed the 
duration of the diagnostic procedure, which might have precluded the efficacy of 
midazolam as a sedative[171] 
Midazolam was associated with a faster onset of sedation in two RCTs[177, 345] and 
slow onset of action in one RCT[331]. 
Two RCTs compared midazolam procedural success with chloral hydrate during CT 
scanning in children aged 2 months to 8 years[171, 177] (Figure 5.3).  
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The pooled risk ratio (RR) of the procedural success rates for midazolam versus 
chloral hydrate was 0.50 (95% CI: 0.34, 0.74) (P= 0.0005), favouring chloral 
hydrate.   
Figure 5. 3: Midazolam versus chloral hydrate  
 
5.3.3.3. MCUG/VCUG  
Six RCTs reported midazolam effectiveness for MCUG/VCUG procedural sedation. The 
number of children recruited was 271, and their ages ranged between birth and 15 
years (median 5 years). In four of these studies, midazolam was administered orally. 
In one, it was given intranasally, and in another, by intravenous injection (Table 5.6). 
The onset of action ranged between 10 and 35 minutes. The procedural success rate 
ranged from 94% to 100%. All procedures were performed successfully. Midazolam 
was effective for all the children in 5 of the 6 studies. In one study, it was less 
effective than chloral hydrate. In three studies, both agents were effective in all 
children. 
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Table 5. 6: RCTs and observational studies for MCUG/VCUG 
Reference, 
country  
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate 
(%) 
Supplementary 
dose/med 
(No.) 
Sedation 
(min) 
Onset Onset 
Stokland et al. 
2003, 
Sweden[332] 
Double-blind 
RCT 
0.5-9.0 years 48 
47 
M 
P 
0.2 IN 100 
100 
NA 
NA 
NA 
NA 
15-
105 
15-85 
Akil et al. 2005, 
Turkey[271] 
Single-blind 
RCT 
0.8-14.5 
years 
17 
18 
18 
M 
CH 
P 
0.6 PO 
25 PO 
 
94 
100 
NA 
NA 
10-35 
10-20 
40-
105 
20-35 
Keidan et al. 
2005, Israel[330] 
Single-blind 
RCT 
3–15 years 24 
23 
M 
N2O 
0.5 PO 
50% inhaled 
100 
100 
NA 
NA 
NA 
NA 
20 
23 
Herd et al. 2006, 
New Zealand 
[346] 
Double-blind 
RCT 
1-14 years 67 
72 
M 
P 
0.5 PO 100 
93 
NA 
NA 
NA 
NA 
NA 
NA 
Thevaraja et al. 
2013, 
India[347] 
Double-blind 
RCT 
4-8 years 17 
17 
M 
K 
1-2 µg IV infusion 
10-20 µg IV infusion 
100 
100 
N 
N 
 
9.40 
6.80 
36 
33.7 
Elder, 
Longenecker 
1995, USA[339] 
Prospective 
observational 
23 months-9 
years 
98 M 0.6 PO 100 N 10-15 NA 
CH= chloral hydrate, IN= intranasal, IV = intravenous K= ketamine, M= midazolam, NA= not available, N2O= nitrous oxide, P= placebo, PO= per oral, 
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The pooled risk ratio (RR) of procedural success rate using midazolam versus placebo 
was 1.02 (95% CI: 0.95, 1.09) (P= 0.59). This shows no statistical difference 
between the use of midazolam and placebo in the success of the procedure (Figure 
5.4).  
Figure 5. 4: Midazolam versus placebo 
 
5.3.3.4. ECG  
Three RCTs evaluated midazolam for sedation during ECGs in 344 children aged from 
6 months to 5 years. Midazolam was given orally in all studies. 
The mean onset of action was 11 minutes; the mean duration of action was 40 
minutes. The success rate was reported between 36% and 100% (median 95%). 
Twenty children (8.4%) needed a supplemental dose of 0.5 mg/kg midazolam (Table 
5.7). 
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Table 5. 7: ECG RCTs  
Reference, 
country  
Study design  Age  No. of 
patients 
Drug 
 
Dose 
mg/kg 
Success 
rate 
(%) 
Supplementary 
dose/med 
(No.) 
Sedation 
(min) 
Onset Onset 
Wheeler et al., 
2001, USA[175] 
Single-blind 
RCT 
1- 5 years 25 
15 
M 
CH 
0.5 PO 
75 PO 
36 
93 
Y (13) 
Y (5) 
mean 
27.3 
mean 
25 
mean 
21.69 
mean 
25.6 
Yildirim et al. 
2006, 
Turkey[348] 
Single-blind  6 months- 3 
years 
30 
30 
20 
M 
M 
control 
0.4 PO 
0.2 IN 
100 
100 
NA 
NA 
10 
NA 
NA 
10 
Layangool et al. 
2008, 
Thailand[173] 
Double-blind  6 months-5 
years 
132 
132 
M 
CH 
 
0.5 PO 
50 PO 
95 
89 
Y (7) 
Y (14) 
11.13 
25.1 
40.10 
78.9 
CH= chloral hydrate, IN= intranasal, M= midazolam, NA= not available, PO= per oral 
  
5 Midazolam for sedation of children during imaging procedures 
 
195 
 
5.3.3.5. EEG  
A prospective observational study by Ashrafi et al. (2013) compared oral midazolam 
0.5 mg/kg to 5% oral chloral hydrate 1 ml/kg [338]. There were 100 children in the 
midazolam group versus 98 in the chloral hydrate group, aged from 2 months to 9 
years (median 4 years). Sleep onset was significantly shorter in children who received 
chloral hydrate, at 20 to 95 minutes (median 32 minutes) versus 45 to 98 minutes 
(median 58 minutes) in the midazolam group (p<0.001). The duration of sedation was 
significantly shorter in the midazolam group, at 12 to 38 minutes (median 25.5 
minutes), versus 56 to 98 minutes (median 66.5 minutes) in the chloral hydrate group 
(p<0.001). 
 Summary of midazolam clinical effectiveness 
We found 23 articles evaluating the use of midazolam for imaging sedation. The 
following table illustrates the success rates per type of imaging procedure (Table 5.8). 
Table 5. 8: Success rate (%) of all types of imaging procedure 
Procedures Midazolam dose  
Range (median dose) 
Success rate 
Range (median 
success) 
MCUG/VCUG  Oral, 0.5 to 0.6 mg/kg  (0.55mg/kg) 
 IV infusion, 0.1 to 0.2 mg/kg/min 
 IN, 0.2 mg/kg 
94 to 100% 
 
(97%) 
ECG  Oral, 0.4 to 0.5 mg/kg (0.45 mg/kg) 36 to 100% 
 
(95%) 
CT  Oral, 0.5 mg/kg 
 rectal, 0.3- 0.6 mg/kg  
 IV infusion, 0.2 mg/kg over 2-4 min 
19 to 100% 
 
(69%) 
MRI  Oral, 0.5 mg/kg 
 IV infusion, 0.2- 0.6 mg/kg/min (median 0.55 
mg/kg) 
0 to 100% 
 
(67%) 
IN= intranasal, IV = intravenous MCUG= micturating cystourethrogram, 
VCUG= voiding cystourethrogram  
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5.3.2. Midazolam safety 
Twenty five studies evaluated midazolam safety. They were published between 1991 
and 2013 and included 6145 children aged from birth to 18 years. RCTs were the 
most common type of study, but most AEs were reported in the prospective 
observational studies (Table 5.9). 
Table 5. 9: Summary of 26 studies that reported on safety of midazolam 
Type of study No. of 
studies  
(N=25) 
Age of children 
(range) 
Children receiving 
midazolam  
(N=2046) 
Adverse 
Events 
(N=301) 
Randomised 
controlled trial 
14 0-15 years 1220 26 
Prospective 
observational  
10 0-18 years 459 244 
Retrospective 
population based  
1 
2 months-14 
years 
367 31 
  
 
Of the 25 studies that monitored AEs, 15 reported one or more. The other 10 studies 
reported no AE (Tables 5.10 & 5.11). The mean age of the children receiving 
midazolam was 41 months, excluding 2 studies which did not report the mean age 
[202, 337]. In total, 2046 children were exposed to midazolam, and there were 301 
reported AEs. This gave an estimated risk of AE as 15 in every 100 patients, or 1 AE 
in every 6 patients. Other than nasal discomfort, the most frequently occurring AEs 
were hypoxia, vomiting, paradoxical reaction and prolonged sedation (Table 5.12). No 
severe AEs or medication-related deaths were reported. 
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Table 5. 10: Summary of 15 studies that reported AEs 
Reference Study design Age No. of patients 
receiving 
midazolam         
N= 1832 
No. of AEs 
N=301 
McCarver-May et 
al. 1996[177] 
RCT Median 14 days 7 8 
D’Agostino, 
Terndrup 
2000[171] 
RCT 2 months-8 
years 
22 1 
Keidan et al. 
2005[330] 
RCT 3-15 years 24 1 
Cengiz et al. 
2006[345] 
RCT 1-7 years 48 8 
Herd et al. 
2006[346] 
RCT 1-14 years 67 2 
Layangool et al. 
2008[173] 
RCT 6 months-5 
years 
132 6 
Solvis et al. 
1993[202] 
Prospective 
observational 
8-18 years 80 16 
Elder, 1995[339] Prospective 
observational 
23 months-9 
years 
98 11 
Ljung, 1996[341] Prospective 
observational 
6 months-15 
years 
233 136 
Malviya et al. 
2000[207] 
Prospective 
observational 
0-18 years 40 14 
Koroglu et al. 
2005[331] 
Prospective 
observational 
1-7 years 40 3 
Singh et al. 
2009[337] 
Prospective 
observational 
6 months-6 
years 
516 57 
Ashrafi et al. 
2013[338] 
Prospective 
observational 
2 months-9 
years 
100 2 
Mekitarian et al. 
2013[342] 
Prospective 
observational 
1 month-5 years 58 5 
Szczepaniak et al. 
2004[340] 
Retrospective 
population-based  
2 months-14 
years 
367 31 
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Table 5. 11: Summary of 10 studies that reported no AEs 
Reference Study design Age Patients receiving 
midazolam (N= 214) 
Coventry et al. 
1991[343] 
RCT 5 months-5 years 15 
Moro-Sutherland et al. 
2000[333] 
RCT 6 months-6 years 26 
Akil. et al. 2005[271] RCT Mean 6 years 17 
Yildirim et al. 2006[348] RCT 6 months-3 years 30 
Gemma et al. 
2009[335] 
RCT 3-7 years 5 
Jain et al. 2010[344] RCT 1- 5 years 29 
Thevaraja et al. 
2013[347] 
RCT 4- 8 years 17 
Chokshi et al 2013[334] RCT Not available* 25 
Doganay et al. 
2001[336] 
Prospective 
observational 
1-18 years 30 
Alp et al. 2002[3] Prospective 
observational 
2- 78 months 20 
* Authors documented the weight of children and it was <10 kg were included 
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Table 5. 12: Reported AEs from 15 studies  
Body system Adverse effects Frequency Incidence (%) 
Respiratory  
Hypoxia 74 3.62 
Apnoea  3 0.15 
Gastrointestinal  Vomiting 21 1.02 
Central nervous  
Paradoxical reaction 16 0.78 
Motor imbalance 7 0.34 
Agitation 4 0.20 
Anger/screaming   3 0.15 
Restlessness 3 0.15 
Aggression 2 0.10 
Irritability 2 0.10 
Lack of consolability  2 0.10 
Crabbiness 1 0.05 
Mood swings  1 0.05 
Wildness 1 0.05 
Cardiovascular   
Decreased mean arterial pressure (MAP) 3 0.15 
Tachycardia  1 0.05 
Other 
Nasal discomfort* 122 5.96 
Prolong sedation 14 0.68 
Hiccup 10 0.49 
Split vision 10 0.49 
Headache 1 0.05 
Total 301 15.0 
*Reported by one study only in children who received intranasal midazolam 
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Hypoxia was the most commonly reported AE.  74 children were documented to have 
had hypoxia with an estimated risk of 3.6 per 100 patients who received midazolam. 
Most cases of hypoxia were mild (SpO2 90-95%) in 42 cases (41/2046, 2.1%) or 
moderate (SpO2 <90%) in 32 cases (32/2046, 1.6%). No imaging procedures were 
discontinued as a result of hypoxia and cases of mild hypoxia were self-limiting. All 
patients with moderate hypoxia responded to supplemental oxygen. One case 
required nebulised salbutamol.   
Three studies reported 32 children who experienced moderate hypoxia, which was 
defined as SpO2<90%. In two of these studies, midazolam was given as an IV bolus 
in doses ranging from 0.1 to 0.2 mg/kg (median 0.15 mg/kg) [177, 340]. The route of 
administration of midazolam was not mentioned in the other study [207]. The mean 
age of the children with moderate hypoxia was 50 months. This is similar to the mean 
age of children in all the studies (Table 5.13). Twenty seven of the 32 children were in 
one large retrospective cohort study [340]. 
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Table 5. 13: Summary of the 32 children who developed moderate hypoxia 
References Study design Patients 
receiving 
midazolam 
Patients 
with 
moderate 
hypoxia 
Age Dose Monitoring 
device(s) and 
intervention(s) 
McCarver-
May et al. 
1996[177] 
Double blind 
cross-over 
7 4 Median  
14 days* 
0.2 mg/kg IV 
bolus 
 Continuously 
monitored 
hemoglobin 
oxygen 
saturation 
 Supplemental 
oxygen therapy 
 Administration of 
albuterol 
nebulization (in 
one patient) 
Malviya et 
al. 2000 
Prospective 40 1 <18 years, 
mean 50 
months* 
 
Mean 0.15 
±0.13 mg/kg, 
route of 
administration 
not mentioned 
 Pulse oximetry 
 Supplemental 
oxygen therapy 
 
Szczepaniak 
et al. 2004 
Retrospective 
population-
based 
367 27 2 months 
to 14 
years, 
mean 46 
months* 
0.1 mg/kg iv 
bolus 
 Continuously 
monitored  
saturation (SaO2) 
and end-
expiratory carbon 
dioxide 
concentration 
(ETCO2) 
 Supplemental 
oxygen therapy 
* Individual patient ages were not given 
 
Vomiting was the second most reported AE, affecting 21 children (21/2046, 1%). It 
was reported in 16 studies (10 prospective observational studies, 5 RCTs and 1 
retrospective cohort study). All the cases were self-limiting and none required medical 
intervention.  
Nasal discomfort was reported in one prospective observational study in which 233 
children received 0.3 mg/kg midazolam nasal drops and 143 children received 0.2 
mg/kg midazolam nasal spray. Nasal discomfort was seen in 66 children (66/233, 
28.3%) in the drops group versus 56 (56/143, 39.2%) in the spray group [341]. 
This systematic review identified one case report by Zaw et al. (2001) that discussed 
two cases of full-term neonates [349]. The first was a 4-day-old who developed 
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myoclonic-like movement of upper and lower extremities, 45 minutes after 
administration of 160 µg/kg IV bolus midazolam. The abnormal movements lasted for 
90 seconds, then the infant became very irritable for about 10 minutes prior to failing 
asleep and received no medical intervention. The other case was a 2-day-old neonate 
who developed myoclonic-like movement of upper and lower extremities 30 minutes 
after administration of 500 µg/kg oral midazolam. The abnormal movements were 
controlled successfully by immediate administration of 20 mg/kg IV phenobarbital. 
 
5.4. Discussion  
This review showed that the success rate for midazolam PS varied across the different 
imaging procedures, with the success rate ranging from 0 to 100%. Midazolam was 
relatively ineffective for both MRI and CT, as the median success rate was 67% and 
69% respectively.   This could be because midazolam has a short duration, and these 
types of procedures usually require more time[343]. 
 Conscious sedation using midazolam was found to be effective in children undergoing 
MCUV/MCUG in five RCTs involving 254 children. This finding supports the results of 
the retrospective observational study published by Elder and Longenecker (1995), 
which found that sedation with midazolam increased the success of VCUG/MCUG 
procedures by reducing anxiety in the children undergoing these procedures[339]. 
Our results indicate that midazolam is less effective than other sedative agents, 
including chloral hydrate, pentobarbital, and thiopental. In comparison with the 
effectiveness of chloral hydrate for imaging procedures (94% and 81% for CT and 
MRI, respectively), as shown in the previous chapter (Chapter 2, Part 2.1), the 
sedation success of midazolam is substantially lower.  
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With regards to the safety of midazolam, the previous studies differed widely in the 
number of reported AEs; some reported none, while others reported that a high 
percentage of patients (up to 45%) experienced them. In general, AEs were less 
frequently recorded in the RCT studies than in the cohort studies. 
Respiratory complications were the most commonly reported AEs. Hypoxia was the 
most frequently reported AE, with 32 cases (32/2046, 1.6%) defined as moderate 
(SpO2 85–89%) and requiring an intervention. It is difficult to determine if the dosage 
or the age of patients were influencing factors for moderate hypoxia, as individual 
data was not provided for individual children in many studies. The frequency of 
moderate hypoxia emphasises the importance of having adequate and continuous 
monitoring during (PS). The incidence of other AEs was lower.  
Hypoxia was also found to be the most commonly reported AE for chloral hydrate, as 
shown in the safety results in the previous chapter (Chapter 2, Part 2.1). However, it 
was reported more often with chloral hydrate PS (774/14439, 5.3%) than with 
midazolam sedation (74/2046, 3.6%). This is consistent with the results of Layangool 
et al. (2008), who found that 13 (9.9%) of the children in the chloral hydrate group 
experienced hypoxia, while only 4 (3%) of the children in the midazolam group 
experienced hypoxia [173].  
Our review found that vomiting was the second most common AE (with an incidence 
of 1% (1/2046)) after hypoxia. There is some evidence that midazolam reduces the 
incidence of post-diagnostic or post-treatment nausea and vomiting in children [350, 
351]. However, the high incidence of vomiting could be due to the bitter taste of 
midazolam itself [345]. 
In our systematic literature search, we tried to find as many AEs as possible in order 
to avoid missing serious AEs. In this extensive search, only one serious AE was found: 
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myoclonic-like movement of the upper and lower extremities. This AE was found in 
two neonates and required medical intervention (administration of 20 mg/kg IV 
phenobarbital) [349].   
 
5.5. Limitations 
The studies included in this systematic review have a number of limitations. Some 
RCTs were not double-blind studies, which means there is a potential for bias in the 
recording of results. In general, the number of studies included in the review was 
relatively small and the type of imaging procedure varied between studies, which led 
to differences in the midazolam dosages and the route of administration. Moreover, 
the definitions of sedation AEs and the effectiveness and outcome measures for (PS) 
varied between trials, which make meta-analysis difficult. It is also possible that the 
rarity of severe AEs with midazolam in some of the reviewed studies could be due to 
improper documentation of the safety data. The difficulty in reporting the safety data 
was compounded by the heterogeneous reporting style of the authors. Many did not 
use a standardized definition for AEs or standardized measures for reporting the 
outcomes. 
5.6. Conclusions  
The success rate for midazolam varies, and the rate is poor with both MRI procedures 
and CT scans. However, midazolam is effective for imaging procedures, such as 
MCUV/MCUG, that require a sedative agent with anxiolytic and amnesic effects. 
Midazolam seems to have a low incidence of AEs, although the occurrence of 
mild/moderate hypoxia emphasises the necessity of monitoring children during 
sedation. Serious AEs associated with PS using midazolam appear to be rare.   
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CHAPTER SIX 
Assessing the Palatability of Chloral Hydrate 
and Midazolam in Children: A literature Review 
6.1. Introduction  
Palatability of an oral medicine has been recognised as one of the most important 
factors in drug treatment adherence as it increases the chance of successful drug 
administration during a therapeutic course [96]. It differs from one drug to another, 
as well as from brand to brand for the same drug, and it also varies from child to child 
[89]. Palatability is influenced by a mixture of sensory perceptions including taste, 
smell, appearance, and temperature. When taking into account the important role of 
the palatability of drugs, particularly oral preparations, taste therefore should be an 
essential issue in the development of medicine [352]. 
There have been relatively few studies of adherence and palatability in children. A 
study by Venables et al. (2015) identified taste as the most frequently reported 
barrier to adherence with long term treatment (p<0.001) [353].  It is reasonable to 
presume that a better tasting medication is easier to administer to young 
patients[354]. The importance of studying the palatability of children formulations has 
been endorsed in the European Paediatric guideline on pharmaceutical development of 
formulations for paediatric use [355]. The FDA also, highlights the importance of 
producing new medications and making them more acceptable [356].  In the previous 
chapters (Chapter 2 and Chapter 5) the effectiveness and safety of chloral hydrate 
and midazolam were evaluated. In this chapter the palatability of these two oral 
sedatives will be evaluated. 
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6.2. Aim 
This literature review aimed primarily to evaluate the current published clinical 
evidence concerning the palatability of the oral sedatives chloral hydrate and 
midazolam in children. A secondary aim was to review the methodology used in 
previous studies of these sedative agents to inform the protocol for a future planned 
study (chapter 7). 
6.3. Methods 
A literature search was performed on MEDLINE (1948–January 2014), EMBASE 
(1980–January 2014), International Pharmaceutical Abstracts (IPA; 1970–January 
2014) and PubMed (until January 2014). Search terms were ‘chloral hydrate’, 
‘midazolam’, ‘palatability’ or ‘taste’. All studies evaluating chloral hydrate and/or 
midazolam use in children up to 18 years undergoing procedural sedation (PS) 
published in all languages were included, if they evaluated or reported palatability 
and/or taste outcomes. The following data were extracted from each study: study 
region, study period, study design, number of children, age group, dose of chloral 
hydrate and midazolam, palatability measurement method, sedation scoring method 
and procedural success rate. Comments, editorials, letters, notes, review articles and 
studies that did not evaluate chloral hydrate and/or midazolam palatability for PS 
were excluded. 
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6.4. Results 
A total of 1007 articles were identified after searching the databases. After limiting the 
results to publications dealing with humans and removing duplicates, 845 articles 
were identified. Following this, 750 articles were removed after initial screening of the 
article title and abstract. The full text of the remaining articles (95) was obtained. 
Nine articles remained after applying the inclusion and exclusion criteria (Figure 6.1).  
The selected 9 articles included a total of 1059 children, published between 1988 and 
2012. Eight were randomised trials and one was a prospective observational study. 
They were conducted in 6 different countries, most originated from the USA (3) [184, 
357, 358]. Sample sizes in these nine studies ranged from 16 to 397 and the age of 
participants ranged from birth to 16 years old. All studies were performed in patients 
with a clinical indication for PS.  The number of sedatives evaluated per study varied 
from 1 to 2. 
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Figure 6. 1: Flow diagram of the search and review process 
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screening abstract for 
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592 Abstracts not 
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114 Duplicate 
citations 
122 Review article 
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18 Conference 
abstracts 
16 Letters 
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6.3.1. Scales to assess palatability 
A few different tools were used in the included studies (Table 6.1, Table 6.2). One 
third (3/9) of the studies assessed children’ opinion using various palatability 
assessment scales. Two studies involved children aged from 1 to 6 years[359, 360]. 
One study used a 3-point scale[359] and the other used the verbal responses of the 
children[360]. Neither study adequately described how they assessed the palatability 
in children less than 2 years old. In the study by Wilson et al. (2007) children aged 
from 10 to 15 years old assessed the palatability of the study sedative agent by 
answering the open-ended question (liked ‘’best’’ or ‘’least’’) about the acceptance of 
the sedative that they had taken [361].  
Table 6. 1: Palatability assessment method used with paediatric patients 
Palatability measurement method Age group Reference 
3-point scale  
((1) good, (2) indifferent, and (3) bitter) 
1– 6 years Almenrader et al. 2007[359] 
Questionnaire response 
Liked ‘’best’’ or ‘’least’’ 
10- 15 years 
 
Wilson et al. 2007[361] 
Verbal response 
The drug has ‘’Bitter Taste’’ or “not” 
2- 6 years Kumar et al. 2012[360] 
 
Most of the studies (6 out of the 9) used parents or nurses to assess palatability. Half 
of the studies used a 4-point scale [357, 358, 362].  
In two studies, in children aged from 6 months–16 years[357, 358], the observers 
used the same scale: 
 Accepted readily,  
 Accepted with facial grimace, 
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 Accepted with verbal complaint, and 
 Rejected entirely 
 In another study in patients as young as 4 years old [362] the scale was 
 Totally refused, 
 Refuses to accept,  
 Dislikes, and  
 The child liked the medicine 
In three studies, nurses assessed the child to estimate the palatability [184, 269, 
363]. The scales used by the nurses ranged from a five point scale to simple 
subjective assessment (Table 6.2) 
Table 6. 2: Measurement method used for parents/nurses interpretation 
Palatability measurement method Age group Reference 
Observer opinion on acceptability using 4-point scale 
((1) accepted readily, (2) accepted with facial grimace, (3) accepted 
with verbal complaint, and (4) rejected entirely) 
1–15 years Marshall et al. 
2000[357] 
6 months–16 
years 
Cote et al. 
2002[358] 
Observer opinion on acceptability using 4-point scale  
((1) totally refused, (2) refuses to accept, (3) dislike, and (4) the child 
liked the medicine)  
  
0- 4 years Kapur et al. 
2004[362] 
Nurse and parent’s opinion on acceptability using 5-point scale ((1) 
yucky, (5) yummy) 
2–13 months 
 
Chung et al. 
2000/ USA[184] 
Nurse opinion on taste acceptance 
’’cooperative’’ or ’’agitated’’  
2–8 years  Isik et al. 
2008[363] 
Nurse opinion on acceptability 
((1) grimacing and struggling, (2) spitting out sedative) 
1-8 years Saarnivaara et al. 
1988[269] 
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6.3.2. Studies that assessed palatability  
Nine studies evaluated the palatability and/or effectiveness of midazolam. Two 
evaluated midazolam in different doses[357, 358], one by different routes[360] and 
one by different added flavours [363]. Three studies compared midazolam with other 
oral sedatives [269, 359, 361], and only one study compared midazolam with 
placebo[362]. 
Two studies evaluated chloral hydrate. One study evaluated chloral hydrate and 
midazolam[269], the other evaluated chloral hydrate and pentobarbital [184] (Tables 
6.3 and 6.4).  
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Table 6. 3: Studies that used children’s opinion to assess palatability  
Reference/ 
country 
Design  Number 
of 
children 
Age  Procedure Drugs Dose(s) 
mg/kg 
Palatability 
assessment 
Sedation-
scoring 
method 
Results 
Almenrader et 
al. 2007/ 
Italy[359] 
Single-blind 
RCT 
34 
30 
1–6 
years 
 
Preoperative 
(repair of 
hernias, 
circumcision,  
orchidopexy) 
Midazolam 
Clonidine  
0.5 PO 
4 Mcg PO 
3- point scale 5-point 
sedation-
scoring 
system 
15% (5/34) children 
refused oral midazolam 
versus (zero) in 
clonidine group (P = 
0.06) 
 
Success rate was 86% 
in the midazolam versus 
83% in clonidine group 
(P = 0.5) 
Wilson et al. 
2007/ 
UK[361] 
Single-blind 
randomised 
cross-over 
36 
36 
10- 15 
years  
Dental 
procedure 
Buccal  midazolam 
N2O/O2  
0.2  
30% / 70% 
Verbal 
response 
Liked ‘’best’’ 
or ‘’least’’ 
Houpt 
Behaviour 
Rating Scale 
Midazolam was accepted 
by (23, 66%) versus 
(32, 89%) patients in 
N2O/O2 group  
 
Success rate was 100% 
in both group 
Kumar et al. 
2012/ 
India[360] 
Double-
blind RCT 
30 
30 
2- 6 
years  
Dental 
procedure 
Intranasal 
midazolam 
sublingual 
midazolam 
0.3 PO 
0.3 PO 
Verbal 
response 
‘’Bitter Taste 
or not’’ 
5-point 
sedation-
scoring 
system 
A bitter taste was 
observed in 45%  
(14/30) of the 
sublingual group 
 
Success rate was 100% 
in both group 
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Table 6. 4: Studies that used nurse’s/parent’s opinion to assess palatability  
Reference/ 
country 
Design  Number 
of 
children 
Age Procedure Drugs Dose(s) mg/kg Palatability 
assessment 
Sedation-
scoring 
method 
Results 
Saarnivaara 
et al. 1988/ 
Finland[269] 
Double-blind 
RCT 
126 
122 
1–8 years  Preoperative 
(adenoidectomy, 
tympanostomy, 
tonsillectomy) 
Midazolam 
 
 
 
Oral chloral 
hydrate 
 
0.4, 0.5, 0.6 PO 
+ 0.7 ml/kg fruit 
juice 
 
25,50, 75 PO 
+ 0.7 ml/kg fruit 
juice 
Nurse’s 
opinion on 
acceptability 
using ((1) 
grimacing and 
struggling, (2) 
Spitting out 
sedative) 
4-point 
sedation-
scoring 
system   
Midazolam was more 
palatable than chloral 
hydrate (12% versus 
6%) (P < 0.001).  
 
Sedation effect of all 
doses was more effective 
in children >5 years in 
both (P <0.001)  
Chung et al. 
2000/ 
USA[184] 
 
Prospective 
observational 
38 
16 
2–13 
months  
CT/MRI Pentobarbital  
+ Cherry 
syrup 
 
chloral 
hydrate + 
Cherry syrup 
  4- 6 PO 
 
 
50- 100      max 
2000 mg  PO 
Nurse’s and 
parent’s  
opinion 5-
point scale 
using  
((1) yucky, 
(5) yummy) 
Not specified Pentobarbital was more 
acceptable than chloral 
hydrate (3.2% versus 
1.7%)  (P < 0.0001). 
 
Success rate was 100% 
in chloral hydrate versus 
97% in pentobarbital 
group 
Marshall et 
al. 2000/ 
USA[357] 
Double-blind 
RCT 
28 
24 
33 
1–15 years  Invasive 
procedures 
Midazolam 
(cherry 
flavoured) 
 
0.25 PO 
0.5 PO 
1.0 PO 
4-point scale  5-point 
sedation-
scoring 
system   
99% (84/85) of children 
accepted the syrup  
Overall  81% of patients  
achieved satisfactory 
sedation within 
30minutes  
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Table 6.4: Studies that used nurse’s/parent’s opinion to assess palatability  
Reference/ 
country 
Design  Number 
of 
children 
Age  Procedure Drugs Dose(s) mg/kg Palatability 
assessment 
Sedation-
scoring 
method 
Results 
Cote et al. 
2002/ 
USA[358] 
Double-blind 
RCT 
132 
132 
133 
6 months–
16 years  
Preoperative 
(elective 
surgery) 
Midazolam 
(cherry 
flavoured) 
0.25 PO 
0.5 PO 
1.0 PO 
4-point scale  5-point 
sedation-
scoring system   
95% of children 
accepted the syrup 
 
Overall  97.5%  of 
patients  achieved 
satisfactory sedation 
within 30 minutes 
Kapur et al. 
2004/ 
India[362] 
Double-blind 
RCT 
20 
20 
4 years Dental 
procedure 
Midazolam 
(strawberry 
syrup)  
 
placebo  
 
0.5 PO 
 
 
 
Normal saline + 
strawberry  syrup   
4-point scale  5-point 
sedation-
scoring system 
Acceptability score 
was 80% in 
midazolam group 
versus 70% in placebo 
group 
 
Success rate was 90% 
in midazolam group 
versus 35% in placebo 
group 
Isik et al. 
2008/ 
Turkey[363] 
Double-blind 
RCT 
75 2–8 years 
 
Dental 
procedure 
Midazolam mixed 
with 4 different 
drinks  
Pepsi Cola, 
10% sodium 
citrate,  
pomegranate 
juice 
grapefruit juice  
 
Midazolam alone 
0.75 PO Verbal 
response 
’’Cooperative’’ 
or ’’Agitated’’ 
Ramsay 
Sedation Scale 
(RSS) 
Pepsi Cola and 10% 
sodium citrate 
formulation were more 
acceptable than others 
(53% & 53% versus 
20%, 40% & 47%)  (P 
< 0.05). 
 
Sedation scores  were 
higher in children 
receiving 10% sodium 
citrate (P < 0.05) 
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6.3.3. Summary of palatability results 
We found 9 articles evaluating the palatability of chloral hydrate and/or midazolam. 
Midazolam was acceptable to most children (median 53%). Chloral hydrate however 
was poorly tolerated (median 3.85%) (Table 6. 5). 
Table 6. 5: Acceptability scores (%) of chloral hydrate and midazolam 
Sedative  Acceptability scores  
Range (median acceptability) 
Chloral hydrate  
1.7% to 6% 
(3.85%) 
Midazolam  
12 to 99% 
(53%) 
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6.5. Discussion 
There were surprisingly few studies of the palatability of the oral sedatives chloral 
hydrate and midazolam in children. The majority of the studies evaluated midazolam 
palatability. Only two studies evaluated chloral hydrate palatability. 
Midazolam was found to be palatable in most of the studies. In contrast, chloral 
hydrate was not palatable.  Poor acceptance of chloral hydrate might be due to 
greater volume and more bitter taste than midazolam [173, 364].  
This literature review showed that, almost all palatability studies were randomised. 
Great variability in the tools used for assessment of palatability was found. Most of the 
studies used parents or nurses to assess palatability in children. Older children (6 
years and older) were considered able to articulate themselves. This was found to be 
in line with the results from previous studies that used children and parental 
questionnaires response to evaluate taste and acceptability of antibiotic 
preparations[365, 366] . 
The 10 mm VAS scale was the most commonly uses for assessing palatability in 
children [95, 367-369]. 
6.6. Conclusions 
In spite of the relatively small number of studies in this literature review, we found 
higher patient acceptance of oral midazolam than oral chloral hydrate. There was 
variability in the tools used for palatability assessment. Further investigation 
evaluating the palatability and effectiveness of the two sedatives will be undertaken in 
the next chapter (Chapter 7). 
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CHAPTER SEVEN 
Pilot Study to Assess the Palatability of Two 
Commonly Used Sedative Medicines in a 
Children’s Hospital 
 
7.1. Introduction 
Chloral hydrate and midazolam are widely used as sedative agents in children. Both 
are often regarded as unpleasantly bitter tasting, which may alter their acceptance 
and the consequent success of the sedation procedure. A prospective study in Italy of 
64 children who were given oral midazolam for procedural sedation (PS) found that 
15% of the children refused the drug entirely[359].  
The taste of oral medicines and the ability of paediatric patients to tolerate them, 
though widely mentioned, are often not taken into consideration[352]. Several studies 
describe the assessment of the palatability of medication used in children, however 
many of these studies were undertaken in adults[90, 96]. It is now recommended that 
assessment of the palatability of drugs that will be administered to paediatric patients 
should be undertaken in children [90].  
In the previous chapter, we identified that midazolam appears to be palatable to most 
children. Chloral hydrate, however, appears to be less palatable. There were however 
only two studies with chloral hydrate.  This study aimed to investigate the palatability 
and acceptability of these two oral sedative agents in children in Derby in the UK, to 
help evaluate current practice. 
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7.2. Study aim and objectives 
7.2.1. Primary objective 
The primary objective of this study was to examine children’s opinions of the taste 
and acceptability of chloral hydrate and midazolam when administered for routine PS. 
7.2.2. Secondary objectives 
The secondary objectives of this study were: 
1- To examine the opinions of parents on the taste and acceptability of the sedative 
agents immediately after their administration.  
2- To examine nurses’ opinions on the taste and acceptability of the sedative agents 
immediately after their administration.  
3- To document any manipulation of medication that is performed by nursing staff to 
encourage children to take the medication. 
4- To assess if there could be a relationship between the acceptability of the medicine 
to children and the success rate of PS.  
5- To record any further sedative agents given required the procedure. 
6- To ask parents, nursing staff and children open questions about what they think 
would make administration of these medicines easier.  
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7.3. Study method  
This study was conducted at the Derbyshire Children’s Hospital, which is part of the 
Royal Derby Teaching Hospitals NHS Foundation Trust, providing healthcare to more 
than 100,000 children each year.  The hospital consists of out-patient, emergency, 
and in-patient departments. This study was conducted in the day-case unit.   
The study’s protocol and ethics application were written by Co-investigator (Badriyah 
Alotaibi) and reviewed by Chief investigator (Dr. Helen Sammons).  
7.3.1. Study design 
Palatability was assessed using a modified 10 cm visual analogue scale (VAS) 
incorporating a facial hedonic scale for children aged from 3 to 5 years. Studies have 
shown that this scale is widely accepted in paediatric patients as young as 4 years and 
they can easily understand and use it to give their opinion about the taste of 
medicines by choosing the faces that reflect their opinion [100, 370] (Figure 7.1).A 
modified 10 cm VAS  was used for children aged from 6 to 16 years as  children of this 
age are known to be able to mark their opinion about the taste of the drug that they 
have taken on the line of the 10 cm VAS scale [102] (Figure 7.2). The two studied 
medicines were chloral hydrate and midazolam (Table 7.1). The primary end point for 
the study was to examine the children’s opinions on the palatability of each sedative 
agent as measured on the VAS. “Acceptable” was defined as any score higher than 
“bad” or measuring more than 2 cm from 0 on the scale. 
The secondary end points were to assess the relationship between the palatability of 
the sedative medicine to children, and the success rate of PS.  
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Figure 7. 1: 10 cm VAS combined with facial hedonic scale for ages 3 - 5 
   
This figure adapted from Matsui (2007) [90]. 
Figure 7. 2: 10 cm VAS combined with facial hedonic scale for ages 6 - 16 
                                                                                                                  
                                              
                0 cm                       Acceptable                                                          10 cm 
             Really bad                                                                                       Really good 
 
This figure adapted from Matsui (2007) [90]. 
Table 7. 1: Composition of medicines under study 
Medicine Composition 
Chloral Hydrate 500mg/5 mL 
oral syrup (Rosemont 
Pharmaceuticals Ltd) 
Each 5 mL contained chloral hydrate 500 mg (equivalent to 
100mg/mL), propylene glycol (E1520), methyl 
parahydroxybenzoate (E218), glycerol (E422), colour E110 and 
sucrose 3g/5mL. 
Midazolam 5mg/mL solution 
for injection/infusion 
(Hypnovel, Roche) 
The ampoules contained, per mL: midazolam 5 mg (as 
hydrochloride), sodium chloride, hydrochloric acid (to produce 
hydrochloride) and sodium hydroxide in water for injection, 
adjusted to pH 3.3 
 
7 
Pilot Study to Assess the Palatability of Two Commonly Used Sedative Medicines in a 
Children’s Hospital 
 
221 
 
7.3.2. Participant selection and recruitment 
When sending appointment letters to parents, the paediatric secretaries and booking 
clerks included information about the study, and, if age-appropriate, included 
information to be read by the children.  
On the day of admission, the researchers approached ward nurses to assess the 
suitability of patients who were scheduled for diagnostic PS or botulinum toxin 
injection, and checked if the patients had been prescribed one of the study medicines. 
On the patients’ arrival at the day case ward, eligible families were asked by the 
nursing staff if they would be happy to speak to one of the researchers. The 
researcher explained the study to the child and parents, confirmed that the family had 
received a child-and-parent information sheet and reviewed this with them. The 
parent(s) were asked by the researcher for written consent for the child to participate 
in the study, and the child’s assent was taken if the child was aged more than 6 years. 
The parents and children were advised that they could withdraw from the study at any 
time.  
Consent of parents and assent of children were monitored through the recording of a 
unique subject number on each consent and assent form. This subject recruitment 
number was written on the data collection form in order to ensure that the patient’s 
details remained anonymised.  The chief investigator kept a key to a locked filing 
cabinet where the patient’s name and hospital number were stored. The consent 
forms were stored separately from the data collection forms, in case of later enquiries. 
All participants (parents and children) were interviewed for approximately 10 minutes, 
depending on the length of time the child took to swallow the drug and decide on their 
answers to the study questions. Data was collected immediately after the drug was 
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administered. Patients were observed for the first 5 minutes after administration to 
record any immediate adverse events, such as vomiting. Further data was collected 
from the sedation record sheet via the nursing staff to gauge the outcome of the 
sedation and success of the procedure. 
We did not use hospital interpreters or translator services in this study because the 
participating children needed to understand verbal explanations or written information 
in English.  
Each potential parent and child were advised that entry into the study was entirely 
voluntary, and that their treatment and care would not be affected by their decision, 
and that they could withdraw at any time without being coerced to remain part of the 
study.  
Children who were included in the study were aged from birth to under 16 years and 
were scheduled for PS or botulinum toxin injection on the wards of the Derbyshire 
Children’s Hospital. This included children who had neurological developmental 
disabilities but were able to understand the study and use the scoring faces scale.  
The children had been prescribed either chloral hydrate or midazolam as a sedative 
agent, using the dosages recommended in the British National Formulary for Children 
and/or the local hospital’s policies. 
The exclusion criteria for this study were: 
 Children who were non-English speaking. 
 Children receiving sedation agents that were not chloral hydrate or midazolam. 
 
Data collection was performed between November 2014 and April 2015. 
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This study did not interfere with the normal running of the ward or the care given to 
the patients. Therefore, no attempt was made to control for potential confounding 
variables such as whether the child’s mouth was free of conflicting tastes. The child 
was asked to rate the medicine at the place of drug administration, if they were happy 
with this, or at their bedside. 
Immediately after receiving the oral sedative, each participant was asked to mark his 
or her impression of the taste of the medicine on the 10 cm VAS line (Figure 7.1, 
Figure 7.2). 
The researcher recorded the acceptability of the medicine, length of time between 
preparation of the medication by nurses and administration to the patient, adverse 
events during the first 5 minutes after administration (such as vomiting), and parental 
comments. The success of the sedation and completion of the procedure were rated 
by the health care professional (nurse or physician).  
A data collection form (DCF) (see appendix B) specific to this study was used for each 
patient. The researcher completed the front page of the DCF, then asked the children 
to rate the palatability of the drug and marked the child's rating. The remainder of the 
DCF was filled in by the investigator who questioned the child together with the 
parent(s). 
The DCF included the following information: 
 Patient unique identification number 
 Date of completion of the study 
 Age at study entry, in years and months  
 Sex 
 Procedure 
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 Sedative agent, its strength and formulation  
 History of given sedative agent 
 Child’s thoughts about the taste of the drug, on a modified 10 cm VAS 
 Time taken to administer the medication, from when the nurse picked up the 
syringe, through approaching the child, to the point when all of the medicine 
was swallowed[103]. 
 The parents’ opinion regarding the acceptability of the sedative agent, for 
children with developmental disabilities, or aged 2 years or younger, according 
to the facial expression of the child, on a modified 10 cm VAS that incorporated 
a 5-point facial scale.  
 Responses to the open-ended question 'How palatable, including easy to 
swallow, do you feel the study medication is? 1 = really good, 2 = good, 3 = 
not sure, 4 = bad, 5 = really bad' [371]. 
 The nurse’s opinion on the acceptability of the given medicine to the patient, 
recorded as a subjective score from 1 to 4 (Table 7.2)[103].  
 Success rate of the procedure post sedation, assessed by recording the 
children’s behavioural responses following a completed procedure, using the 
Houpt scale for all age groups and measuring the degree of sleep, body 
movements, crying and overall behaviour (Table 7.3)[372].  
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Table 7. 2: Acceptability score used by nurse 
1. Totally refused  
2. Refuses to accept, but forced 
3. Dislike, but accepts 
4. The child liked the medicine 
This figure adapted from Uhari et al. (1986) [103]. 
Table 7. 3: Scoring criteria for sedation 
a. Rating Scale for Sleep Score 
1. Fully awake, alert  
2. Drowsy, disoriented  
3. Asleep  
b. Rating Scale for Movement 
1. Violent movement that interrupts treatment  
2. Continuous movement that makes treatment difficult  
3. Controllable movement that does not interfere with treatment  
4. No movement 
c. Rating Scale for Crying 
1. Hysterical crying that interrupts treatment  
2. Continuous, persistent crying that makes treatment difficult  
3. Intermittent, mild crying that does not interfere with treatment  
4. No crying 
d. Rating Scale for Overall Behaviour 
1. Aborted - No treatment 
2. Poor - Treatment interrupted, only partial treatment completed 
3. Fair - Treatment interrupted but eventually all completed 
4. Good - Difficult, but all treatment performed 
5. Very Good - Some limited crying or movement 
6. Excellent - No crying or movement 
This figure adapted from Houpt et al. (1986) [372]. 
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Ethical approval was obtained from the Officer for Research Ethics Committee 
Northern Ireland (ORECNI) (Ref: 14/NI/1061 14075). In addition, approval was 
obtained from the Derbyshire Hospital’s NHS Foundation Trust Research and 
Development (R&D) department (Ref: DHRD/2014/078) (see appendix A).  
The data was analysed using the Statistical Package for Social Sciences software 
(SPSS version 22, IBM United Kingdom Limited, Hampshire, UK) to generate simple 
descriptive statistics. Histograms and the Kolmogorov–Smirnov test were used to test 
the distributions of the continuous variables. The results were estimated as mean 
inter-quartile ranges (IQR). 
The palatability scores between any two drugs were compared using the Mann–
Whitney U test. Spearman’s correlation coefficient was used to test the effect of the 
children’s age and number of times a medicine was taken.  
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7.4. Results  
63 children were approached during the period from November 2014 to April 2015. 
41 consented to participate. 40 were given a study medicine and provided data. One 
child did not receive medicine due to an upper respiratory tract infection (Figure 7.3).  
Figure 7. 3: Recruitment flow chart 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
Total children approached 
(n=63) 
Drug not 
given  
(n=1) 
 
Not 
consented  
(n=22) 
Drug given 
(n=40) 
Consented 
(n=41) 
Chloral 
hydrate 
(n=20) 
Midazolam     
(n=20)  
 11 did not attend 
 4 patients had 
gastrostomy 
 2 patients refused to 
take medicine via oral 
route 
 1 parent refused 
 1 patient was not 
given appropriate 
sedative 
 2 patients did not fast 
 1 patient had facial 
paralysis 
 
 
 7 Child’s opinion 
 13 Parent’s opinion 
 15 Child’s opinion 
 5 Parent’s opinion 
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7.4.1. Demographic data 
Of the 40 recruited children, the majority (30, 75%) were male. There were 20 
patients in each group. The patients underwent the procedures in the following 
numbers: MRI (24), botulinum injection (10), brainstem auditory evoked potential 
(4), and CT (2). There were no adverse effects.  
The children who received chloral hydrate were younger than those who received 
midazolam Figure (7.4) (p = 0.0001). The median age of children in the chloral 
hydrate group was 2.4 years, (IQR 1 - 3.6), and for children sedated with midazolam, 
it was 6.6 years (IQR 5.1 - 9.2). This is because chloral hydrate is recommended by 
the NICE guideline (2010) for children under 15 kg undergoing painless imaging 
procedures and midazolam in children from 1 month to 18 years undergoing painful 
procedures[80]. Thus the results of this study were analysed separately for each drug 
group in the next sections due to the differences in the patient groups and ages. 
There was a higher number of children in the midazolam group with developmental 
disabilities (n=7) than in the chloral hydrate group (n=1) (p = 0.01) (Table 7.4). 
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Table 7. 4: Patient demographics (N = 40 Patients) 
Patients Chloral hydrate Midazolam Total No. 
Gender        N= 20 N= 20 N = 40 
Male       14       16        30 
Female         6        4        10 
Age     
Infant (0-< 2 years)     8    0     8 
Children (2- ≤11 years)       12      16       28 
Adolescent (12 - < 16 years)         0        4        4 
Development    
Normal        19      13     32 
Developmental disabilities         1        7       8 
Procedures     
MRI       17        7    24 
Botulinum injection          0      10    10 
Brainstem auditory evoked potential         1        3     4 
CT         2        0     2 
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Figure 7. 4: Distribution of ages of children in both study groups 
 
     
 
 
7.4.2. Acceptability of the study agents  
7.4.2.1. Manipulation of medication 
The nurses mixed midazolam with blackcurrant juice for 12 children and with orange 
juice for 2 children. The doses of midazolam for the remaining 6 children were not 
mixed with any juice because in 4 patients the doses were high so if mixed with juice 
this would produce a large volume, while in the other 2 patients the nurse did not 
specify.  
Chloral hydrate was given to children without mixing it with any juice or flavour. It 
was not possible to add juice to the chloral hydrate due to the large volume of liquid 
required for the dose of chloral hydrate. As the Chloral hydrate’s concentration is 
Chloral hydrate 
Midazolam  
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100mg/ml and the dosage ranged 50- 100 mg/kg, for example for 15 kg child, the 
dose of chloral hydrate is 1500 mg (15 mls).  
To increase the acceptance of both studied medicines, the nurses tried to verbally 
motivate the children to swallow the prescribed sedative. 
7.4.2.2. Patients’ opinions  
The child’s opinion about the taste of the prescribed sedative was recorded for 
children aged 3 years and older, while the parents’ opinion was taken for children with 
significant developmental disabilities and children 2 years and younger (section 
7.3.2). Table (7.5) and Table (7.6) present the individual data for chloral hydrate and 
midazolam groups. 
Table 7. 5:  individual data including drug acceptance and sedation success 
for children and parents in chloral hydrate group 
Opinion  Patients    Taste scores in mm Additional sedation  Successful procedures 
 
 
Children  
C1 0 Yes Yes 
C2 20 NO Yes 
C3 100 NO Yes 
C4 0 NO Yes 
C5 20 Yes Yes 
C6 0 NO Yes 
C7 0 Yes Yes 
 
 
 
 
Parent  
C8 0 Yes Yes 
C9 15 NO Yes 
C10 50 NO Yes 
C11 0 NO Yes 
C12 0 NO Yes 
C13 0 NO Yes 
C14 0 NO Yes 
C15 18 NO Yes 
C16 18 NO Yes 
C17 0 Yes NO 
C18 0 NO Yes 
C19 0 NO Yes 
C20 50 NO Yes 
Total 20 - - 19 
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Table 7. 6: individual data including drug acceptance and sedation success 
for children and parents in midazolam group 
Opinion Patients    Taste scores in mm Additional sedation Successful procedures 
 
 
 
 
 
 
 
Children  
M1 0 NO NO 
M2 25 NO NO 
M3 16 Yes Yes 
M4 0 NO Yes 
M5 10 NO Yes 
M6 50 Yes NO 
M7 0 NO Yes 
M8 0 NO NO 
M9 0 NO NO 
M10 0 NO NO 
M11 50 Yes Yes 
M12 50 Yes NO 
M13 80 NO Yes 
M14 75 NO Yes 
M15 100 NO Yes 
 
 
Parent  
M16 0 NO Yes 
M17 50 NO Yes 
M18 50 NO Yes 
M19 25 Yes NO 
M20 50 NO Yes 
Total 20 - - 12 
 
1. Chloral hydrate group 
The child’s opinion was recorded for 7 children aged from 2.5 to 4.8 years (mean 3.7 
years, (IQR 2.8- 4.7). The mean VAS measurement was 20 mm (IQR = 0- 20 mm). 
Parents’ thought about taste was recorded from 13 parents (one child with 
developmental disabilities) aged from 0.5 to 4 years old (mean 1.6, IQR= 0.8 and 
2.2). The mean VAS measurement was 11.62 mm (IQR = 0- 18 mm).  
The mean VAS measurement for chloral hydrate taste for both children’s and parents’ 
opinion was 14.55 mm (IQR = 0- 19.5 mm) (Figure 7.5). 
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2. Midazolam group 
Children’s opinion about the taste was recorded from 15 patients (4 children with 
developmental disabilities) aged from 4 to 13.9 years (mean 7.4 years, (IQR 5.4- 
8.8)). The mean VAS measurement was 30.40 mm (IQR 0- 50 mm). Parents’ thought 
about taste was recorded from 5 parents for children (3 children with developmental 
disabilities) aged from 2.4 to 12 years old (mean 7.1, IQR= 2.7- 12). The mean VAS 
measurement was 35 mm (IQR 12.5 - 50 mm).  
The mean VAS measurement for midazolam taste was for both children’s and parents’ 
opinion was 31.55 mm (IQR 0- 50 mm) (Figure 7.5). 
 
Figure 7. 5: Rated taste in mm for the medicines under study 
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7.4.2.3. Nurses’ opinions  
1. Chloral hydrate group 
The time required to administer chloral hydrate by the nurse ranged from 35 to 600 
seconds (mean 162, IQR 53 – 270) 
Scores of acceptability showed that, 10 (50%) of children disliked the medicine but 
still agreed to take it, 8 (40%) children rejected the medicine, but were forced to take 
it by nurses and one patient completely refused chloral hydrate. There was only one 
child who liked the taste of chloral hydrate.  
2. Midazolam group 
The time required to administer midazolam by the nurse ranged from 10 to 900 
seconds (mean 116, IQR 42- 71) 
Assessment of palatability found that 15 (75%) children disliked the medicine but still 
accepted it. No children totally refused to take midazolam; however, 5 children 
refused the medicine, but were forced to take it. There were no children who liked the 
taste. 
7.4.3. Procedural success  
No patient in the chloral hydrate group were undergoing painful procedures, while 
10/20 patients in midazolam group were having painful procedures. This is because 
chloral hydrate has only a hypnotic effect and is therefore recommended by the NICE 
guideline for painless imaging procedures for children < 15 kg. Midazolam however is 
recommended for either painless imaging painless procedures for children ≥ 15 kg 
and also for painful procedures due to its anxiolytic effect [80].  
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In the chloral hydrate group 19 of the 20 procedures were performed successfully 
(Table 7.5). In contrast, only 12 of the 20 procedures in the midazolam group were 
performed successfully (Table 7.6). Five patients from each group required additional 
sedation (paraldehyde) to augment the sedation effect. Procedural success was also 
measured on the Houpt sedation scale (Table 7.3) which included the degree of sleep, 
crying, body movements, and overall behaviour. The overall evaluation data was 
dichotomised to represent the success of (PS), which was defined as the ability to 
complete the designated procedure.  
 
1. Chloral hydrate group 
For sleep evaluation, three quarters (15) of children were given a score of 3 (asleep) 
and movement evaluation showed that 13 (65%) of children scored a 4 (no 
movement). 15 (75%) of children scored a 4 for no crying and 16 (80%) of the chloral 
hydrate group scored a 5 (very good) or higher for overall behaviour. Table (7.7) 
shows the mean scores and IQR for sleep, crying, body movements, and overall 
behaviour in chloral hydrate group.   
5 children required additional sedation (rectal paraldehyde). The age of these children 
ranged from 3 to 5 years (mean 3.46 years, IQR = 2.3 - 4.35). Four children 
completed their procedures successfully. 
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Table 7. 7: Mean sedation scores, IQR for chloral hydrate groups  
Rated score Mean  IQR 
Sleep 2.75  2.25 - 3 
Movement 3.55  3 - 4 
Crying  3.70  3.25 - 4 
Overall behavior 5.25  5 – 6 
 
2. Midazolam group 
Just over half (11, 55%) of the midazolam group scored a 2 (drowsy) for sleep, while 
for movement evaluation (8, 40%) of subjects scored a 3 (controllable movement). 
Eight children 40 per cent in midazolam group scored a 4 for no crying and only 7 
(35%) scored a 5 (very good) or higher for overall behaviour. Table (7.8) shows the 
mean scores and IQR for sleep, crying, body movements, and overall behaviour in 
midazolam group.  
5 children required supplemental sedation with paraldehyde (PR). The age of these 
children in the ranged from 5 to 14 years (mean 7.46 years, IQR = 5.25 - 10.25). 
Only two of these 5 children completed their procedures successfully.  
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Table 7. 8: Mean sedation scores, IQR for midazolam groups  
Rated score Mean  IQR 
Sleep 1.65 1 - 2 
Movement 2.70   2 - 3 
Crying 3.05  2 - 4 
Overall behavior 3.30   1 - 5 
 
7.4.4. Acceptability and sedative effect   
When drug acceptance and overall behaviour for sedation success were evaluated for 
each group, in the chloral hydrate group a direct trend was seen for better (PS) effect 
with higher taste scores (Figure 7.5). However in the midazolam group there is an 
inverse relationship between (PS) effect and the taste scores (Figure 7.6). 
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Figure 7. 6: Medicine acceptance and procedural success in chloral hydrate group  
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Figure 7. 7: Medicine acceptance and procedural success in midazolam group 
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7.4.5. Comments on improving medicine acceptability  
23 answers were collected from the patients and their parents when they were asked 
what would make administration easier for these medicines. The differences between 
age or gender for each drug group were not statistically significant. Thirteen of the 
patients suggested making the medicines sweeter and six suggested making the taste 
fruitier. Strawberry flavour was preferred by girls, but the difference was not 
significant. One patient in each group found the taste better than expected. The 
remaining participants asked to improve the taste of the medicine and make it better 
without specifying the taste or flavour.  
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7.5. Discussion 
Palatability  
In the present pilot study, no extra flavour was used to make chloral hydrate suitable 
for oral ingestion. This is because of the large volume of most calculated doses. In 
order to mask the taste with sweetened syrup, the total volume required would be 
excessive. The coercion of children to take the whole dose of chloral hydrate may 
result in spitting out or vomiting, leading to not only children’s distress, but also the 
possibility for lower or higher dosing. 
The acceptance of oral chloral hydrate was shown to be poor as judged by the 
children, the children's parents and nursing staff. Those who were seen to have 
excellent sedation showed a trend to having scored the taste better. Chloral hydrate is 
one of the most commonly used sedatives, however, bitter taste and gastric irritation 
are the most common drawbacks [121, 268]. Chung et al. in a prospective study of 
oral chloral hydrate and pentobarbital for imaging procedures, observed that 
acceptance of pentobarbital was always superior to that of chloral hydrate [184]. 
Results published by Millichap show that triclofos was significantly more palatable in a 
greater percentage of children than chloral hydrate [174].  
 Oral midazolam was prepared using parenteral midazolam by mixing it with a 
blackcurrant juice or orange juice as has also been done in previous studies [373, 
374]. It has been found that midazolam has relatively good acceptance and the 
opinions of parents were more likely to prefer midazolam. There was no obvious link 
between taste score and sedation success. Saarnivaara et al. (1988) evaluated the 
palatability of chloral hydrate and midazolam in three different sedative doses (25, 50, 
75 mg/kg) and (0.4, 0.5, 0.6 mg/kg) respectively[269]. Chloral hydrate was always 
significantly less palatable than midazolam 12% versus 6.4% respectively (P < 
0.001).  
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Effectiveness 
In this study 50- 100 mg/kg chloral hydrate provided satisfactory effectiveness and 5 
children were administered supplementary sedation. Most of these children completed 
their procedures successfully. This is in line with the study by Rooks et al. (2003) who 
found that the 75 mg/kg dose of chloral hydrate provided good effectiveness (100%), 
while midazolam in the 0.5 mg/kg dose produced low effectiveness (50%) in children 
aged from 2 months and 8 years old [194]. Only one child in the chloral hydrate group 
required supplementary sedation; however, 12 children in the midazolam group were 
given sedation supplementations [194]. Chung et al. (2000) in a prospective study 
showed that chloral hydrate in doses ranging from 50 to 100 mg/kg provided good 
sedation for children aged up to 13 months and none of the patients required 
supplementations [184]. A study by Marchi et al. (2004) found that chloral hydrate for 
diagnostic procedures was effective in 99% of children aged 3 months to 12 years 
[217].  
With regards to midazolam, the present results showed low success rate with 
midazolam sedation and most children needing supplementary sedation failed to 
complete their procedures successfully. It is important to note however, that half of 
the children were undergoing painful procedures as opposed to none of those with 
chloral which could have influenced the results. This is in accordance with the study by 
Wheeler et al. (2001) which found that 0.5 mg/kg midazolam is less effective when 
compared to chloral hydrate 75 mg/kg for children aged from 1 to 5 years [175]. 
However, our findings are in contrast with the results of a study by Kazak et al. 
(2010) which found that 0.25 mg/kg midazolam with presence of parents or 0.5 
mg/kg midazolam without presence of parents provided a good sedation effect 
compared to the patients who were not given any sedative and only with presence of 
parents [375].  
7 
Pilot Study to Assess the Palatability of Two Commonly Used Sedative Medicines in a 
Children’s Hospital 
 
243 
 
7.6. Limitations 
This study is a pilot study which was designed to not interfere with or alter normal 
care provided by the nursing and medical staff to the patients. Therefore, control for 
possible confounding variables, such as if the patient’s mouth was free of other 
conflicting tastes was not attempted, however, all participants were fasting as per the 
hospital protocol. An additional limitation to this study was that we cannot compare 
the opinion of the children and parents because of the very small participants’ number 
and the differences of the age groups. Other study limitations include that only 
English- speaking families were included however there is a possibility that cultural 
differences may affect taste preferences as mentioned in the previous literature.  
7.7. Conclusion 
The results of this pilot study suggest that oral chloral hydrate has a relatively good 
sedation effect, but it was poorly accepted by the children. On the other hand, 
midazolam was shown to be more accepted by patients; however its effectiveness was 
low. Further studies directly comparing the palatability and effectiveness of the two 
drugs are required. 
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CHAPTER EIGHT 
Use of Sedation in the Middle East Countries: A 
literature Review 
8.1. Introduction 
In the previous chapters, the effectiveness and safety of some of the most commonly 
used sedatives in paediatrics were discussed and evaluated systematically. In this 
chapter, the use of sedatives in children in the Middle East is evaluated further, as it is 
where I am from and where I will return to work.  
The “Middle East” refers to the geographic region where Africa, Asia and Europe meet. 
It includes 17 countries which are; Bahrain, Cyprus, Egypt, Iran, Iraq, Israel,  Jordan, 
Kuwait, Lebanon, Oman, Palestine, Qatar, Saudi Arabia, Syria, Turkey, United Arab 
Emirates, and Yemen.  The population of these countries is approximately 300 million 
[376]. Children (younger than 15 years old) in these countries constitute 35% of the 
population compared to approximately 18% in developed countries [376]. Middle East 
countries are ranked economically into High Income Countries (HIC); Bahrain, Israel, 
Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (UAE), the Upper-
Middle Income Countries (UMIC); Iran, Jordan and Lebanon and the Lower-Middle 
Income Countries (LMIC); Egypt, Palestine, Syria, Yemen and Iraq [377]. The health 
care systems in the Middle East countries differs between countries [378].  There have 
been very limited numbers of studies that have evaluated the patterns of sedative 
prescribing in the Middle East 
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8.2. Aim 
This review aims to evaluate the use of sedative agents for procedural sedation (PS) 
outside the operating theatre in the Middle East, and to assess the use of practical PS 
guidelines in these countries.  
8.3. Method 
Literature searches were conducted using MEDLINE (1948–January 2015), EMBASE 
(1980– January 2015), International Pharmaceutical Abstracts (IPA) (1970 to January 
2015), and PubMed database (until January 2015). The reference lists of the relevant 
studies were searched manually to identify further related papers.  
An initial search for related terms was conducted in order to select the most specific 
and sensitive key words for the search strategy. These terms were used by previously 
published studies by Lourenço-Matharu et al. 2012 and Kastner et al. 2006 [166, 
379].  The search terms were Children or infant or pe*diatric* or neonate or 
adolescence or adolescences or adolescent and Hypnotics or Sedatives or Anti-Anxiety 
Agents or Sedation or Conscious sedation or Preanesthetic medication or 
preanaesthetic medication or sedate or Anxiety or anxiety or anxious or fear$ or 
fright$ or stress$ or distress$ or phobi$ or uncooperative or un-cooperative or unco-
operative and Middle East countries or Bahrain or Cyprus or Egypt or Iran or Iraq or 
Israel or Jordan or Kuwait or Lebanon or Oman or Palestine or Qatar or Saudi Arabia 
or Syria or Turkey or United Arab Emirates or Yemen. 
All languages were included and the search was limited to data from humans.  The 
inclusion criteria were original studies assessing or reporting the use of sedative 
agents in children and adolescents from birth up to 18 years, undergoing PS. Letters, 
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comments, editorials or review articles were excluded.  The full articles of all related 
abstracts were read carefully according to the study inclusion criteria. 
8.4. Results 
8.4.1. Search results 
Searching throughout the electronic databases yielded 5424 references. Limiting the 
search to humans and removing duplications gave 3746 articles.  Reading the 
abstracts for potential related articles excluded 3672 articles, as they did not fulfil the 
review’s inclusion criteria (Figure 8.1), leaving 74 articles. The full texts of these 
remaining articles were read carefully and 37 of them were considered to be not 
relevant. This left a total of 37 articles that fulfilled the inclusion criteria (Figure 8.1). 
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Figure 8. 1: Flow chart for search and review process 
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8.4.2. Countries with data 
The search produced information for 7 of the 17 countries of the Middle East. The 
highest numbers of studies were conducted in Turkey followed by Iran, Israel and 
Saudi Arabia (Table 8.1). There were no publications available for the use of sedation 
in the following countries: Bahrain, Cyprus, Iraq, Lebanon, Oman, Palestine, Qatar, 
Syria, United Arab Emirates, and Yemen.  
Table 8. 1: Number of studies for each country  
Country Number of studies 
 
Turkey 
16 
Iran 
8 
Israel 
4 
Saudi Arabia 
4 
Jordan 
3 
Egypt 
1 
Kuwait 
1 
Total 
37 
 
All 37 studies were published between 1979 and 2014. RCTs were most common 
(n=21, 57%), followed by prospective studies (n=9) (Figure 8.1). The total number of 
children was 3070, with ages that ranged from birth to 18 years.   
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Figure 8. 2: Types of included studies 
 
 
Twelve different sedative agents were evaluated: chloral hydrate, dexmedetomidine, 
diphenhydramine, diazepam, clonidine, ketamine, melatonin, midazolam, nitrous 
oxide (N2O), promethazine, propofol, and triclofos. Painless procedures such as 
CT/MRI were most common (Figure 8.3). Ketamine was the most frequently 
evaluated, followed by Chloral hydrate and midazolam Figure (8.3).  
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Figure 8. 3: Flow chart for the use of sedative agents in the Middle East  
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 Turkey  
16 studies were conducted in Turkey. They included 11 RCTS, 3 prospective 
observational studies and 2 case reports (Table 8.2, 8.3, 8.4).  
Two RCTs were conducted in the same institution (a University teaching hospital)[348, 
380]. Both studies evaluated the effectiveness of midazolam. The first study 
compared the effectiveness of oral midazolam with intranasal midazolam, in children 
aged from 6 months to 3 years[348]. They underwent an ECG and they found that 
both routes were 100% effective. The other study (Caliskan et. al, 2013) compared 
the effectiveness of intravenous paracetamol (15 mg/kg) and dipyrone (15 mg/kg) as 
analgesic agents, in 60 children scheduled for elective surgery, as premedication. All 
children were administered intravenous midazolam before surgery[380]. They found 
that (24, 40%) needed additional sedation (intravenous bolus of Propofol).  
Two RCTs were conducted by Mirzak to evaluate the effectiveness of 
dexmedetomidine, ketamine and propofol as premedication[381, 382]. The first study 
conducted between September 2005 and April 2006 evaluated ketamine and propofol. 
Ketamine significantly reduced preoperative agitation compared to propofol 
(p=0.0001)[381]. Between February 2009 and August 2009 they assessed the 
effectiveness of dexmedetomidine versus placebo as premedication. They found that 
dexmedetomidine was significantly more effective in reducing agitation scores than 
placebo (P=0.01)[382].  
Alp et al. (2002) compared the effectiveness of three sedative agents including 
midazolam, thiopental, and cocktail (meperidine, chlorpromazine and pheniramine) for 
CT/MRI procedures, in a prospective observational study [3]. They found that 
thiopental and the cocktail were more effective than midazolam for CT scan, while 
midazolam and the cocktail were more effective than thiopental for MRI. A prospective 
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observational study in the same hospital evaluated chloral hydrate effectiveness for 
taking a blood test[242]. The success rate was 100%.  
Other studies were conducted in different hospitals within the country.  Four RCTs 
evaluated oral midazolam effectiveness for CT/MRI, dental and MCUG procedures 
[271, 345, 383, 384]. Midazolam procedural success rate was variable, ranging from 
54% to 100%. The effectiveness of rectal midazolam for CT/MRI procedures was 
evaluated in a prospective observational study [336]. All procedures were completed 
successfully.  
Two studies evaluated ketamine safety and/or effectiveness for painful procedures 
(lumbar puncture and circumcision) [385, 386]. They were conducted between 2004 
and 2007 and found that ketamine was 100% effective.  
One study compared the effectiveness of dexmedetomidine with propofol in 60 
children aged from 1 to 7 years, who underwent MRI[331]. The results demonstrated 
that procedural success was 100% in both groups.  
Two case report studies reported the toxicity of chloral hydrate (Table 8.4)[225, 296]. 
Both cases described respiratory toxicity requiring intervention.  
None of the studies conducted in Turkey mentioned the existence of sedation 
guidelines. 
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Table 8. 2: RCTs conducted in Turkey 
Reference, 
country   
Design/ Setting Hospital name  Duration  Number 
of 
children 
Age (Y)  Drugs/dose (mg/kg) Procedure  Findings  
Akil  et al. 
2005[271] 
Single- blind RCT 
/ University 
teaching hospital 
Celal Bayar 
University 
hospital, Manisa 
2002-2003,  53 0.6-15  Chloral hydrate / 25 PO 
midazolam / 0.6 PO 
MCUG Success rate was 100% for  chloral  
and 94 % for  midazolam  group 
 
Onset of sedation ranged from 10- 
20 minutes for  chloral  and 10- 35 
minutes for  midazolam   
Cengiz et al. 
2006[345] 
Double- blind 
RCT / University 
teaching hospital 
Harran 
University, 
Sanliurfa 
NA 96 1- 7  Midazolam / 0.5 mg/kg 
PO+ Placebo  
Midazolam / 0.5 mg/kg 
PO+  
Diphenhydramine / 
1.25 mg/kg PO 
MRI Success rate was 59% for 
midazolam+ placebo and 82%  for 
midazolam+ Diphenhydramine 
 
Onset of sedation was ranged from 
15- 30 minutes for M and 15- 43 
minutes midazolam+ 
Diphenhydramine 
Koroglu et al. 
2005[331] 
Single- blind RCT 
/ University 
teaching hospital 
Inonu 
University, 
Malatya 
NA 60 1- 7  Dexmedetomidine / 1 
Mcg/kg/hr.  IVI  or 
Propofol /  100 
Mcg/kg/min  IVI 
MRI Success rate was 100% for both 
groups 
 
Hypoxia ( 4 cases in Propofol 
group) 
 
Yildirim S. et 
al. 2006[348] 
Single- blind RCT 
/ University 
teaching hospital 
Baskent 
University, 
Ankara 
March 
2006- May 
2006 
80 0.6 -3  Midazolam / 0.4 PO 
Midazolam / 0.2 IN 
ECG Success rate was 100% for both 
groups 
 
Po=orally, IN=intranasal, IVI=intravenous infusion 
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Table 8.2: RCTs conducted in Turkey  
Reference  Design/ 
Setting 
Hospital 
name  
Duration  Number 
of 
children 
Age 
(Y)  
Drugs/dose (mg/kg) Procedure  Findings  
Dilli et al. 
2008[385] 
Single- blind 
RCT / Tertiary 
hospital 
Ministry of 
Health 
tertiary 
hospital, 
Ankara 
January 2004-  
December 2006 
99 2-14  Ketamine /1 IV 
Ketamine+ midazolam/1 
IV+ 0.1 IV  
Lumbar 
puncture 
Success rate was 100% for both 
groups 
 
Hypoxia ( ketamine (0); ketamine& 
midazolam (3)) 
 
Dizziness ( ketamine (5); ketamine & 
midazolam (10)) 
 
Vomiting ( ketamine (10); ketamine & 
midazolam (5))  
Sayin et al. 
2008[386] 
Single- blind 
RCT / 
University 
teaching 
hospital 
Yeditepe 
University, 
Istanbul 
January 2006-  
July 2007 
100 NA* 5%  ketamine / 10 PR 
2.5%  ketamine /10 PR 
Circumcision Success rate was 100% for both 
groups 
 
Mean sedation score was significantly 
higher in 5% K group (P = 0.02).  
Baygin et al. 
2010[383] 
Double blind 
RCT / 
University 
teaching 
hospital 
Gazi 
University, 
Ankara 
NA 60 5–8  Midazolam / 0.7, PO 
Ketamine / 3 PO  
Midazolam / 0.25 PO+ 
40% N2O+ 60% O2 
Dental 
procedures  
0.7 mg/kg midazolam was 
significantly more effective than other 
groups (54% for 0.7 midazolam group 
versus 33% for ketamine group, 13 
for midazolam 0.25, and 7% for 
control group)  (P< 0.05) 
Demir et al. 
2012[384] 
Single- blind 
RCT / Tertiary 
hospital 
Tatvan State 
Hospital, 
Bitlis 
NA 100 2- 12  Midazolam / 0.5 PO 
Placebo 
CT/MRI Success rate was 100% for both 
groups  
 
Mean duration of sedation was 21 min 
for M and 26 min for  placebo  group 
*Authors reported the weight only and it was 10-20kg 
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Table 8.2: RCTs conducted in Turkey 
 
 
Reference   Design/ 
Setting 
Hospital name  Duration  Number 
of 
children 
Age  Drugs/dose 
(mg/kg) 
Procedure  Findings  
Caliskan et 
al. 
2013[380] 
Double blind RCT 
of analgesia / 
University 
teaching hospital 
Baskent 
University, 
Ankara 
NA 60 7- 15  Midazolam / 0.05 IV  
Paracetamol/Dipyrone 
IV 
Preoperative (24, 40%) needed additional 
sedation (propofol /0.5–1.0 
mg/kg  IV bolus)  
Mizrak et al. 
2013[382] 
Double blind RCT 
/ University 
teaching hospital 
Gaziantep 
University, 
Gaziantep 
December 2008-
April 2009 
60 5- 15  Dexmedetomidine / 
0.5 IV  
Placebo 
Preoperative Sedation scores significantly 
higher with dexmedetomidine 
mean scores 3 versus 1 
respectively (P=0.001). 
 
Dexmedetomidine  significantly 
reduced the agitation scores  (P 
< 0.01) 
Mizrak et al. 
2010[381] 
Double blind RCT 
/ University 
teaching hospital 
Gaziantep 
University, 
Sahinbey 
February  2009- 
August 2009 
60 4-11  Ketamine/ 1 IV 
Propofol/ 3 IV 
Preoperative  Agitation score was significantly 
lower in ketamine group (P = 
0.0001). 
 
Vomiting (one case in K and 4 
cases in Pro group.   
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Table 8. 3: Prospective observational studies conducted in Turkey  
Reference  Setting  Hospital 
name 
Duration  Number of 
children 
Age 
group  
Drugs 
(Mg/kg) 
Procedure  Findings  
Doganay et 
al. 
2001[336] 
Tertiary 
hospital 
Anabilim 
hospital, 
Istanbul  
NA 30 1- 18 
years 
Midazolam/ 0.35 PR CT/MRI Success rate was 100% 
 
Alp et al. 
2002[3] 
University 
teaching 
hospital 
Atatürk 
University, 
Erzurum 
NA 70 2- 78 
months 
Midazolam/ 1 PR 
Thiopental/ 25-50 PR  
Cocktail/0.1 mL from (meperidine 
11 mg/mL, chlorpromazine 2.8 
mg/mL and pheniramine 2.8 
mg/mL) 
CT/MRI Success rate of CT scan was 
0% for M, 77% for T, and 
24% for cocktail. 
 
Success rate of MRI was 36% 
for M, 9% for T, and 55% for 
cocktail  
Ikbal et 
al.2004 
[242] 
University 
teaching 
hospital 
Ataturk 
University, 
Erzurum 
NA 18 31- 55 
days 
Chloral hydrate / 50 PO Blood test Success rate was 100%. 
 
Po=orally, PR=Rectally, IV=intravenous 
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Table 8. 4: Case reports conducted in Turkey  
Reference  Setting Number of 
children 
Age  
 
Drugs Procedure  AEs Treatment 
Kirimi et al. 
2002[225] 
University 
teaching 
hospital 
1 28 
days 
Oral 250mg/kg chloral hydrate CT Respiratory distress,  
Excessive salivation, 
Respiratory depression, 
Severe hypoxia 
IV fluid. 
O2 therapy 
Cecen et al. 
2009[296] 
University 
teaching 
hospital 
1 4 
months 
50mg/kg chloral hydrate rectally, 
then after 5 min another dose of 
50mg/kg was given orally 
Vaccination 
(agitation)  
Tachycardia, 
dyspnea, 
cyanosis 
Intubation, 
O2 therapy 
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 Iran 
There were 8 studies (7 RCTs and one prospective observational study) conducted in 
Iran. These included 805 children aged from one month to 16 years (Table 8.5). Three 
of the 7 RCTs were conducted in the same hospital [387-389].  
These three studies were conducted one after each other from January 2010 to 
August 2012 and all examined the effectiveness of sedation for EEG. The first 
compared chloral hydrate with promethazine in children aged from 1 to 10 
years[388], the second melatonin and midazolam in children aged from 1 to 8 
years[389], and the final study compared chloral hydrate/promethazine and chloral 
hydrate/hydroxyzine in children aged 1 to 7 years[387]. Initially, chloral hydrate was 
found to be more effective[388], in the next study melatonin was more effective than 
midazolam, but still less effective than chloral hydrate[389]. Finally the combination 
of chloral hydrate and promethazine was found to give the best results[387].  
The other (5) studies were conducted in different hospitals to evaluate the 
effectiveness of various sedatives. Three studies evaluated the effectiveness of 
midazolam for GI endoscopy[390], CT[391] and for dental procedures[392]. The 
success rate of midazolam ranged from 59% to 100%.  
The remaining two RCTs evaluated either the effectiveness of clonidine to reduce 
anxiety in patients undergoing adenotonsillectomy[393], or the effectiveness of 
chloral hydrate and melatonin for EEG procedure[176]. None of the studies mentioned 
the existence of a sedation guideline.   
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Table 8. 5: Studies conducted in Iran 
Reference  Design/ 
Setting 
Hospital 
name 
Duration  Number 
of 
children 
Age  Drugs/dose 
(mg/kg) 
Procedure  Findings 
 
Jahromi et 
al. 
2009[393] 
Double blind 
RCT/ Tertiary 
hospital 
Rajaee 
Hospital, 
Qazvin 
NA 120 3- 12  Paracetamol / 20 PO 
Clonidine / 4Mcg/kg 
PO 
Preoperative Both drugs reduced anxiety (mean 
anxiety scores 6.08 and 6.13 for 
clonidine and paracetamol 
respectively) 
Ashrafi et 
al. 
2010[176] 
Single- blind 
RCT/ University 
children hospital 
Tehran 
University 
hospital, 
Tehran 
2007-2008 348 0.1- 5.4 Chloral hydrate / 50 
PO  
Melatonin/ 2-6  
EEG Success rate was 100% for both 
groups 
 
Onset of sedation ranged from 10-
150 min for CH and  5-210 min for 
Melatonin 
 
Duration of sedation was 15-240 min 
for both group 
Rafeey et al. 
2010 [390] 
Single- blind 
RCT/ University 
children hospital 
Tabriz 
University 
hospital, 
Tabriz  
March 2007- 
March 2008 
61 1-16  Midazolam / 0.5 PO 
Midazolam / 0.05–0.1 
IV  
GI 
endoscopy 
Procedural success rate was 100% 
for both groups. Recovery time was 
longer with oral group compared to 
IV group (mean 55 min versus 42 
min) respectively.   
Fallah et al. 
2013[388] 
Single- blind  
RCT/ University 
teaching 
hospital 
Shahid  
sadoughi 
hospital, 
Yazd 
January 2010-
February 2011 
60 1-10  Chloral hydrate / 70 
PO  
Promethazine / 1 PO 
EEG Chloral hydrate was more effective 
than promethazine (98% and 70% 
respectively (P = 0.02). 
Vomiting (6 cases, 20%) of chloral 
hydrate group 
Agitation (2 cases, 7%) of 
promethazine group.   
Onset of sedation was more rapid 
with chloral hydrate (mean 32 versus 
52 min, P<0.001).  
IV=intravenous, Po=orally  
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Table 8.5: Studies conducted in Iran  
Reference  Design/ 
Setting  
Hospital 
name 
Duration  Number 
of 
children 
Age  Drugs/dose (mg/kg) Procedure  Findings 
 
Fallah et al. 
2014[389] 
Single- blind 
RCT/ University 
teaching 
hospital 
Shahid  
sadoughi 
hospital, 
Yazd 
September 
2011- March 
2012 
60 1-8  Melatonin/ 0.3 PO  
Midazolam/ 0.75 PO 
EEG Melatonin was more effective than 
Midazolam (73% and 37% 
respectively (P = 0.004). 
 
Fallah et al. 
2014[387] 
Single- blind 
RCT/ University 
teaching 
hospital 
Shahid  
sadoughi 
hospital, 
Yazd 
April- August 
2012 
 
90 1–7  Chloral hydrate/ 40 PO  
Chloral hydrate /40 PO+ 
Promethazine/ 1 PO  
Chloral hydrate /40 PO+ 
hydroxyzine/  2 PO  
EEG Chloral + promethazine was more 
effective than chloral hydrate and 
chloral hydrate + hydroxyzine 
groups (98% versus and 70% and 
95% respectively (P = 0.02). 
Vomiting (5 cases, 17%) of chloral 
group, (7 cases, 2%) of chloral + 
promethazine, and (7 cases, 2%) 
of chloral hydrate + hydroxyzine 
Agitation (1 case, 3%) of chloral 
hydrate group. 
Hypotension (1 case, 3%) of 
chloral hydrate +hydroxyzine 
group.  
Tavassoli-Hojjati 
et al. 2014[392] 
Cross-over RCT 
/ University 
teaching 
hospital 
Shahed 
University 
hospital, 
Tehran 
NA 18 2.5- 
6  
Midazolam/0.3 buccal  
Midazolam/0.5 PO   
Dental 
procedures 
Success rate was 89% for oral 
midazolam and 83% for buccal 
midazolam group. 
Mohammadshahi 
et al. 2014[391] 
Prospective 
observational 
study/university 
teaching 
hospital 
AJA 
University 
hospital, 
Tehran 
NA 48 1- 7  Midazolam/ 0.5 PO+ 
diphenhydramine/ 1.25 
PO 
Midazolam/0.5 PO 
CT Success rate was higher with 
midazolam + diphenhydramine 
compared to M alone (86% versus 
59%) respectively.  
Po=orally  
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 Saudi Arabia 
Four studies were found (two prospective observational studies, one RCT and one 
retrospective study) (Table 8.6). Two studies were conducted in the same institution 
in May 1999- February 2002 and in July 2005- October 2006 for CT/MRI. The first 
study evaluated chloral hydrate effectiveness[196], the second compared chloral 
hydrate with midazolam in children aged from birth to 12 years[394]. Chloral hydrate 
was found to be more effective than midazolam. 
The remaining two studies were conducted in different hospitals. Firstly a prospective 
observational study was conducted in a tertiary hospital to evaluate chloral hydrate in 
children undergoing brainstem auditory evoked potential procedures[395]. Procedural 
success rate was 100%.   
A retrospective cohort study was conducted to evaluate the use of sedative agents in 
the paediatric emergency department of a university teaching hospital[396]. The most 
commonly prescribed sedative was Ketamine (IV), which was used for painful PS 
including; repair of bone fracture, abscess drainage and laceration repair. The authors 
documented the use of American college of emergency physicians’ guideline (Table 
8.6). 
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Table 8. 6: Studies conducted in Saudi Arabia  
Reference   Design/ Setting Hospital name  Duration  Number 
of 
children 
Age  Drugs/dose (mg/kg) Procedure  Findings  
Hijazi et al. 
2005 [196] 
Prospective 
observational 
study/tertiary 
hospital 
King Abdulaziz 
Medical City, 
Riyadh 
May 1999- 
February 
2002 
148 0-12  Chloral hydrate / 100 PO  CT/MRI Success rate was 89% 
Vomiting reported in 3 
patient and hyperactivity in 
one patient 
 
Hijazi et al. 
2014 [394] 
Double blind RCT 
/ Tertiary 
hospital 
King Abdulaziz 
Medical City, 
Riyadh 
July 2005-
October 2006 
275 0-12  Midazolam/ 0.5 mg/kg PO   
Chloral hydrate/ 100 
mg/kg PO  
CT/MRI Procedural success rate was 
89% for chloral hydrate and 
33% for midazolam 
 
Al-Ayadhi 
2008[395] 
Prospective 
observational 
study/university 
teaching hospital 
King Saud 
University 
hospital, Riyadh 
September 
2005- April 
2006 
61 0-10  chloral hydrate / 50 PO BAEP* Success rate was 100% 
 
BAEP: Brainstem auditory evoked potential 
 
 
 
 
 
 
 
 
8 Use of Sedation in the Middle East Countries: A Literature Review 
 
263 
 
Table 8.6: Studies conducted in Saudi Arabia  
Reference   Design/ Setting Hospital name  Duration  Number 
of 
children 
Age  
(Y) 
Drugs/dose (mg/kg) Procedure  Findings  
Salleeh et al. 
2014[396] 
Retrospective 
study/university 
teaching hospital 
King Khalid 
University 
Hospital, Riyadh  
December 
2005- July 
2008 
179 0.4-13  Ketamine IV (mean 1.2) 
Ketamine IM (mean 3 ) 
Ketamine+ midazolam 
(mean 1.2 + 0.066) 
Ketamine+ propofol 
(mean + 1) 
Ketamine+ fentanyl 
(mean 2.5 Mcg/kg+ 1.8 
Mcg/kg) 
Midazolam+ fentanyl 
(mean 0.3 Mcg/kg+ 1 
Mcg/kg) 
Midazolam 0.1  
Repair of bone 
fracture, repair 
of injury, 
abscess 
drainage, repair 
of laceration 
and removal of 
foreign body  
The most common used 
sedative was ketamine IV in 
90% of children with 
success rate of 100% 
 
Vomiting developed by 6 
patients  
 
Hypoxia (SpO2 80%) 
developed by one patient* 
 
Emergence reaction 
developed by 2 patients**  
 
Seizure ( jerky movement 
and shivering ) developed 
by one patient*** 
* Patient was managed by using mask ventilation with 100% oxygen 
** One patient required treatment using midazolam, the other was required no treatment 
*** Patient was treated by 100% oxygen and IV midazolam
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 Jordan 
Three studies were found (one RCT, one prospective observational study, and one 
retrospective study) (Table 8.7). The first study was conducted to evaluate the 
effectiveness of midazolam and clonidine, in children who underwent tonsillectomy. 
Midazolam was found to be more effective than clonidine in reducing preoperative 
anxiety (75% versus 25%) respectively[397]. A study by Abdul-Baqi (1991) evaluated 
the effect of chloral hydrate on middle ear pressure in children during brainstem 
auditory evoked potential procedure[199].  Neither study mentioned they used 
sedation guideline. 
 Finally, a study by Miqdady et al. (2011) evaluated the use of midazolam and 
ketamine for endoscopy. It reported that it used an institutional sedation 
guideline[398].  
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Table 8. 7: Studies conducted in Jordan  
Reference   Design/ 
Setting 
Hospital name  Duration  Number 
of 
children 
Age 
(Y) 
Drugs/dose (mg/kg) Procedure  Findings  
Qteshat,  
2011[397] 
Double blind RCT 
/ Tertiary 
hospital 
King Hussein 
Medical City,  
Amman 
September 
2008- May 
2009 
54 6- 14  Midazolam/ 0.5 PO  
Clonidine/ 4 Mcg/kg PO  
Preoperative Midazolam produced rapid 
sedation effect than 
Clonidine (mean 42 minutes 
and 75 minutes 
respectively.  
Midazolam was more 
effective in reducing 
preoperative anxiety than 
Clonidine (75% versus 
25%) respectively.  
Abdul-Baqi K 
1991[199] 
Prospective 
observational 
study/university 
teaching hospital 
Jordan 
University 
hospital,  
Amman 
NA 34 0.9-7  Chloral hydrate / 40 PO BAEP* Middle ear pressure 
increased significantly in all 
patients (p<0.05) 
 
Miqdady MS 
et al. 
2011[398] 
Retrospective 
study/university 
teaching hospital 
 King Abdullah 
University 
Hospital,  Irbid 
August 2002 
- July 2008 
301 1-18  Midazolam/ mean 0.16 IV+ 
Ketamine/ mean 1.06 IV 
Endoscopic 
procedures  
Sedation was effective in 
79% 
Hypoxia (37, 12%) patients 
Respiratory distress ( 4, 
1%) patients 
* BAEP: Brainstem auditory evoked potential 
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 Israel 
Four studies (one RCT[330] and three case reports[222, 315, 399]) evaluated the 
safety and/or effectiveness of different sedatives (Table 8.8 and 8.9). A RCT was 
conducted to evaluate the effectiveness of chloral hydrate and nitrous oxide for VCUG 
procedure, with both sedatives were found to be 100% effective. Two studies reported 
the toxicity of chloral hydrate and triclofos as sedative agents[222, 315]. One study 
described successful treatment with nitrous oxide[399].  
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Table 8. 8: Studies conducted in Israel   
Reference   Design/ 
Setting 
Hospital name  Duration  Number 
of 
children 
Age 
(Y) 
Drugs/dose (mg/kg) Procedure  Findings  
Keidan et al. 
2005[330] 
Single- blind RCT 
/ Tertiary 
hospital 
Tel-Aviv 
University 
hospital, Tel-
Aviv 
June 2003- 
February 
2004 
47 3- 15 
years 
Midazolam / 0.5 mg/kg PO  
N2O/ 50% inhaled  
VCUG Success rate was 100% for 
both groups  
Mean duration of sedation 
was 20 min for M and 23 
min for N2O group 
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Table 8. 9: Case reports conducted in Israel  
Reference  Setting Number 
of 
children 
Age (Y) 
 
Drugs Procedure  AEs Treatment 
Shahar et 
al. 
1979[315] 
Teaching 
hospital 
1 0.2  Oral 1600- 1800 mg 
triclofos  
Circumcision  Deep coma,  
Severe hypothermia,  
Hypotension,  
Lack of tendon reflexes 
Intravenous fluids 
Farber 
Abramow 
1985[222] 
Tertiary 
hospital 
1 1.6 Oral 100 mg/kg 
chloral hydrate 
CT Sever dyspnea, 
Tachycardia,  
Tachypnea severe, 
Severs laryngeal edema, 
Respiratory acidosis 
Hydrocortisone (IV), 
Racemic adrenalin (INH) 
Moskovitz 
et al. 
2005[399] 
Teaching 
hospital 
2 Case1: 4.7  
Case2: 14  
Case1:  
3.7 mg/kg 
hydroxyzine and 
50% N2O/ O2, 
6 mg diazepam and 
50% N2O/O2 
 
Case2:  
5 mg diazepam and 
50% N2O/O2 
Dental 
procedures 
None None 
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 Other countries 
A study by Mostafa and Morsy (2013) in Egypt evaluated the effectiveness of 
midazolam and dexmedetomidine in 96 children, aged from 2 to 8 years, for bone 
marrow biopsy[400]. Nitrous oxide was used for dental procedures in a study 
conducted by Muhammad and colleagues (2011) in center-based clinics in Kuwait, and 
involved 118 children aged from 6 to 13 years [401]. None of the studies stated the 
use of a sedative guideline (Table 8.10).  
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Table 8. 10: Prospective observational studies continued 
Reference  Country Design/ 
Setting 
Hospital 
name 
Duration  Number 
of 
children 
Age 
(Y) 
Drugs Procedure  Finding 
Mostafa, Morsy 
2013[400] 
Egypt Double blind 
RCT / 
Teaching 
hospital  
Asyut 
University 
hospital, 
Asyut 
NA 96 2- 8  Midazolam/ 0.2 mg/kg 
IN  
Dexmedetomidine/ 1 
Mcg/kg IN 
ketamine / 5 mg/kg IN 
Bone 
marrow 
biopsy   
Dexmedetomidine 
produced faster effect 
compared to other groups 
sedatives (p <0.05).  
 
Muhammad et 
al. 2011[401] 
Kuwait Prospective 
observational 
study 
Ministry of 
Health 
hospital, 
Salmiya 
NA 118 6- 13  N2O Dental 
procedures 
99% of parents preferred 
the use of BMT versus 
20% of parents who 
preferred N2O sedation. 
BMT= behavioral management techniques, Po=orally, IN=intranasal 
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8.5. Discussion  
This is the first review of studies that evaluated the use of sedation in the Middle East. 
Almost half the studies were from Turkey.  
Most of the studies were RCTs (57%). Comparative studies can only give a potential 
snap shot of the research question, and do not allow comments on regional or 
national practice. Moreover, from the studies identified in this review, it was difficult 
to compare practices, because they were mostly single-centre studies that examined a 
single procedure. One study retrospectively examined sedative prescribing, and this 
was confined to painful procedures in the emergency department [396]. 
Few studies from the Middle East referenced the use of a sedation guideline. A 
national survey in the UK conducted in 2006 revealed that 80% of responding 
hospitals used a sedation guideline (ages of the patients were not specified) [402]. 
The current research consists of isolated studies, which did not follow each other 
sequentially. For example, Mizrak et al (2010) showed ketamine was better than 
propofol as a pre-medication[381]. The subsequent study compared dexmedetomidine 
to a placebo[382]. It would have been better to compare dexmedetomidine to 
ketamine. In contrast, Fallah et al. (2013) and (2014) in Iran examined sedation for 
EEG and showed that the combination of chloral hydrate and promethazine was more 
effective than chloral hydrate alone[387, 388]. 
Ketamine was the most commonly examined drug for painful procedures in five 
countries. It was given by various administration routes, IV and IM routes most 
commonly. The dose of ketamine varied widely. This may have reflected the divergent 
literature related to several procedures, and contributed to the reported variable 
efficacy of ketamine. Results showed that ketamine was effective and safe in most 
cases. This is in line with the study by Green et al. in the USA which evaluated the 
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safety and effectiveness of IM Ketamine mainly for laceration repair and fracture 
reduction, in 1022 children younger than 15 years[403]. The researchers found that 
ketamine was highly effective in 98% of the children and had a good safety profile. 
Ketamine was associated with a high incidence of adverse events, especially vomiting 
(17, 6%), but all cases were mild and improved without treatment. This review also 
reported four patients who were given ketamine and developed serious adverse 
events; three of them required medical intervention.  
Midazolam and chloral hydrate were the second most studied sedatives across the 
Middle East. Chloral hydrate was used for painless procedures, while midazolam was 
used for both painless and painful procedures. The dosage varied according to the 
type of procedure and patient age.  
Practice around chloral hydrate, midazolam and ketamine is similar in the Middle East 
and the UK. Chloral hydrate is used for painless imaging procedures for patients who 
weigh less than 15 kg. Midazolam is recommended for painless imaging procedures in 
children who weigh more than 15 kg and in children undergoing painful procedures 
[80]. Ketamine is used alone as a second-line option for painful procedures. As a 
second sedative, chloral hydrate was associated with adverse events. Vomiting was 
the most frequent adverse event (14, 6.7%). All cases were mild and self-limiting. 
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8.6. Conclusion 
This review is the first study that aimed to evaluate the use of sedation in the Middle 
East. Although the studies originating from the Middle East were relatively few in 
number, there was a similarity between studies in the use of sedation for specific 
paediatric procedures. The use of guidelines or protocols for sedation was rare, which 
was reflected in inappropriate clinical sedation practice. The indications for the use of 
a sedative drug in the Middle East are quite similar to the UK. Vomiting was reported 
to have occurred frequently, mainly with chloral hydrate and ketamine. 
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CHAPTER NINE 
A Survey of Procedural Sedation Practices in 
Children in the Kingdom of Saudi Arabia 
9.1. Introduction  
The Kingdom of Saudi Arabia (KSA) occupies about 850,000 square miles, which 
represents the largest area of the Arabian Peninsula [404]. The population of the 
country was placed by the last official census, in 2010, at 27.1 million [405]. The 
population younger than 30 years comprises 67%, and 37% are below 15 years of 
age[406]. The infant mortality rate for the year 2012 was 16.2 per 1000, which is 
63% less than the regional rate (44 per 1000) and 56% less than the global rate (37 
per 1000) [407].  
The KSA is one of the fastest growing and richest countries in the Middle East and is a 
dominant producer and exporter of oil, which comprises the major percentage of the 
country’s incomes[408, 409]. National income per capita for Saudi individuals 
increased from US$8,140 in 2000 to US$24,726 in 2008 (a three-fold increase) [376, 
410, 411] and this improvement is expected to positively affect its services, including 
heath care. 
Health care services in the KSA have improved and increased dramatically over the 
past decade [412]. In 1925, the first public health section was established in the city 
of Mecca by royal decree [413]. It was responsible for providing free health care for 
residents and pilgrims by establishing hospitals and dispensary clinics [413]. In 1950, 
the Saudi Ministry of Health (MOH) was established by royal decree and this step 
represents the fundamental advance in the health care system [413].  
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The health care sector in the KSA is mainly managed by the government through the 
MOH and a number of government agencies that operate various hospitals and 
medical facilities for their employees. Additionally, the private sector runs many 
hospitals that provide medical services in the Kingdom [407]. The MOH provides 
universal health care coverage for the whole country [407]. There are a total of 415 
hospitals (58,126 beds) including private hospitals [414]. The MOH operates 62% of 
the hospitals and 53% centers and clinics; other health care facilities are operated by 
various government agencies, including the Ministry of Education, the Ministry of 
Defense, the Ministry of the Interior, the National Guard Ministry and the Red Crescent 
Society. The total number of hospitals operated by the MOH is 259, with 35,828 beds 
(Figure 9.1) [400] 
The main health care system in the KSA is managed by the MOH and its 
responsibilities include management, strategic and technical planning, formulation of 
health policies and supervising all delivery programs of health services, in addition to 
private sector health services. In conformity with the KSA constitution, all citizens and 
expatriates employed by the public division are provided free and full access to all 
health care services [414, 415]. According to a WHO report, the total government 
expenditure on the public health sector in Saudi Arabia during 2009 was 5% of total 
domestic product which is less than the USA (16%) and Japan (7%) [416].. 
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Figure 9. 1: Distribution of the MOH’s hospitals and primary health care 
centres according to the regions of Saudi Arabia 
 
PHC= Primary Health Care Centers 
 
Currently, the MOH operates 2,259 primary care centers all over the country, each 
serving approximately 10,000 people [417]. The primary care centers are responsible 
for providing residents with various services, including educating the people regarding 
common health problems and ways to avoid and control them; providing adequate 
sources of safe water; increasing the food supply and ensuring suitable nutrition; 
providing comprehensive paediatric and maternal care; administering immunisation to 
children against various infectious diseases; controlling and preventing endemic 
diseases that develop locally; and giving immediate treatment for injuries and 
common diseases[418, 419]. In addition, primary care centres act as the gateway to 
secondary health care centres when a patient’s condition requires special treatment.  
57 Hospitals 
509 PHCs 
 
32 Hospitals 
248 PHCs 
66 Hospitals 
638 PHCs 
29 Hospitals 
170 PHCs 
 
 
75 Hospitals 
694 PHCs 
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The secondary health care services mainly are delivered at the regional level in 
approximately 395 general hospitals managed by the local directorates. The number 
of secondary care hospitals is increasing as a result of decentralisation in the delivery 
of health care services. The goal of this decentralisation is for each region of the 
country to have its own general hospital(s). 
There are 56 tertiary hospitals covering most regions in Saudi Arabia, these include 20 
hospitals for obstetrics and paediatric patients.  
Government agencies usually provide health care services for their employees. They 
have their own budgets, administration management, medical policies and 
procedures. These agencies, for instance, include the Ministry of Education hospitals 
and the Saudi Red Crescent Authority. With regard to private sector providers, they 
offer around 20% of the total health care services to the general public in the 
kingdom [420]. They have specialised children’s hospitals that provide health care for 
paediatric patients. 
The MOH for Health Care Accreditation has been establishing hospital quality and 
safety appraisals since 1995[417]. The guidelines for administration of medications, 
including sedative agents, fall under the assessment of health care accreditation 
criteria. Hence, more hospitals will have achieved the procedural sedation (PS) 
guidelines as accreditation developments. However, the treatment and/or diagnostic 
procedure guidelines in most hospitals differ, and in some instances health care 
professionals tend to neglect them[417].  There is limited data regarding the use of 
sedation in the Middle East, especially in Saudi Arabia, as shown in the previous 
chapter (Chapter 8).  
Saudi Arabia is one of the biggest countries in the Middle East region. Moreover, it is 
the country where I am from and where I will return to work. Therefore, it was 
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decided to examine practice further and to survey clinical practice patterns to evaluate 
how often sedative agents are used for treatment and/or diagnostic procedures. We 
consequently designed a web-based survey to evaluate practitioner’s use of sedation 
in paediatric patients in the kingdom of Saudi Arabia. 
 
9.2. Aim 
Sedation in children and young people has become a standard tool in several 
diagnostic and therapeutic procedures. The aim of this chapter was to gain 
information on current practice and to evaluate the views of practitioners on; use of 
sedation, availability of guidelines, the drugs being used and the level of practice 
being undertaken.  
9.3. Methods 
No standardised questionnaire was found in the literature. One was therefore 
composed to include multiple-choice and open-ended questions, with the chance to 
expand answers to some given questions in free text. Following a moderate response 
to the sending of the initial survey, a shortened survey was resent focusing on the 
questions felt to be most relevant. The results were analysed as one group, including 
only questions common to both surveys. It consisted of two main sections including; 
demographic questions and general questions (Appendix C). 
9.3.1. Demographic questions 
The questions in this section were designed to obtain individual data from the 
respondents about their working area, and type of hospital.  
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9.3.2. General questions 
This section was designed to collect data about the current sedation practices 
including; sedation guidelines, patients monitoring during PS, medical instructions 
during and after PS and the most commonly used sedative drug(s) including: route of 
administrations. 
9.3.3. Study design and population 
A web-based survey was sent throughout all hospitals that belong to the MOH of 
Saudi Arabia across the country. The study participants were paediatric doctors and 
nurses who were members of the Saudi Commission for Health Specialties. A 
questionnaire and cover letter describing the study were available through an internet 
link (Survey Monkey), this provider was used as it was readily recognisable by 
professionals. A response to the survey was requested through email. A second and, if 
needed, a third mailing message were sent to remind the non-responders. 
9.3.4. Data analysis 
Categorical data was described by frequencies. Chi-squared test was used for analysis 
of variables. Differences were considered to be statistically significant at P < 0.05. 
9.4. Results  
In total, 571 questionnaires were sent electronically. Questionnaires were completed 
by 93 (16.3%) respondents. The middle area of the country represented 44% of the 
total respondents. This is owing to it being the largest area and includes the capital 
city (Riyadh), which contains a large number of specialist and universities’ hospitals 
(Figure 9.1). Approximately 60% of the respondents were working in a tertiary 
hospital (Table 9.1).  
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Table 9. 1: Demographic data of the respondents 
Variable  Number of respondents 
Area of work 
 Middle 41       (44%) 
 South 16      (17%) 
 West 13      (14%) 
 East 12     (13%) 
 North 11     (12%) 
Type of hospital 
 Tertiary 56      (60%) 
 Community 18      (19%) 
 University 12      (13%) 
 Ambulatory centre 7      (8%) 
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A sedation guideline was reported to be used by 59 (63%) of the respondents, of 
which 34 (58%) had an institutional sedation guideline, and 25 (42%) used the 
American Academy of Pediatrics and American Society of Anesthesiology guideline.  
51 (63%) reported that they had a written procedural sedation (PS) informed consent 
form. Discharge criteria after (PS) were mentioned by 44 (54%) respondents, and a 
discharge instruction form were specified by 31 (38%) (Table 9.2).  
Table 9. 2: Sedation practice 
Variable  Number of respondents 
  
Use of sedation guideline 
 Yes 59       (63%) 
 No 34       (37%) 
Discharge criteria 
 Yes 51        (55%) 
 No 42        (45%) 
Use of discharge instructions form 
 No 62       (67%) 
 Yes 31        (33%) 
 
9.4.1. Monitoring during procedural sedation 
Monitoring of patients during procedures took place frequently (91%), however 9% 
reported that they don’t monitor patients during procedures. Approximately half of 
these did not feel that the monitoring of sedation is necessary, whilst others referred 
to either shortage of staff (22%) or shortage of equipment (22%).  
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9.4.2. Procedural sedation and the most common sedative used 
Imaging procedures such as CT and MRI were the most common painless procedures 
for which sedation was used, while dental procedures and bronchoscopy were the 
most common painful procedures (Figure 9.2).  
 
Figure 9. 2: Painless and painful procedures and how often sedation is being 
used  
 
Overall all, chloral hydrate was the most frequently stated sedative agent (84, 93%) 
used by respondents, followed by midazolam (71, 76%), diazepam (56, 60%), and 
lorazepam (34, 40%) (Table 9.3). 
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Table 9. 3: Sedatives commonly used  
Sedative  Number of respondents % of respondents 
Chloral hydrate  84 93 
Midazolam 71 76 
Diazepam 56 60 
Lorazepam 37 37 
Ketamine 34 40 
Propofol 21 23 
N2O inhalation 20 22 
Thiopental 20 22 
Etomidate 7  8 
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9.5. Discussion  
This survey is the first study of the use of sedation in children in Saudi Arabia. The 
results of this survey showed that the sedation practice in Saudi Arabia is not ideal. 
As shown in the chapters in my thesis, sedative agents have the potential to cause 
respiratory, CNS, or cardiovascular adverse events. The use of sedation guidelines can 
reduce or prevent the development of many of these adverse events [2]. Despite the 
advantages of using sedation guidelines, not all responding practitioners have them.  
There are no national or standard guidelines for PS in hospitals in Saudi Arabia; 
therefore, physicians use institutional or international guidelines in each hospital, or 
provide PS to children without a guideline in some hospitals. In this survey, 63% of 
the respondents used a sedation guideline, 55% had criteria for patient’s discharge 
after PS, however only 33% provided discharge instructions to the patients after PS. 
This is comparable with the results from an Australia and New Zealand survey that 
evaluated sedation practice in children [421]. They found that 58% of the general 
departments used sedation guidelines.   
Many sedation guidelines recommend patient monitoring during PS in order to prevent 
the development of any potential adverse event [21, 422]. Fortunately, the results of 
this study demonstrated that 91% of the respondents monitored their patients during 
PS. These results show that there is an interest in the safety of sedation in children. 
The exact methods and equipment used for monitoring, and the recommendations for 
practice in the local guidelines, would be useful to explore further. 
Chloral hydrate and midazolam were the most common sedatives respondents said 
they used for both painless procedures and painful procedures (93%, 76% 
respectively). This finding is in line with the NICE guideline recommendations for the 
use of these agents, which recommends them for painless diagnostic imaging 
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procedures [80]. The use of chloral hydrate for painful procedures is in contrast with 
the guideline in which the use of chloral hydrate is recommended for only painless 
procedures [80]. 
9.6. Limitation  
It is important to mention the limitations of this survey. The data presented in this 
study has been composed from questionnaires completed by health care professionals 
and involves individual-reporting of behaviour instead of objective data. Furthermore, 
the response rate was relatively low which happens commonly with web surveys. 
However, the wide ranges of hospitals responding from different areas make it likely 
that the results of this study give a reasonable indication of practice. 
9.7. Conclusion 
The results of this survey suggest that there is room for improvement in the practice 
of PS for children in Saudi Arabia. Unified PS guidelines were rare in surveyed 
hospitals. Chloral hydrate and midazolam were the most frequently used sedative 
agents for both painless and painful procedures. Our study suggests that development 
and implementation of a national PS for paediatric patients are required as early as 
possible.  
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CHAPTER TEN 
General conclusion 
 
10.1. Introduction  
For any medication used regularly in children it is important to consider the safety and 
clinical effectiveness. At the start of this thesis the clinical literature was searched for 
guidelines and the local hospital consulted for its policy on sedation. Consequently, I 
performed systematic reviews of the literature evaluating the sedatives that are most 
frequently used. Palatability has been shown to play a major role in drug treatment 
adherence [96]. This thesis adds new evidence about the palatability of two sedative 
medicines commonly used in children. This was achieved by evaluating published 
studies and by conducting a prospective study to assess their palatability clinically in a 
children’s hospital. This thesis also adds new evidence about the use of sedation in the 
Middle East, particularly focusing on Saudi Arabia, since this area is particularly 
important for its author.  
10.2.  Summary of findings 
10.2.1. Evaluation of the most commonly used sedatives 
Three systematic reviews were conducted to evaluate the safety and effectiveness of 
chloral hydrate, its derivative (triclofos) and midazolam. Meta-analysis was not 
performed due to the heterogeneity of the studies. 
Chloral hydrate’s safety and effectiveness were evaluated via three types of 
procedures including painless, painful, and treatment procedures (Chapter 2). The 
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success rate for painless and painful procedural sedations was variable (50%–100%), 
higher for shorter imaging procedures such as CT imaging. The success rate for 
treatment procedures was higher, ranging from 86% to 100%. One in seven children 
undergoing painless procedures and one in six for painful procedures, receiving chloral 
hydrate, experienced an AE.  Hypoxia was the most commonly reported AE, occurring 
in approximately one in nineteen children. It was usually mild. Moderate hypoxia 
(SpO2 <90%) was uncommon, occurring in less than 2% of cases and was reversible 
after using simple manoeuvres, such as supplemental oxygen therapy. No deaths 
were reported; however there were seventeen serious AEs, all requiring medical 
interventions and/or hospitalisation.  Hypoxia was more common in infants under two 
years. Vomiting was the second most frequently reported AE occurring in 
approximately one in thirty children. The majority occurred during dental procedures. 
The incidence of AEs was higher during painful procedures (17.3%, 313AEs/1810 
patients) than in painless procedures (13%, 1,951AEs/14439 patients).  
 
The incidence of AEs was even higher in children who were given chloral hydrate for 
treatment of agitation (18.5%, 81AEs/438 patients) with hypoxia affecting one in six 
children; severe complications such as hypoxia and respiratory depressions were 
reported in 7 children. 
 
The systematic review that evaluated triclofos safety and clinical effectiveness during 
procedural sedation (Chapter 3) also identified vomiting and hypoxia as the most 
commonly reported AEs, 10% (62/613) and 7.8% (48/613) respectively. All cases of 
hypoxia were mild and none required medical intervention. The incidence rate of 
reported AEs was dramatically higher for painful procedures (27.3%, 121/444) 
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compared to painless (7.7%, 13/169) procedures. The success rate was higher for 
painless procedural sedation (84-100%) compared to painful procedures (50–98%). 
 
We noticed that paraldehyde is still used for sedation in children as a part of the local 
hospital sedation policy, but not the NICE guidance. Therefore it was felt to be 
important to conduct a systematic review to evaluate its effectiveness and safety in 
children.  Just five studies were identified (Chapter 4) and only two of these evaluated 
paraldehyde safety in 29 children. Meta-analysis was not performed due to the 
heterogeneity of the studies. Vomiting was the most commonly reported AE, with an 
incidence rate of 25% (2 cases/8 patients). Three studies evaluated paraldehyde 
effectiveness, with a procedural success rate that ranged from 75% to 93.1%. The 
quality and number of studies were very limited. 
 
Chapter 5 evaluated midazolam effectiveness and safety during imaging procedures.  
Procedural success rates ranged from 0% to 100%, with a median of 82%. Midazolam 
was incompletely effective for both MRI and CT (median success rate was 67% and 
68.5%) respectively. The most common AE was hypoxia affecting one in 74 children. 
Most cases were mild. Most of the moderate cases were reversible after simple airway 
manoeuvres. Vomiting was the second most frequently reported AE, occurring in 1% 
of children. 
 
In conclusion there is good evidence to support the use of chloral hydrate, as 
recommended in the NICE guidance. It has a moderate rate of adverse events and 
because of the risk of hypoxia, children should always be monitored closely and 
managed by an experienced practitioner who is able to perform airway manoeuvres 
and resuscitation if required[423]. Its use for procedures such as dental extractions 
should be limited by community dentists, this is supported by it not being 
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recommended in the current UK guidance[424].  Midazolam is primarily recommended 
for use as a sedative for imaging procedures, although it was found to have less than 
a two thirds success rate for MRI [80]. This is not sufficient to recommend its regular 
use in practice and many hospitals are now moving towards general anaesthetic[424]. 
The evidence for the use of paraldehyde in sedation is very limited and does not 
support its continued use without further studies.     
10.2.2. Palatability of the two most commonly used sedatives 
 After taking into consideration the effectiveness and safety of the most commonly 
used sedatives, it known that factors such as taste, which may affect the ease of drug 
administration and therefore treatment adherence, should be taken into account. It 
was therefore decided to evaluate the palatability of the two most commonly used 
sedatives in children (chloral hydrate and midazolam) (Chapter 6 and Chapter 7). 
Only 9 studies were identified in a systematic review (Chapter 6).  The majority of the 
studies (8) evaluated midazolam’s palatability, while only two studied chloral hydrate. 
There was a great variability in the tools used for assessment of palatability. 
Midazolam was acceptable to most children; however, chloral hydrate was found to 
have a poor palatability. 
The results from the prospective observational study (Chapter 7) reinforced the 
results found in the systematic review, showing a poor acceptance of oral chloral 
hydrate as judged by the children, their parents and nursing staff. Midazolam, 
however, had a relatively good acceptance and parents were more likely to prefer 
midazolam. Despite this, chloral hydrate was associated with a high success rate 
(19/20), whereas the success rate with midazolam was lower (12/20), with sedation 
supplementation given to 5 patients in each group. This could be because half of the 
procedures using midazolam were painful compared to none of those with chloral 
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hydrate. This limited effectiveness is in line with the results previously shown in the 
systematic reviews.    
10.2.3. Evaluating the use of sedation in Middle Eastern countries 
The safety and effectiveness of sedative agents for procedural sedation of children 
have been well evaluated in Western countries. However, there have been very few 
clinical studies of their use in children in Middle East countries. I have focussed on this 
area as it is the region where I am from, and where I will return to work. A literature 
review and survey study (Chapter 8 and Chapter 9) were conducted and, to my 
knowledge, these studies are the first to look at the use of sedation in children in the 
Middle East. 
The literature review (Chapter 8) showed that the number of studies that evaluated 
the prescribing patterns of sedative agents in paediatric patients was limited. More 
than half originated from one country (Turkey) and most studies were conducted at a 
single centre and assessed a single procedural sedation. Sedation guidelines and/ or 
protocols were used rarely, which may indicate the possibility of inappropriate use of 
sedative agents and a lack of coordinated practice in the region.  
A survey study was therefore carried out to evaluate the use of sedation in the 
Kingdom of Saudi Arabia, and involved 81 health care professionals from throughout 
the country (Chapter 9). It demonstrated that the practice of administering sedation 
in Saudi Arabia is not ideal. The majority (90%) of respondents reported the use of 
monitoring during sedation. However only 61% of the respondents reported the use of 
sedation guidelines, 54% had discharge criteria and 36% reported the use of consent 
for sedation. Chloral hydrate and midazolam were most commonly reported to be 
used as sedative agents, for both painless and painful procedures. 
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10.3. Conclusions from this thesis  
The results of this work have provided some recommendations for paediatric 
professionals and clinical practice in both the UK and worldwide. 
 Chloral hydrate is appropriate for sedation for painless imaging procedures in 
young children.  
 Midazolam was found to be more effective for procedures that require a sedative 
agent with anxiolytic and amnestic effects. 
 Midazolam does not provide good sedation for longer procedures like MRI, with 
only a two thirds success rate overall in the literature.   
 Chloral hydrate and midazolam both have a significant incidence of hypoxia, 
reinforcing the importance of monitoring children during sedation. 
 The palatability of chloral hydrate is poor. 
 Due to the very limited clinical studies evaluating the use of paraldehyde for 
sedation in children, its effectiveness and safety in this setting remain 
questionable. Its use in children should be avoided.  
 Further work is needed to support the administration of sedation in Middle Eastern 
countries. Work both nationally and regionally should be undertaken to consider 
implementation of a unified procedural sedation guideline.  
 Awareness of health care professionals about sedation guidelines in the Middle 
East region should be raised. 
 
10.4. Lessons learned and future plans 
During my PhD studies I have learned how to design a research project including 
creating a research question based on the existing bibliographic knowledge. Moreover, 
I have learned how to manage a research project through setting up and designing 
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the study protocols; collecting, archiving and interpreting results. Additionally I have 
learned how to conduct a systematic literature review and have improved during my 
studies and am now aware of how to use a good methodology, this is reflected in 
improvements in the quality of my midazolam systematic review compared to the 
chloral hydrate systematic review. In addition to the above, I have acquired some 
complementary skills and experiences which will be helpful for my future job such as 
oral presentations, organising meetings, managing my time and organising work. 
 
10.5. Implications for future research and practice 
 Although this thesis evaluated the most commonly used sedatives, further 
research studies are required to evaluate other sedatives that are still currently 
used in paediatric patients, such as ketamine.   
 More clinical studies are needed to evaluate the effectiveness and safety of 
paraldehyde, for its continued use for the sedation of children. 
 The rarity of reported severe AEs from clinical studies may possibly be due to 
improper documentation of safety data or the lack of large prospective studies. 
This underscores the importance of developing a reporting system that is easy to 
use and directly accessible to all health care professionals and patients.  
 Palatability in children’s medicines development is important and should continue 
to be assessed by conducting studies to inform the pharmaceutical companies 
about children’ opinions, by paying attention to patients’ feedback about 
adherence and compliance. 
 Further evaluation of sedation guidelines in the Middle East is needed. 
 The successful establishment of guidelines needs substantial planning, continuous 
education, and training (Taylor, 2003). Therefore, my suggestions on how to 
establish guidelines in Saudi Arabia include: 
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 A local PS quality and assurance monitoring group. This group, working as 
an authorised hospital committee, with various responsibilities, including 
local application of the recommendations in the PS guidelines, quality 
control, implementing and developing local protocols, and local training.  
 A national PS support group. This group, comprised of experts in children’s 
procedural sedation, will coordinate the establishment of the guidelines. 
This working group could have responsibility for conducting pilot-trials in 
particular settings and hospitals. Moreover, this group may assist in 
consultations. 
 Training for PS. Currently, there are no national training credentials for PS 
in children in Saudi Arabia. However, designing a universal training 
program for the various types of procedural sedation is difficult. All health 
care professionals involved in paediatric sedation should have skills in 
airway management and resuscitation. Future training courses could 
educate health care professionals in the following fields: administration of 
sedation, monitoring patients before, during, and after procedural sedation, 
policy, and research.   
 
In closing, the use of sedatives has increased globally; this has led to a rise in 
concerns about their safety and effectiveness, particularly in the paediatric population. 
The effectiveness of most frequently used sedatives was variable according to the 
type of procedural sedation.  Palatability was seen to influence drug acceptance. The 
significant incidence of AEs (especially respiratory complications), highlights the 
importance of close patient monitoring. Some of the current practice identified for PS 
for children in the Middle East was not ideal. Thus, national PS guidelines must be 
developed and implemented. 
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